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SUMMARY 
 
Low back pain (LBP) is a prevalent symptom that more than 80% of the population 
experience once in their lifetime. This can lead to severe impairment of the workaday life 
and cause enormous costs in the society. Because LBP mostly appears as a non-specific 
back pain symptom, provoked by the spine or its environment, the evaluation of the 
source is bearing some challenge. Whereas the pathomorphological source of pain is well 
defined in the specific spinal pathology, such as in the case of a scoliosis or sciatica, 
finding a correlation between the source of pain and a certain abnormality is difficult in 
non-specific LPB symptoms. This is accompanied by the disadvantage of finding a 
suitable treatment. One possible source of LPB represents the intervertebral disc (IVD), 
which can alter from a pain free (asymptomatic) to a painful (symptomatic) IVD during 
degeneration, leading to so called discogenic back pain. Provocative discography is to 
date the only means to assign LBP to a degenerated disc, with its usage being under 
dispute. 
The IVD has an important function as a shock absorber, as there is a high load on the 
spine. During a lifetime, our IVD becomes degenerated which means its matrix is more 
catabolized then anabolized, leading to an overall matrix breakdown and decreased 
quality of the IVD. The matrix consists of long protein chains and sugars, responsible for 
the ability to attract water, comparable to a sponge. Due to the reduction and loss of these 
main components during degeneration, the IVD loses height and we get smaller during 
aging. This is a normal process which is pain free in most cases, meaning asymptomatic. 
But there is a certain subpopulation complaining about pain without showing any special 
pathomorphological changes. Thus far it was demonstrated that symptomatic degenerated 
IVDs produce more cytokines (IL-6, IL-8, IL-1β, TNF-α) and that these molecules are 
able to provoke pain sensation directly. The first part of this thesis aims to identify factors 
leading to a pro-inflammatory cascade in a degenerated IVD as well as the involved 
pathways. 
The matrix of the IVD consists of abundant structure proteins such as collagen or 
fibronectin as well as of a special sugar, the hyaluronic acid. During disc degeneration, 
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these huge molecules become fragmented and catabolized. In this study we were able to 
show that hyaluronic acid fragments (fHA) provoked a pro-inflammatory and catabolic 
cascade in IVD cells in vitro. With gene silencing and inhibition of activity, we could 
detect TLR2 to be engaged in the up-regulation of IL-6 synthesis in fHA treated IVD 
cells. Furthermore, inhibition experiments demonstrated an involvement of the MAP 
kinases ERK and JNK, two classical enzymes in inflammatory reactions. Surprisingly, 
we could not observe any NF-κB involvement, another important pathway in 
inflammatory signalling.  
The second part of this work is dedicated to potential anti-inflammatory and anti-
catabolic herbal agents for a possible application in the treatment of discogenic back pain. 
Resveratrol, curcuma (curcumin) as well as triptolide showed anti-inflammatory and anti-
catabolic effects on IL-1β prestimulated IVD cells in vitro. Interestingly, all of these 
substances had no influence on the NF-κB pathway. Curcumin, an ingredient of curcuma, 
reduced JNK phosphorylation and thereby its activation. Triptolide instead limited p38 
and ERK phosphorylation. Resveratrol did not show any effect on the investigated 
pathways (NF-κB and MAP kinases), but exhibited an analgetic effect in vivo, conducted 
in a rat model.  
All tested substances showed promising effects for a possible use for the treatment of 
symptomatic degenerated discs, either by an intradiscal or epidural injection, e.g. by 
usage of an appropriate slow release system. 
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ZUSAMMENFASSUNG 
 
Rückenschmerzen gehören zu den am häufigsten auftretenden Symptomen in unserer 
Gesellschaft. Weltweit leiden über 80% mindestens einmal in ihrem Leben an 
Rückenschmerzen. Diese Schmerzen können zu einer grossen Beeinträchtigung im 
alltäglichen sozialen und beruflichen Leben führen und verursachen dabei auch sehr hohe 
Arztkosten. Es gibt mehrere Ursachen die zu Rückenschmerzen führen können, und es ist 
deshalb nicht immer einfach, die eigentliche Quelle des Schmerzes zu finden. Selten ist 
die direkte Verbindung zwischen Schmerzäusserung und spezifischem Krankheitsbild so 
offensichtlich wie im Falle von definierten Wirbelsäulenerkrankungen, z.B. 
Verkrümmung der Wirbelsäule (Skoliose) oder Verengung des Wirbelkanals 
(Ischiassyndrom). Unspezifische Erkrankungen der Wirbelsäule und deren Umgebung 
die zu Schmerzempfindungen führen können treten im Allgemeinen häufiger auf und 
erschweren die Suche nach einer passenden Behandlung. Eine mögliche Ursache des 
Schmerzes kann eine degenerierte Bandscheibe (englisch: intervertebral disc = IVD) sein, 
die sich von einer schmerzfreien (asymptomatischen) zu einer schmerzhaften 
(symptomatischen) Bandscheibe verändern kann (discogenic back pain). Die provokative 
Diskographie ist zur Zeit die einzige – jedoch umstrittene - Methode, 
bandscheibenbedingte Rückenschmerzen als solche zu identifizieren.  
Unsere Bandscheibe hat eine wichtige Stossdämpferfunktion, denn es wirken enorme 
Kräfte auf unsere Wirbelsäule. Im Verlaufe eines Lebens degeneriert die Bandscheibe, 
d.h. ihre Matrix wird mehr abgebaut als aufgebaut, wodurch sich die Qualität der 
Bandscheibe verringert. Diese Matrix besteht aus vielen langkettigen Eiweissen und 
Zuckern, die viel Wasser anziehen können, vergleichbar mit einem Schwamm. Durch den 
Abbau und Verlust dieser Hauptbestandteile kommt es bei einer Degeneration zu einer 
immer flacher werdenden Bandscheibe und wir werden mit dem Alter immer kleiner. 
Dieser Prozess ist in der Regel schmerzfrei, also asymptomatisch. Nun gibt es aber 
Patienten, die über Schmerzen im Rücken klagen, jedoch keine besondere 
pathomorphologische Merkmale aufweisen. Bisher konnte gezeigt werden, dass 
symptomatisch degenerierte Bandscheiben einen erhöhten Zytokinlevel aufweisen (IL-6, 
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IL-8, IL-1β, TNF-α) und dass einige dieser Botenstoffe direkt Schmerzempfindungen 
auslösen können. Welche besonderen Faktoren in einer degenerierten Bandscheibe zu 
dieser proinflammatorischen Stimulierung führen und welche Signalwege dabei 
involviert sind, ist der erste Teil dieser vorliegenden Arbeit gewidmet.  
Die Matrix der Bandscheibe besteht neben Strukturproteinen wie Kollagen oder 
Fibronektin auch aus einem besonderen Zucker, der Hyaluronsäure. Während der 
Degeneration der Bandscheibe werden diese langkettigen Moleküle in kleinere Einheiten 
fragmentiert und abgebaut. Wir konnten in vitro zeigen, dass Hyaluronsäurefragmente 
(fHA) eine proinflammatorische wie auch katabolische Wirkung auf Bandscheibenzellen 
aufweisen. Dabei wurde TLR2 durch Inaktivierung auf Genebene wie auch durch 
Blockierung seiner Aktivität auf Proteinebene als ein Rezeptor identifiziert, der bei der 
Behandlung der Zellen mit fHA an der Ausschüttung von IL-6 beteiligt zu sein scheint. 
Mittels Inhibitionsexperimenten konnten wir weiter zeigen, dass dieses Signal 
hauptsächlich über die MAP Kinasen ERK und JNK vermittelt wird, zwei klassische 
Enzyme, welche die Zellen bei Entzündungsreaktionen aktivieren. Erstaunlicherweise 
konnten wir keine Beteiligung von NF-κB detektieren, ein weiterer wichtiger Signalweg 
in Entzündungsreaktionen.  
Der zweite Teil der Arbeit widmete sich pflanzlichen Wirkstoffen. Diese wurden auf ihre 
antiinflammatorische wie auch antikatabolische Wirkung hinsichtlich eines möglichen 
Einsatz in der Behandlung gegen schmerzhafte degenerierte Bandscheiben getestet. 
Resveratrol, Curcuma sowie auch Triptolide, alles Substanzen pflanzlicher Herkunft, 
zeigten in vitro antiinflammatorische wie auch antikatabolische Wirkung auf mit IL-β 
vorstimulierte Bandscheibenzellen. Die Substanzen zeigten interessanterweise keinen 
Einfluss auf den NF-κB Signalweg. Curcumin, einer der Inhaltsstoffe von Curcuma, 
reduzierte jedoch die JNK Phosphorylierung und somit die Aktivierung dieses 
Signalwegs. Triptolide hingegen hatte einen hemmenden Einfluss auf die 
Phosphorylierung von p38 und ERK. Resveratrol zeigte keine Wirkung auf die 
untersuchten Signalwege (NF-κB und MAP Kinasen), jedoch konnte in vivo ein 
analgetischer Effekt nachgewiesen werden, durchgeführt in einer Studie an Ratten. 
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Für einen möglichen Einsatz in der Behandlung von symptomatisch degenerierten 
Bandscheiben zeigten sich alle drei Substanzen als interessante Kandidaten, die entweder 
intradiscal oder epidural (möglicherweise in einer slow-release Formulierung) eingesetzt 
werden könnten. 
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ABBREVIATION 
 
AP-1 = activating protein-1 
AD = ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs 
BSA = bovine serum albumin 
DRG = dorsal root ganglion 
DTT = 1,4-Dithio-DL-threitol 
DD = disc degeneration 
DDD = disc degenerated diseases 
ECL = enhanced chemiluminescence reaction 
ECM = extracellular matrix 
EDTA = ethylendiamintetra-acetat 
ELISA = enzyme linked immunosorbent assay 
ERK = extracellular signal regulated kinase  
FACS = fluorescence activated cell sorting 
fHA = fragmented hyaluronic acid 
GAG = glycosaminoglycan 
GPCR = G protein-coupled receptor 
HA = hyaluronic acid 
HAS = hyaluronic acid synthase 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMWHA = high molecular weight hyaluronic acid  
HRP = horseradish peroxidase 
Hyal = hyaluronidase 
IHABP = intracellular hyaluronic acid binding protein 
IVD = intervertebral disc 
JNK = c-Jun aminoterminal kinase 
LBP = low back pain 
MAP kinases = mitogen-activated protein kinases 
MDR = multi-drug resistance 
MMP = matrix metalloproteinase 
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MSC = mesenchymal stem cells 
NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells 
OA = osteoarthritis  
PBMC = peripheral blood mononuclear cells 
PBS = phosphate-buffered saline  
PMSF = phenylmethanesulfonyl fluoride 
PVDF = polyvinylidene fluoride 
RA = rheumatoid arthritis 
RHAMM = receptor for hayluronan mediated motility  
RT = room temperature  
RTK = receptor tyrosine kinase 
SDS-PAGE = sodiumdodecylsulfat-polyacrylamid-gelelectrophorese 
TBS = tris-buffered saline 
TIMP = tissue inhibitor of metalloproteinase 
TLRs = toll-like receptors 
VEGF = vascular endothelial growth factor 
WCE = whole cell extract  
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INTRODUCTION 
 
1. Low back pain 
1.1. Symptoms 
Back pain is a prevalent symptom that more than 80% of the population experience once 
in their lifetime. The most common symptoms are neck and low back pain (LBP), which 
can lead to a severe impairment of the workaday life and cause enormous costs in the 
society. Because LBP mostly appears as a non-specific back pain symptom, provoked by 
the spine or its environment, determining the source of this problem possess a serious 
challenge. Whereas the pathomorphological source of pain is well defined in the specific 
spinal pathology, such as in the case of a scoliosis or sciatica, finding a correlation 
between the source of pain and a certain abnormality is often difficult in non-specific 
LPB symptoms. This is accompanied by the disadvantage of finding a suitable treatment.  
The development of LBP is a multi-factorial process in which all spinal structures as well 
as aspects such as age-related changes  and life style can contribute. Physiological and 
psychological aspects have to be considered as well when we are questioning the origin 
of the pain sensation. The spine as a source of pain involves the vertebrae, the facet 
joints, the muscle, the ligaments or the intervertebral disc (IVD), while age related 
changes of the spine can appear as a loss of muscle mass, decreased structural strength of 
the vertebral body, cartilage endplate calcification and ossification, facet joints 
osteoarthritis or a decreased tensile strength of ligaments. Another possible source of 
LPB represent the intervertebral disc (IVD), which can alter from a pain free 
(asymptomatic) to a painful (symptomatic) IVD during degeneration, which is then called 
discogenic back pain.  
Individual risk factors to generate LPB can be age, gender, body weight, general health 
status, heredity, smoking or a sedentary lifestyle as well as morphological factors such as 
e.g. scheuermann disease, disc herniation or, as already mentioned, a degenerated IVD. 
Of course, all these risk factors do not necessarily lead to pain sensation [1].  
  14 
The diagnostic triage further classifies LBP either to specific spinal pathology (specific 
structural pathology is consistent with the clinical picture), nerve root pain/radicular pain 
or non-specific low back pain. Pain can additionally differentiated into nociceptive pain, 
neurophathic pain, functional pain or inflammatory pain [2]. Nociceptive pain is 
provoked by a noxious peripheral stimuli like heat, cold, mechanical force or chemical 
irritants to the nociceptors whereas direct damage or disease of neurons in the peripheral 
or central nervous system is typical for neurophatic pain. The functional pain is an 
abnormal responsiveness or function of the nervous system, and there are no neurological 
or peripheral abnormalities detectable. The inflammatory pain arises from injured tissue 
and inflammatory mediators such as cytokines, provoking pain sensation at nociceptors 
[1, 3]. For a diagnostic evaluation, it is important to consider all the above mentioned 
possible sources of LBP in order to find an appropriate treatment for the patient. 
 
1.2. Treatments 
Treatment options for LPB are pharmacological, physiotherapy and operative 
applications. Opioids, non-opioid, non-steroidal anti-inflammatory drugs and adjuvants 
are applied as pharmacological drugs. Among the most commonly used opioids are 
morphine, hydromorphone, methadone, oxycodone, oxymorphone and fentanyl, which 
are mostly applied in cases of acute severe pain. The most frequently used non-opioid 
analgesic is paracetamol. The non-steroidal anti-inflammatory drugs are e.g. celecoxib, 
rofecoxib, valdecoxib, used for inflammatory pain treatment. They mainly block the 
synthesis of prostaglandine E2 (PGE2), responsible for the direct pain sensation, but have 
the disadvantage of also inhibiting the activities other prostaglandins, which have tissue 
protective functions. Often, antidepressants, anticonvulsants, anxiolytics, muscle 
relaxants and sleep-promoting medication are also administered as adjuvants. 
For invasive intervention for LBP, spinal injection of selective nerve root blocks such as 
bupivacaine in combination with methylprednisolone or lidocaine with betamethasone 
are used as a diagnosis to differentiate symptomatic and asymptomatic alteration and as a 
treatment of various spinal disorders as an adjunct to non-operative care. Corticosteroids 
are used for epidural injections with the aim to diminish the inflammatory component of 
a neural compromise. Provocative discography is used to distinguish asymptomatic from 
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symptomatic disc degeneration as an alteration is not detectable with classical imaging 
technique like MRI. It is applied in patients who are potential candidates for surgery. 
Thereby, a non-ionic contrast agent is injected intradiscally into the suspected diseased 
pain evoking IVD. During leakage, the patient has to describe the pain sensation, which 
is thought to arise through the expulsion of pathological metabolites such as 
neuropeptides or cytokines from the disc to the outer part of the annulus, resulting in 
irritation of the nerve endings. A healthy IVD that does not provoke pain serves as an 
internal control. Risk factors of this treatment are infections, allergic reactions or nerve 
root sheath injuries. This diagnostic value also remains a matter of debate as long term 
studies have shown only moderate pain relief. Furthermore, a study by Carragee et al. 
[2009] could demonstrate that the applied discography technique, puncturing the 
intervertebral disc using a small gauge needle, led to a greater progression of disc 
degeneration compared to control (non-punctured) [4]. Thereby the healthy disc which 
serves as a control would be affected. Beside the loss of disc height, this method also 
seems to accelerate disc herniation.  
Surgical treatments for degenerative lumbar diseases, spinal fusion or disc replacements 
are performed if a non-operative method is not helpful. Thereby, either autologous bone 
from anterior or posterior iliac crest (as cancellous bone, corticocancellous bone chips or 
tricortical bone blocks), allograft bone or bone graft substitutes (such as calcium 
phosphates and demineralized bone matrix) are considered for the disc replacement. 
However, in the long term, these treatments have not been proven to be more effective 
than alternative treatment in cases of severe chronic LBP. In addition, physical therapy 
for LBP, and staying as active as possible, can improve the pain relief and function 
melioration in the short term, but also lacking evidence for improvement for long term 
[1]. 
To better understand the sources and mechanism leading to LPB, it is important and 
worthwhile to proceed the investigations on LBP and thereby revealing new and 
appropriate treatments. 
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2. Intervertebral disc 
2.1. Structure 
 
Figure 1. Schematic axial illustration of the IVD showing the NP (inner part) and the AF 
(outer part) (From Norbert Boos, Max Aebi: Spinal Disorders; Fundamentals of 
Diagnosis and Treatment). 
 
The human spine consists of a total of 23 IVDs, which lie between the vertebral body, 
bordered by two end plates (hyaline cartilage), forming the integral part. The main 
structure of the IVD is formed by the nucleus pulposus (NP) and the annulus fibrosus 
(AF) (Figure 1) and is an important tissue for dissipating the high loads of the spine. 
Nutritional substances reach the disc by passive diffusion through the end plates [5, 6] as 
it is an avascular and aneural tissue, except at a sparse penetration of capillaries and 
nerves into the outer part of the AF [7, 8]. The IVD cells are embedded in an acidic pH 
and have to deal with a low oxygen supply (2%). It is reported that IVD cells can even 
remain viable for many days without oxygen [9, 10]. Cells form only 1% of the disc 
volume and are environed by a dynamic matrix structure. This matrix experiences an 
overall degradation during aging, resulting in a weakened ability to retain water, an 
important feature in the functionality of the IVD as a shock absorber. Besides water as a 
major component of the IVD, the extracellular matrix (ECM) (Figure 2) consists of 
abundant proteoglycans like aggrecan, lumican, biglycan, decorin and fibromodulin, 
important key players for the tissue hydration, keeping thereby the pressure within the 
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disc to dissipate the high loads on the spine. Important structure proteins are collagen 
(predominantly collagen I and II) and elastin, responsible for stability and tension of the 
spine. Glycosaminoglycans (GAGs) such as hyaluronic acid, chondroitin sulfate and 
keratan sulfate are mainly responsible for the retention of the water within the IVD due to 
their highly negative charge. Main glycoproteins in the IVD are fibronectin and amyloid, 
one function may be (beside others) to regulate fibril thickness. 
 
 
Figure 2. Simple schematic representation of some important components of the IVD 
ECM. 
 
The AF (fibroblast-like cells) defines the outer part of the IVD. It consists of about 60% 
collagen which are organized as fibres (major type I collagen) to ensure stability in the 
spine. These fiber bundles are arranged in a criss-cross pattern [5]. The NP (chondrocyte-
like cells) is a gelatinous fluid consisting of approximately 30% of randomly organized 
collagen fibres (more type II collagen), possessing more proteoglycans than the AF. The 
NP provides flexibility and functions as the shock absorber of the spine. For the 
development and differentiation to AF and NP, notochordal cells seem to play a leading 
role [11]. Some studies provide evidence that NP cells are notochordal cells in origin [12, 
13]. 
The determination of typical markers for NP and AF cells for the discrimination has not 
been very successful so far. One study for instance tried to overcome this problem by 
comparing collagen I (Col-I), collagen-II (Col-II) and aggrecan synthesis ratio of NP and 
AF cells with articular chondrocytes (AC). They could only show a different distribution 
of these structure proteins [14]. Minogue et al. [2010] [15] as well as Power et al. [2011] 
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[16] tried to identify genes that could be used to distinguish NP cells from AC and AF in 
bovine and human respectively, where they came up with several genes either to be up or 
down regulated. For a fast and easy characterization and discrimination of NP and AF 
cells, a specific marker is unfortunately still missing.  
As the ECM of the IVD is a very dynamic structure, it gets constantly anabolized and 
catabolized. Key players in this action are degrading enzymes such as matrix 
metalloproteinases (MMPs), aggrecanases, cathepsin and hyaluronidases (Hyals) [5, 17].  
 
2.2. Degenerated intervertebral disc 
 
 
 
Figure 3. Representation of the degeneration of the IVD. Left side shows a healthy 
young disc, right side demonstrates an aged degenerated disc. (Pictures provided by 
Norbert Boos). 
 
During aging, the IVD is degenerated and thereby suffers a significant loss in disc height 
(Figure 3). This process of disc degeneration already begins early on in life (20 yrs of 
age) and is characterized by a higher catabolism then anabolism of the disc tissue leading 
to an overall matrix breakdown. The degeneration is also accompanied by a calcification 
of the endplates [18], which might contribute to the reduced nutrient transport, measured 
to be present in degenerated IVDs in a study of Grunhagen et al. [2006] [6]. Not only is 
aging a factor leading to the degeneration of the disc tissue. As there is a high mechanical 
demand on the IVD, also mechanobiological effects have to be considered, as well as the 
change of osmotic pressure as its consequence. Compression on the disc leads to shearing 
and tensile stresses and radial expansion. As resident cells interact with matrix 
compounds, the loads which are distributed on the proteoglycan-collagen rich ECM will 
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lead to a cellular response. This may contribute to tissue failure, depending on loading 
type, magnitude or duration [19]. Whereas low frequency of compression and high stress 
on a motion segment in a rodent model led to an increase in proteoglycan content [20], 
high frequency of loading increased mRNA levels of catabolic enzymes like MMPs or 
aggrecanases. Several studies in human have also confirmed a general up-regulation of 
mRNA and protein synthesis of degrading enzymes such as MMPs [21-23] or 
aggrecanases [24-27] during disc degeneration. In addition, results from a study using a 
rabbit model of intervertebral disc degeneration demonstrated that the expression of 
endogenous inhibitor of MMPs, named tissue inhibitor of metalloproteinase 1 (TIMP-1), 
remained low during degeneration process [28]. The expected consequence of these 
findings fits with the observation of different other studies documenting an accumulation 
of matrix degradation products such as fragmented fibronectin [29, 30] and aggrecan [27, 
31, 32] in degenerated discs. Furthermore, decreases in aggrecan and collagen II mRNA 
level have been observed in a rabbit model of IVD degeneration. This loss of aggrecan 
may support further degeneration of the IVD, as aggrecan has been shown to protect 
cartilage collagen from proteolytic cleavage [33]. Further studies by Antoniou and 
Hollander et al. [1996] showed denatured collagen type II and a loss of proteoglycans are 
more prevalent in a degenerated disc [34-36] resulting in a loss of hydration and osmotic 
pressure [37]. Degenerated IVDs have also been reported to be greater innervated [38, 
39], but whether it is more vascularized or not is a current debate as different studies 
show opposite results [39, 40]. The activated innervations could be partly due to the loss 
of aggrecan during degeneration as an in vitro study showed that human IVD aggrecan 
inhibited nerve growth [41]. Furthermore, an increased NO production was observed 
[42]. It is known that NO is able to react together with superoxide to form peroxynitrite, 
which in turn has been shown to induce MMP expression [43]. Degenerated and aged 
IVDs also show a higher distribution of TNF-α, its receptor and the activating TNF-α-
converting enzyme [44] as well as higher level of IL-1β and IL-1β receptor [45]. In 
addition, a higher formation of oxidation products have been detected. Specifically, levels 
of advanced glycation endproducts (AGE) [46] such as carboxymethyl-lysine (CML) 
together with a high AGE receptor (RAGE) expression level [47] were shown to be 
increased compared to a young disc. Furthermore the loss of notochordal cells seems to 
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be implicated in the degenerative process of the IVD as demonstrated by Erwin et al. 
[2011]. They could show that these cells protect NP cells from apoptosis and that they 
lead to an up-regulation of genes contributing to anabolic activity and matrix protection 
[48]. 
Several studies exist which investigated the risk factors for disc degeneration. A more 
frequent disc degeneration was observed in smokers [41] and individuals with reduced 
physical activity [49]. In general we can say that besides a genetic influence, also 
environmental factors have an influence on disc degeneration, as discussed by Battié 
[1995] [50]. This is further supported by a longitudinal MRI imaging investigation of 
lumbar disc degeneration in asymptomatic individuals conducted by Elfering et al. [2002] 
to investigate risk factors for the development or deterioration of lumbar disc 
degeneration [51]. They could show in a 5-year follow up assessment that the extent of 
disc herniation, lack of sports activities and night shift work were significant predictors 
for disc degeneration. 
 
2.3. Symptomatic degenerated intervertebral disc 
There is a certain patient subpopulation developing pain sensation during degeneration of 
the IVD, leading to so-called discogenic back pain. As the morphology of these 
symptomatic discs is the same as within the asymptomatic IVDs and no alteration is 
detectable with classical imaging technique like MRI, provocative discography is often 
used as a method to identify the source of pain. In fact, it is currently the only means to 
differentiate symptomatic from asymptomatic disc degeneration. However, the accuracy 
of this test is still challenged, as clinical outcomes could not prove a significant 
melioration of pain relief after removal of the suspected diseased disc [52, 53].   
What contributes to a symptomatic degenerated disc is still elusive. So far it has been 
shown that symptomatic IVDs secrete high levels of PGE2 as well as pro-inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, IL-8 [44, 54-56], demonstrated e.g. by the 
increased TNF-α positive cells measured in patients with degenerative disc diseases and 
LBP [57]. A study by Lee et al. [2009] could detect a significant higher level of TNF-α 
and IL-8 in patients with degenerated disc diseases compared to the group with herniated 
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nucleus pulposus [58]. Current findings of elevated cytokines in disc degenerated 
diseases (DDD) are shown in table 1.  
 
Table 1: Elevated expression level of cytokines in disc degenerated diseases (DDD). 
Elevated cytokine 
in DDD 
Detection  
of 
Comparison 
 to Reference 
IL-1β Protein control Akyol et al. [2010] [56] 
 
mRNA + 
protein 
degree of DD Le Maitre et al. [2007] [45] 
TNF-α Protein HNP Lee et al. [2009] [58] 
 Protein Age +  degree of DD Weiler et al. [2005] [59] 
 Protein control Akyol et al. [2010] [56] 
 Protein degree of DD Dongfeng et al. [2011] [57] 
 Protein Age +  degree of DD Bachmeier et al. [2007] [44] 
 
mRNA + 
protein 
degree of DD Le Maitre et al. [2007] [45] 
IL-2 Protein control Akyol et al. [2010] [56] 
IL-4 Protein control Akyol et al. [2010] [56] 
IL-6 Protein Sciatica Burke et al. [2002] [60] 
IL-8 Protein Sciatica Burke et al. [2005] [60] 
 Protein HNP Lee et al. [2010] [58] 
IL-10 Protein control Akyol et al. [2010] [56] 
IL-12 Protein control Akyol et al. [2010] [56] 
IL-17 Protein control Shamji et al. [2010] [61] 
IFN-γ Protein degree of DD + 
scoliosis 
Cuellar et al. [2010] [62] 
control=age matched autopsy, DD=disc degeneration, HNP=herniated nucleus pulposus 
 
These cytokines are widely discussed to have the potential to provoke pain sensation [63-
67]. For instance, disc herniation commonly results in radicular pain, which is considered 
as a result of the mechanical compression and chemical irritation of the dorsal root 
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ganglion (DRG) and/or spinal nerve root. Several interesting studies with animals 
demonstrated now a contribution of inflammatory cytokines in the development of pain 
sensation. In a study of Cunha et al. [1991], a dose-dependent hyperalgesia was evoked 
in the hind paw of rats by an injection of IL-8, which could be lowered with symphatic 
neurone-blocking agent (guanethidine), dopamnine1 receptor or β-adrenoceptor 
antagonists [68]. The role of TNF-α  in NP mediated pain was demonstrated by different 
studies. It could be shown that an enhanced response of rats to noxious heat and 
mechanical stimuli after the application of nucleus pulposus on DRG was due to the 
TNF-α contained in the NP [69, 70]. The study of Rothman et al. [2009] detected 
elevated mRNA levels of TNF-α, IL-1β and IL-6 in the spinal cord and ipsilateral DRG 
of rats 1 hour later after applied compression at C7 root for 15 min. Furthermore they 
observed an increased mechanical allodynia in these treated rats, assessed with a classical 
method by measuring paw withdrawals of the animal, stimulated with von Frey filaments. 
When they neutralized TNF-α action with TNF-receptor-1, they observed decreased 
allodynia in these treated rats and could show that inflammatory cytokines contribute to 
lumbar radiculopathy [66]. There are several studies demonstrating a role of IL-6 in 
nociception and pain [64, 71-74]. A study by Arruda et al. [1998] measured a central, 
spinal production of IL-6 in response to a peripheral nerve injury in a rat model [73]. 
Intrathecal injection of a neutralizing antibody for IL-6 significantly decreased the 
provoked allodynia in these rats [75]. Another study measured an increased mRNA level 
of IL-6 in the DRG of mice following constriction nerve injury [76]. Further, Ramirez et 
al. [2008] detected an increased IL-6 receptor level after sciatic nerve crush injury in 
schwann cells [77]. Several studies have also reported a correlation between nerve 
ingrowth in diseased IVD and pain, and claim that discogenic back pain is accompanied 
by a greater innervation into the disc tissue [78-80].  
 
As both symptomatic and asymptomatic degenerated discs can be morphologically very 
similar, it is reasonable to search for biochemical differences. In relation to an aged and 
degenerated disc, there are several potential factors which can act as pro-inflammatory 
and catabolic mediators, thereby evoking pain sensation and supporting IVD 
degeneration. These will be discussed further in the next chapter. 
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3. Pro-inflammatory and catabolic mediators 
3.1. Pro-inflammatory cascade 
3.1.1. TLRs 
The initial sensing of infection is mediated by innate pattern recognition receptors 
(PRRs), which include the Toll-like receptors (TLRs). The PRRs recognize broad 
structural motifs, called the pathogen-associated molecular patterns (PAMPs) which are 
highly conserved among microbial species but are generally absent from the host, as well 
as endogenous molecules released from damaged cells, termed damage associated 
molecular patterns (DAMPs). Sensing of PAMPs and DAMPs lead to an up-regulation of 
genes involved in inflammatory response [81]. 
The TLRs are well characterized, consisting of a leucin-rich region at the N-terminus 
being glycosylated, a trans-membrane helix and a cytoplasmic Toll/IL-1R homology 
(TIR) domain [82]. In humans there are so far ten different TLRs described. On the 
plasma membrane located are TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11, in the 
endolysosome TLR3, TLR7, TLR9 and TLR10. They recognize the different PAMPs and 
DAMPs, and so far it is assumed that LPS is specifically recognized by TLR4, 
lipoproteins by TLR2, dsRNA by TLR3, and flagellin by TLR5 [83]. Upon ligand 
binding, the molecule is sandwiched between two extracellular domains, forming an “m”-
shaped dimer. TRL2 can build a dimer with TLR1, recognizing triacylated lipopeptides, 
or TLR6, responding to diacylated lipopeptides, and complexing additionaly with CD14. 
TLR4 forms a homodimer and complexes with the co-receptor MD-2 as well as CD14 or 
dimerizes with TLR6 together with the cofactor CD36. LBP (LPS-binding protein) also 
acts as a cofactor for surface TLRs. It can bind LPS as well as lipoteichoic acid, 
peptidoglycan and lipopeptides, facilitating the response by transfer of these PAMPs to 
CD14. CD36 is also a cofactor of TLR2-TLR6 dimerization. Other accessory molecules 
are TRIL (for TLR3 and TLR4), progranulin (for TLR9), HMGB1 (for TLR9, possibly 
TLR3 and TLR7) and LL37 (possibly for TLR7 and TLR9) [83]. Upon dimerization of 
the TLRs, the TIR domain dimers in the cytosol are recognized by adaptor proteins such 
as MyD88, MAL, TRIF and TRAM. The triggered downstream signalling leads to the 
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expression of inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-12, antiviral and 
anti-pathogen proteins and to the initiation of the adaptive immune response [81]. 
It has been recognized in the recent years that TLRs are not restricted to the initiation of 
the innate and adaptive immune reaction, but are also important for the maintenance of 
homeostasis and are thus implicated in chronic inflammatory and autoimmune diseases 
[84]. PRRs are not only expressed on monocytes/macrophages but also on non immune 
cells such as synovial fibroblast [85-87], chondrocytes [88, 89] and hepatic cells [90] 
showing an increased expression of certain TLRs in degeneration or diseases e.g 
osteoarthritis (OA) [89], rheumatoid arthritis (RA) [86] or playing a role in fibrosis or 
liver carcinogenesis [90]. Downstream signalling targets of TLRs known today are the 
NF-κB pathway and MAP kinases [81-83, 91].  
 
3.1.2. NF-κB  
Nuclear factor kappa enhancer binding protein (NF-κB) regulates diverse biological 
processes including immunity, inflammation, cell proliferation, differentiation, apoptosis 
and tumorigenesis [92-94]. The NF-κB family consists of five protein subunits, p50, p52, 
p65 (also known as RelA), c-Rel and RelB [95], shuttling between cytoplasm and nucleus 
either as homodimer or heterodimer. p50 and p52 are produced by proteasomal 
processing of the precursors p105 and p100. The NF-κB dimers are retained in the 
cytoplasm by IκB proteins (IκBα, IκBβ, IκBγ, IκBε, IκΒ−R and Bcl-3). IκB 
phosphorylation, ubiquitination and proteasomal degradation leads to the release of the 
NF-κB dimer, which is now free to translocate into the nucleus and to bind to its 
consensus sequence on the DNA together with co-activators such as p300/CBP. 
Stimulation of the cell with TNF-α, IL-1β or TLR ligands activate the canonical NF-κB 
pathway. This includes the IκB kinase (IKK) complex with its two catalytic subunits 
IKKα and IKKβ, responsible for the phosphorylation of IκB, being NEMO (NF-κB 
essential modulator, or IKKγ) as a regulatory subunit and p50/p65 as the dimer. In the 
nucleus, further modification of NF-κB can be phosphorylation, methylation, acetylation 
and ubiquitination to either enhance or weaken the affinity to the DNA or to the co-
activators. Upon activation of transcription of target genes, it also up-regulates IκBα, 
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which can enter the nucleus and transport NF-κB back to cytoplasm and thereby forming 
a negative feedback loop. The noncanonical NF-κB pathway includes activation of NF-
κB-inducing kinase (NIK) and the IKKα subunit, phosphorylation and subsequent 
polyubiquitination of p100, proteasomal processed to p52, and translocation of the dimer 
p52/Rel-B into the nucleus [96]. 
 
3.1.3. MAP kinases 
Mitogen-activated protein (MAP) kinases are serine/threonine-specific protein kinases 
that respond to extracellular stimuli (mitogens) such as e.g. growth factors, cytokines or 
oxidative stress, having their signals further transmitted by receptor tyrosine kinase 
(RTK), cytokine receptors but also G protein-coupled receptors (GPCRs). Upon 
stimulation, MAP kinases are activated by their upstream kinases, the MAPK kinase 
(MAPKK) and MAPKK kinase (MAPKKK), specificity mediated by binding to scaffold 
proteins. MAP kinases then translocate as a dimer into the nucleus and phosphorylate 
many different proteins. Recent finding also suggest nuclear importing proteins are 
involved in this step. Among the target proteins of MAP kinases are various transcription 
factors, controlling early-response genes which regulate various cellular activities such as 
cell cycle (e.g. c-Fos, c-Jun) and differentiation or immune and inflammatory responses. 
One of the best characterized pathways is the RTK/Ras/MAP kinase pathway. After 
ligand binding, the dimerization of RTK leads to the activation of its tyrosine kinase and 
autophosphorylation. Subsequent binding of adapter proteins activates Ras, a GTPase, by 
the exchange of GDP to GTP, which in turn then binds Raf (a MAPKKK), also a 
serine/threonine kinase. Hydrolysis of this GTP releases Raf, which then triggers 
phosphorylation of MEK (a MAPKK). MEK activates its MAP kinase (ERK1/2) by 
phosphorylation on threonine and tyrosine residues [97, 98]. In mammals, fourteen MAP 
kinases have been characterized. Among the MAP kinase family, the conventional one 
are the extracellular signal-regulated kinase 1/2 (ERK1/2 also named MAP kinase 3 and 
1), ERK5 (also named MAP kinase 7), Jun N-terminal kinase (JNK1/2/3 also named 
MAP kinase 8, 9 and 10) and the four p38 isoforms α, β, γ , δ, (also named MAP kinase 
14, 11, 12 and 13, respectively) [97, 99].  
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Activators and target genes of NF-κB and MAP kinases revealed in the past few years 
concerning inflammatory and catabolic reaction in IVD diseases are summarized in a 
publication of Wuertz et al. [2008] [100]. For instance, NF-κB pathway in IVD is 
activated by IL-1β, TNF-α and peroxynitrite, MAP kinases by IL-1β, TNF-α, low 
oxygen and low osmolarity. As target genes for NF-κB, ADAMTs and MMPs were 
identified, for MAP kinases collagen, iNOS, MMPs and TIMPs. 
 
3.1.4. Cytokines; the wide variety of IL-6 effects 
Cytokines are low-molecular–weight regulatory proteins or glycoproteins secreted by 
white blood cells and various other cells in the body in response to a number of discrete 
stimuli. Their secretion is generally short-lived, ranging from a few hours to a few days. 
These proteins assist in regulating the development of immune effector cells, and some 
cytokines possess direct effector functions of their own. Cytokines bind to specific 
receptors on the membrane of target cells, triggering signal-transduction pathways that 
ultimately alter gene expression in the target cells. Cytokines can mediate biological 
effects at picomolar concentrations, because their affinities to their receptor are high. The 
activity of cytokines was first recognized over 50 years ago, have since been classified in 
4 different groups based on their structure and function: the hematopoietin family, the 
interferon family, the chemokine family and the tumor necrosis factor family. Common 
to all groups are the low molecular weight (among 30 kDa) and a high degree of 
α-helical structure. 
Cytokines are not only required for the regulation of hematopoiesis, proliferation and 
differentiation, thereby only affecting target cells bearing appropriate receptors, but are 
also important for the development of cellular and humoral immune responses, the 
induction of the inflammatory response as well as wound healing. Cytokines often induce 
the synthesis of other cytokines, resulting in a cascade of activity, culminating in either 
synergistic or antagonistic effects. IL-6 is known to be secreted by macrophages, 
fibroblasts and endothelial cells and is described to act in the innate immune system and 
influences the adaptive immunity by stimulating the proliferation and antibody secretion 
of B cell lineage. In the hematopoiesis it is released by myeloid progenitor cells and 
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directs the differentiation to leukocytes, mainly responsible for platelet production. A 
redundant and pleiotropic effect of IL-6 together with IL-1β and TNF-α is the induction 
of fever via the prostaglandin synthesis stimulation, the synthesis of acute-phase proteins 
and the increase of vascular permeability (Goldsby: Immunology). IL-6 has a soluble 
(sIL-6R) and a membrane bound receptor (gp130). sIL-6R is generated either by 
proteolysis of membrane bound protein or by alternative splicing. gp130 can consists of 
an additional subunit, a ligand specific subunit designated IL-6Rα (gp80) [101], but is so 
far only found on some cells including hepatocytes and some leucocytes [102]. Signalling 
through its dimerization with gp130 receptor leads to the activation of the JAK/STAT 
pathway [103]. More and more functions of IL-6 are becoming realized, suggesting that 
IL-6 not only plays an important role in the acute phase in the immune system, but also in 
catabolic metabolism, apoptosis and even in mediating pain. A participation of IL-6 in 
pathophysiology includes autoimmune diseases, osteoporosis, alzheimer’s, neoplasia 
aging and cancer [104]. 
Studies demonstrating a role for IL-6 in nociception and pain are discussed in the chapter 
of symptomatic degenerated intervertebral disc. In summary, IL-6 and its receptor were 
found to be up-regulated in peripheral nerves, DRG and spinal cord during experimental 
pain. Furthermore, IL-6 increased the responses to thermal and mechanical stimuli and 
pain in animals, which could be prevented by neutralizing IL-6. Moreover, an elevated 
IL-6 level has been found in disc tissue of patients with discogenic back pain compared 
to sciatica patient [60]. It is therefore one of our main aims to reveal the responsible 
factors involved in regulating IL-6 synthesis in symptomatic degenerated discs.  
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3.2. The ECM as an inflammatory and catabolic mediator 
There has now been recognition that degradation products of the ECM can effect an 
inflammatory reaction involving specific immune cells (e.g. macrophages, B-cells, T-
cells) but also extended to other cells such as e.g. fibroblasts, chondrocytes, smooth 
muscle cells or malignant cells [105]. Furthermore, several studies could demonstrate a 
participation of ECM fragments in degenerative and destructive cartilage diseases and 
thus may play a central role in mediating OA and RA. 
To date, the majority of studies investigating the involvement of ECM fragments in 
disease have been focused on fibronectin fragments. In a study of Forsyth et al. [2002] it 
has been shown that fibronectin fragments, which have been found to be increased in 
cartilage and synovial fluid of OA and RA patients [106, 107], activate MMP13 in human 
articular chondrocytes through the MAP kinases p38, ERK and JNK pathway by integrin-
mediated signalling [108], claiming that this may play a role in the process for 
progressive cartilage degradation in arthritis. NF-κB-dependent increases in cytokine and 
chemokine production [109, 110], as well as NO production in human chondrocytes 
[111], were detected upon treatment with fibronectin fragments [112, 113]. In 
macrophages, fibronectin fragments increased secretion of MMP9, MMP12, IL-1, IL-6 
and TNF-α [113-116]. Studies from Homandberg et al. [1992] demonstrated that 
fibronectin fragments causes chondrolysis in vitro [117] associated with release of 
catabolic cytokines [109] and severe depletion of cartilage proteoglycans [118] in vivo 
[119]. Furthermore, a study conducted in rabbit IVD cells demonstrated that exposure to 
fibronectin fragments leads to an up-regulation of MMPs [120]. 
Such effects are not limited to fibronectin fragments only, but may also extend to other 
ECM components such as collagen, laminin and elastin. Jennings et al. [2001] observed 
an increased gelatinase activity and an induction of matrix degradation in cultured bovine 
and human chondrocytes and human cartilage explants when fragmented Col-II was 
added [121]. Fichter et al. [2006] investigated these effects in more detail in a study 
conducted with bovine articular chondrocytes. They demonstrated a stimulating effect of 
Col-II fragments on mRNA and protein level for MMP2, MMP3, MMP9 and MMP13 
[122]. Data from studies by Guo et al. [2009] support these findings where fragments of 
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Col-II up-regulated proteinases MMP1, MMP3, MMP13 and ADAMTS-5 and decreased 
proteoglycan content in a cartilage tissue culture model, thereby playing a role in 
physiologic cartilage damage [123]. Klatt et al. [2009] revealed a p38- and NF-κB-
dependent increase in MMPs and cytokines upon Col-II treatment of primary human 
chondrocytes [124]. 
Also laminin and elastin fragments have been shown to possess inflammatory and 
catabolic effects. Several studies could demonstrated that laminin fragments induce 
expression of MMP9 [125-127] and TNF-α in monocytes/macrophages [128]. Damaged 
elastin for instance is implicated in respiratory diseases [129]. It is reported that elastin 
fragments in the airway as well as in other organs can cause chemotaxis and cell 
proliferation [130-134]. Different studies on the biological effect of degraded elastin on 
cells proclaim an overall inflammatory and remodeling profile [130, 135, 136], as they 
have been shown to increase cytokine and MMP9 expression in lymphocytes [137]. 
Elastin fragments are also proposed to be involved in the pathogenesis of COPD [138]. In 
asthma, an increased neutrophil elastase level has been measured [139-141]. 
A study conducted in IVD cells by Haschtmann et al. [2008] characterized the biological 
response of isolated IVD fragments to in vitro culture condition and observed an 
increased necrotic and apoptotic cell death combined with a catabolic, pro-inflammatory 
and chemoattractant gene response [142]. 
Beside the above discussed proteolytic arised fragments of the ECM such as e.g. 
fibronectin, collagen, laminin or elastin, it has also been demonstrated that fragments of 
the polysaccharide hyaluronic acid exhibit important inflammatory and catabolic effects.  
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3.3. Hyaluronic acid 
3.3.1. Structure and function 
  
 
 
Figure 4. Representation of the viscous HMWHA (upper part) and the repeating 
glucuronic acid and N-acetyl-glucosamine (lower part). 
 
Hyaluronic acid, or hyaluronan (HA) (Figure 4), is generally regarded as an extracellular 
matrix component being a high molecular polysaccharide composed of repeating O-
linked disaccharide glucuronic acid and N-acetyl-glucosamine (-D-glucuronic acid-β1,3-
N-acetyl-D-glucosamine-β1,4-]n. At high molecular size, it can reach a weight of 4 x 102 - 
2 x 104 kDa and thereby be composed of 2 x 103 - 105 sugars. It is known to facilitate cell 
locomotion, proliferation, differentiation and participates in wound healing. HA 
dependent pericellular matrix consists of a network of HA filaments, associated with 
proteoglycans like aggrecan and stabilizing molecules such as link proteins like tenascin, 
TSG-6, pentraxin, TSP-1 and inter-α-inhibitor. HA is anchored to the cell surface via 
CD44 [143, 144] or RHAMM (receptor for hyaluronan mediated motility, CD168) [145-
148], with CD44 being the most widely expressed HA receptor [149-152] that plays an 
important role in detaching and locomotion of the cells. CD44 is an ubiquitous 
  31 
multistructural and multifunctional cell surface adhesion molecule involved in cell-cell 
and cell-matrix interaction. There exist several isoforms, encoded by a single gene and 
generated by alternative splicing (extracellular part, membrane proximal region) and 
post-translational modifications (N-glycosylation, O-glycosylation, attachment of GAGs, 
sulfation). The different spliced variants as well the degree of N-glycosylation affects the 
ligand-binding characteristic and can alter the affinity to HA [153-158]. CD44 has one 
transmembrane spanning region, a N-terminal extracellular domain and a C-terminal 
cytoplasmic functional tail with several phosphorylation sites that appear to regulate the 
interaction of CD44 with the cytoskeleton. Additional CD44 ligands include osteopontin, 
serglycin, collagens, fibronectin and laminin [159-161]. CD44 is implicated in tumor 
invasion and metastasis. In cancer cells, CD44 is cleaved at the membrane-proximal 
region, demonstrated to be inhibited in a cell free assay by the tissue inhibitor of 
metalloproteinase-1 (TIMP-1) [162]. Alteration in CD44 and HA interaction is not only 
implicated in cancer progression [163-165], but also in RA [166]. CD44 plays a crucial 
role in inflammation [167]. The soluble form of CD44 (sCD44), which seems to be 
proteolytically cleaved cell-surface CD44 [162], has been detected to be low in the 
plasma in immunodeficiency and is increased in malignant diseases, in immune 
activation and inflammation [168]. 
RHAMM has also different isoforms by alternative splicing and is described to be a non-
integral cell surface hyaluronan receptor and is reported to be part of a multimeric cell 
surface-bound complex, termed the HA receptor complex (HARC) [169]. The interaction 
of RHAMM and HA triggers a phosphorylation cascade [170], leading to cell signalling 
and migration. It has been implicated in cancer progression as evidenced by its abnormal 
expression on the surface of B and plasma cells of patients with multiple myeloma [171, 
172] or advanced prostate cancer diseases [173]. Together with CD44, it forms 
complexes with ERK and sustains high basal motility in breast cancer cells [174]. It has 
been shown that RHAMM can compensate CD44 action in inflammation [175] or wound 
healing [176] and that it is physically linked to CD44 in aggressive breast cancer cell 
lines [177]. It is reported that RHAMM is poorly expressed in normal human tissues and 
is increased during wound repair in response to hypoxia and fibrogenic factors such as 
TGF-β1. When stimulated with TGF-β1, RAHMM has been shown to promote cell 
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locomotion together with HA in a fibroblast cell line. TGF-β1 even triggers the 
transcription, synthesis and membrane expression of RHAMM [178]. 
With its highly charged character, HA participates in the hydration of the tissue and can 
act as a space filler, lubricant or shock absorber. It is abundantly present e.g. in the ECM 
of connective, epithelial and neural tissue, the cartilage, the eye, in the fluid of joint 
capsule and the umbilical cord. It has now also been reported that HA is not restricted to 
the extracellular milieu, but is also present intracellularly. It was found in rough 
endoplasmic reticulum membranes, plasma membranes, inside lysosomes, multivesicular 
bodies, caveolae and nuclei. Nuclear staining was associated with the dense chromatin 
[179, 180]. Ripellino et al. [1988] discovered HA in developing and adult rat brain, 
showing intense intracellular staining in neurons and astrocytes [181]. HA was localized 
to proliferating cells [182] and furthermore shown to accumulate in premitotic and 
mitotic cells, colocalized with microtubules, RHAMM and the mitotic spindle [183]. 
Studies in breast cancer cells implicate an overexpression of intracellular RHAMM and 
suggested to substitute it by the name “intracellular hyaluronic acid binding protein” 
IHABP [184-186]. IHABP is also thought to be linked to the cell surface by either 
glycosylphosphatidylinositol anchor or by a so far unidentified linker protein [187]. Other 
recently identified intracellular HA-binding proteins are P32 and CDC37 [179, 188-190]. 
HA is synthesized on the cytoplasmic surface of the plasma membrane [191] by several 
HA synthases (HAS) which are glycosyl transferases and transferred to the outside 
possibly by the multi-drug resistance (MDR) transporter system [192, 193]. It is not 
sulfated like all other GAGs. In the ECM, HA serves as the backbone for a non-
covalently binding to the molecule aggrecan, which is composed of other GAGs such as 
chondroitine sulfate and keratan sulfate, together promoting tissue hydration and 
sustaining the function of the NP as a shock absorber.  
Three pathways are nowadays known to degrade HA. The local turnover includes 
binding, internalization and degradation within the cell by different hyaluronidases 
(Hyals) (Figure 5). It has been shown that IL-1β and TNF-α are able to induce activation 
of certain Hyals. At tissue level, HA is released, drained into the vasculature and 
lymphatic, with final steps at liver, kidney and possibly spleen. Scission of HA can also 
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be achieved by free radicals [194-196] leading to different sizes of fragmented HA 
(fHA).  
 
Figure 5. Schematic representation of HMWHA cleavage. 
 
Beside the mentioned structural properties, HA also has a signalling function, depending 
on HA size. High molecular weight HA (HMWHA) has been described to be anti-
angiogenic [197, 198], anti-inflammatory and immunosuppressive [199, 200] whereas 
fHA can have opposite effects like angiogenic, inflammatory and immunostimulatory and 
even enhance cancer progression. Depending on cell type, different responses and 
involved receptors and pathways upon fHA stimulation have been described in the past 
decades. 
 
3.3.2.   Hyaluronic acid fragment effects, engaged receptors and 
pathways 
Depending on the size of the investigated fHA and cell type, different responses 
involving various receptors and pathways have been described so far upon treatment with 
fHA. The majority of studies to date have focused on examining the effects of fHA on 
human articular chondrocytes. Several studies exist regarding the effects of fHA on 
fibroblasts, macrophages, dendritic cells or human melanoma (see table 2). However, no 
studies have sought to determine the effects of fHA on IVD cells. 
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Table 2: Elevated expression level of cytokines, MMPs and NO in fHA treated cells. 
Increased 
mRNA 
level 
Increased 
protein 
level 
Engaged 
receptor 
Not 
engaged 
receptor 
General 
pathway fHA size 
 
Cell type Reference 
IL-6 IL-6 
TLR4  
  
NF-κB 
4-mer 
Mouse 
chondrocytes 
 Campo et al. 
[2012] [212] 
IL-1β IL-1β    
TNF−α TNF−α       
IL-6 IL-6 
TLR4 and 
CD44 
  
NF-κB 
6-mer 
Human 
chondrocytes 
 Campo et al. 
[2010] [208] 
IL-1β IL-1β    
TNF−α TNF−α       
MMP3 MMP3       not determined 
Bovine 
chondrocytes 
Schmitz et al. 
[2010] [213] 
            
 
IL-8 
 
IL-8 TLR4     4-6-mer 
  
Human 
melanoma 
Voelker et al. 
[2007] [207] 
MMP2 MMP2   TLR4     
IL-2   TLR2  NF−κB 200 kDa (≈1000-mer) Primary 
lymphocytes 
Scheibner et al. 
[2006] [206] 
MMP2 MMP2   TLR4       
MIP-1α MIP-1α TLR2 TLR4 CD44   
200 kDa 
(≈1000-mer) 
Murine 
alveolar 
macrophage 
MH-S 
Scheibner et al. 
[2006] [206] 
              
iNOS iNOS       4-8-mer Human and 
bovine 
chondrocytes 
Iacob et al. 
[2006] [210] 
  NO           
  NO CD44     4-8-mer COS-7 Iacob et al. [2006]  
iNOS iNOS     JNK 500-800 kDa 
(≈2500-4000-
mer) 
Murine 
microglia 
Wang et al. 
[2004] [214] 
 NO   p38   
MMP13 MMP13   TLR4 CD44 
NF−κB 
not 
determined 
MEF, 3LL Fieber et al. [2004] [202] 
MMP9 MMP9  TLR4 
CD44 
RHAMM 
  
      
MMP13 MMP13   CD44  NF−κB 
6-mer Bovine chondrocytes 
Ohno et al. 
[2006] [211] 
       p38   
  TNF−α TLR4 TLR2 p38 4-6-mer Dentritic cells Termeer et al. [2002] [215] 
    ERK    
        NF−κB       
MME MME       
200 kDa 
(≈1000-mer) Mouse alveolar 
macrophage 
Horton et al. 
[1999] [205] 
              
 IL-8    800 kDa 
(≈4000-mer) Human uterine 
fibroblasts 
Kobayashi et al. 
[1997] [216] 
 IL-1β     
  TNF−α CD44         
IL-8         35 kDa  (≈175-mer) Murine alveolar 
macrophage 
MH-S 
McKee et al. 
[1996] [204] 
MIP-1α MIP-1α      
MIP-1β MIP-1β CD44         
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For instance, in dendritic cells, Termeer et al. [2002] showed that fHA (20 µg/ml, 4-6-
mer) treatment resulted in an increased TNF-α synthesis with an involvement of p38, 
ERK and NF-κB. They also monitored an engagement of TLR4 but not TLR2, 
interestingly together with a downregulation of mRNA for TLR4 and TLR2 level as well 
as a decreased TLR4 surface-expression upon fHA treatment [201].  
Interested in tumor progression, Fieber et al. [2004] investigated fHA response in tumor 
cells. They detected an induced transcription of MMP9 and MMP13 upon fHA (100 
µg/ml, size not determined) treatment, but ruled out an involvement of the hyaluronan 
receptors CD44, RHAMM/IHABP and TLR4. They suggest with their study that HA 
degradation in tumors or in areas of inflammation might promote invasion or ECM 
remodeling by activating MMP expression [202]. Sugahara et al. [2003] instead 
demonstrated a participation of CD44 in fHA (5-100 µg/ml, 3-18 ds) treated tumor cells. 
They revealed that fHA enhanced CD44 cleavage and tumor cell motility [203].  
In a murine alveolar macrophages cell line (MH-S), chemokine expression was increased 
upon treatment with 35 kDa fHA (100 µg/ml) in a study of McKee et al. [1996] [204]. 
Further, Horton et al. [1999] measured an increased expression of the metalloproteinase 
MME (murine metalloelastase) upon treatment with 200 kDa fHA, suggesting that HA 
fragments may be an important player in inflammatory lung disorders [205]. MH-S was 
also used in a study by Scheibner et al. [2006], in which they observed that the increased 
expression of macrophage inflammatory protein 1α (MIP-1α) upon fHA exposure was 
not due to TLR4 or CD44 engagement but TLR2 [206]. 
TLR4 instead was involved in the response to fHA (50 µg/ml, 4-6 ds) in melanoma cells, 
leading to an induction of IL-8 but TLR4 independent MMP2 up-regulation [207], thus 
fHA might contribute to tumor growth and progression. 
In primary human chondrocytes, Campo et al. [2010] revealed a TLR4 and CD44 
engagement in the induced inflammation (increased mRNA and protein level of IL-1β, 
TNF-α and IL-6) by fHA (10-40 µg/ml, 6-mer) as well as a NF-κB involvement. In 
contrast to the study by Termeer et al. [2002] where a decrease in TLR4 and TLR2 
mRNA was observed, Campo et al. [2010] measured an increase in TLR4 and CD44 
mRNA and protein upon fHA treatment in primary chondrocytes [208]. Further actions 
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of fHA in chondrocytes observed by other groups were the induction of the cleavage of 
CD44 (250 µg/ml, size not determined, also seen with 10 ng/ml IL-1β) [209] and the 
activation of nitric oxide synthase and production of nitric oxide via CD44 (20 µg/ml, 4-
8-mer) [210]. 
In bovine chondrocytes, Ohno et al. [2006] demonstrated that fHA (250 µg/ml, 6-mer) 
enhanced expression of MMP13, mediated in part by CD44. Induction mechanisms were 
associated with the activation of NF-κB as well as p38 MAP kinase [211]. Recent studies 
from Campo et al. [2012] demonstrated a TLR4 dependent increase in cytokines TNF-α, 
IL-1β and IL-6 in mouse chondrocytes upon stimulation with fHA (40 µg/ml, 4-mer) 
with an involvement of the NF-κB pathway [212].  
 
3.3.3. Hyaluronic acid fragments involved in diseases 
A study of Eldridge et al. [2011] showed increased hyaluronic acid fragmentation and 
ROS production during pulmonary ischemia in a mouse model. Pretreatment with an 
antioxidant could reduce ROS as well as fHA production, but did not change Hyal 
activity, suggesting that ROS released during acute ischemia contributes to HA 
fragmentation [217]. In a study of Katsumura et al. [2004], they checked the effect of 
AGE, increased in vitreous of diabetic patients, on HA depolymerization. They could 
measure an increased HA depolimerization in vitro by exposure to light and in 
combination with AGE, claiming that this could provide a new mechanism for diabetic 
vitreopathy [218]. A current study suggests a contribution of fHA in the skin 
inflammation disease ACD (allergic contact dermatitis). By inhibiting ROS formation or 
Hyal activity in a murine keratinocyte cell line or directly in a ACD mouse model, they 
could measure a decreased fHA production together with a melioration of the inflamed 
situation [219]. 
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4. Potential biodrugs for the treatment of LBP 
The great interest of complementary and alternative therapy by the use of natural 
products derived from plants for the treatment of diverse diseases such as arthritis, cancer 
or pain, is demonstrated by the surprising amount of studies investigating healing 
potential of herbal compounds. Since ancient times, phytopharmaceuticals have been 
used for the treatment of inflammatory and other disorders. An amazing high number of 
studies exist for resveratrol, curcuma or triptolide, demonstrating that these substances 
possess great anti-inflammatory and anti-catabolic effects. We were interested whether 
these natural herbs also provide beneficial outcome on IVD cells in regard of disc 
degeneration and as possible treatment substances for discogenic back pain in the near 
future. 
 
4.1. Resveratrol 
 
 
The phytoalexin resveratrol (trans-3,5,4’-trihydroxystilbene) is found in various plants 
such as peanuts, berries or grapes, produced by the plant when under attack of pathogens 
like bacteria or fungi. This polyphenol has attracted great interest in the latest decades as 
a potential biodrug for the treatment against various diseases such as cancer, type 2 
diabetes, osteoarthritis, asthma as well as cardiovascular and neurological diseases, 
because of its documented anti-inflammatory and antioxidant properties. An amazing 
number of in vitro studies are available, investigating resveratrol for different beneficial 
inhibitory purposes on different cell types. Consequently, numerous reviews about the 
effects of resveratrol now exist, describing its various molecular targets and epigenetic 
changes within the cell, and possible therapeutic applications [220-228]. For instance, the 
potential of resveratrol as a therapeutic agent for the treatment of osteoarthritis has been 
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investigated. Zhou et al. [2009] showed that resveratrol is able to promote osteoblastic 
differentiation from pluripotent mesenchymal cells by augmenting the Wnt signalling 
pathway [229]. They subsequently proposed that resveratrol could be a potential 
substance for the prophylactic treatment of osteoarthritis. The investigations of Shakibaei 
et al. [2008] in human IL-1β prestimulated chondrocytes provide evidence that 
resveratrol inhibits the expression of VEGF, MMP3, MMP9 and COX-2. They were 
furthermore able to show that resveratrol has inhibitory effects on apoptosis and NF-κB, 
caspase-3 activation and PARP cleavage [230]. By contrast, several cancer-based studies 
demonstrated enhanced apoptosis induced by elevated resveratrol usage [231-237]. These 
contrary results could be explained by a study of Howitz et al. [2003], who observed that 
low doses (0.5 µM) of resveratrol stimulated activity of SIRT1, while high doses (>50 
µM) had the opposite effect [238]. SIRT1 is a deacetylase and in the active state it 
decreases the activity and half-life of p53, which is a key player in the regulation of cell 
cycle arrest and apoptosis. 
In adipocytes, resveratrol inhibited NF-κB mediated cytokine expression, making this 
compound interesting for an application in chronic inflammatory adipose tissue and 
thereby for type 2 diabetes mellitus as well as cardiovascular diseases [239]. Besides 
having an inhibitory effect on NF-κB activation, resveratrol also influenced MAP kinases 
and AP-1 [240]. 
In vivo studies also showed promising effects. In an asthmatic mouse model, resveratrol 
suppressed IL-4 and IL-5 release by T-helper-2 as well as on eosinophilia and mucus 
hypersecretion, suggesting an application in the treatment of bronchial asthma [241]. 
Sebai et al. [2009] were able to counteract LPS induced acute phase response in rats with 
resveratrol, therefore it could be envisaged as a preventing and healing natural compound 
in endotoxemia induced sepsis [242]. The observed reduced tumorprogression after 
treatment of a mice xenograft model with resveratrol also hold promise [231]. 
Resveratrol already showed promising effects on bovine IVD concerning cartilage 
homeostasis. Li et al. [2008] demonstrated an anabolic effect of resveratrol by the 
increased proteoglycan accumulation in the IVD after treatment with resveratrol [243], 
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thus supporting the need for further investigations into the use of resveratrol as a biodrug 
in diseased IVDs. 
 
4.2. Curcuma (Curcumin) 
 
 
The beneficial effects of curcuma and its component curcumin have been extensively 
studied over the last three decades and include anticancer, antiviral, antiarthritic, 
antioxidant and anti-inflammatory properties. For centuries, curcumin has been used in 
some medical preparation or used as a food-coloring agent. Curcumin is a major 
component of the turmeric, a yellow spice derived from dried rhizomes of Curcuma 
longa. 
In head and neck squamous cell carcinoma, curcumin exhibited anti-cancer properties by 
suppressing NF-κB activation and stimulating apoptosis via up-regulation of p16 and 
p53. It showed inhibitory effects on tumor angiogenesis and metastasis via suppression of 
a variety of growth factors including VEGF, COS-2, MMPs and ICAMs [244]. 
Yodkeeree et al. [2009] demonstrated anti-carcinogenic effects of curcumin in human 
fibrosarcoma cells. They could show that curcumin exhibited a significant inhibition on 
cell invasion and the secretion of active MMP2, MMP9 and urokinase plasminogen 
activator (uPA) [245]. 
Interested in OA and RA, Buhrmann et al. [2010] tested the ability of curcumin to 
modulate chondrogenic differentiation of mesenchymal stem cells (MSCs). Curcumin 
showed inhibitory effects on IL-1β prestimulated MSC cells co-cultured with primary 
chondrocytes. They measured a decreased NF-κB and caspase-3 activation, COX-2 
concentration and increased Col-II, cartilage specific proteoglycans as well as β1-
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integrin, claiming that curcumin facilitated  chondrogenesis of MSC-like progenitor cells 
in vivo [246]. Curcumin also suppressed NF-κB activation in an in vitro study performed 
in human articular chondorcytes by Shakibaei et al. [2007]. They also could show an 
inhibitory effect on COX-2 and MMP9 synthesis as well as a reversion of the IL-1β 
induced Akt activation and downregulation of Col-II and β1-integrin receptor [247]. 
These results indicate that curcumin could serve as a potential naturally occurring anti-
inflammatory agent for treating OA. In a study of Ma et al. [2010], curcumin activated 
p38, decreased COX-2 concentration and caspase-3 activity in cultured podocytes [248]. 
In combination with resveratrol, curcumin inhibited NF-κB mediated cytokine (TNF-α, 
IL-1β, IL-6) expression in adipocytes [239]. In vivo, curcumin (200 mg/kg) suppressed 
mucosal macromolecular leakage, mediated through NF-κB activation, in helicobacter 
pylori-infected rats, suggesting curcumin for the use as a potent antibacterial agent [249]. 
 
4.3. Triptolide 
 
 
Triptolide is a diterpene lacton and extract of the herb Tripterygium wilfordii. It has been 
used for centuries in Chinese natural medicine as an anti-inflammatory agent for diseases 
such as RA. Triptolide has not been as extensively investigated as resveratrol or curcuma, 
but the interest in this natural compound has increased over recent years. There are now 
also many studies available investigating triptolide for its possible use in inflammatory, 
autoimmune and immune deficiency diseases or cancer, due to its potent anti-
inflammatory, immunosuppressive and tumor suppressive activities. 
Interested in anti-inflammatory effects, Matta et al. [2009] used triptolide (50 nM) on 
LPS stimulated macrophages. cDNA microarray analysis revealed that triptolide acts as a 
selective transcriptional blocker, predominatly affecting genes involved in the immune 
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response. They could not observe that triptolide was effecting NF-κB activity [250]. 
Alternatively, Premkumar et al. [2010] demonstrated NF-κB involvement as well as TLR 
and downstream targets such as MyD88 and TRIF in the suppressive effect of triptolide, 
suggesting that triptolide may have multiple cellular targets contributing to its strong anti-
inflammatory and immune suppressive properties [251]. Jonhnson et al. [2011] could 
show that triptolide inhibited proliferation and migration of colon cancer cells. Cell cycle 
was disturbed by decreased RNA levels of c-myc and A, B, C, and D-type cyclins. 
Triptolide also decreased expression of VEGF, COX-2 as well as multiple cytokine 
receptors [252]. In prostate cancer (PC) cells, triptolide inhibited cell growth and induced 
cell death in vitro through caspase activation. In vivo, triptolide suppressed xenografted 
PC-3 tumor growth progression [253].  
 
 
5. Aim of the thesis 
5.1. Purpose 
The methods nowadays to treat discogenic back pain are either conservative in nature or 
dependent on medication, and in the worst cases, invasive through surgical intervention 
with high risks for the patient as well as high costs for the society. The use of medication 
suffers in part from the disadvantage of side effects and surgical treatments lack long-
term benefits. For a better and more specific targeting of the source of discogenic back 
pain, it is worth to reveal the biochemical factors and associated signalling pathways 
leading to this pain sensation. As such, disruption of these signalling pathways through 
the use of locally administered anti-inflammatory and/or anti-catabolic biodrugs with 
analgesic effects may be an alternative and less invasive treatment. 
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5.2. Hypothesis 
As high cytokine levels are detected in patients with discogenic back pain and the fact 
that cytokines may play a role in causing pain sensation directly through nociceptors, we 
hypothesize that these cytokines from symptomatic IVDs, generated by the disc cells 
themself, diffuse through the cleft and tears of the disrupted tissue and irritate the nerve 
endings at the outer part of the AF. We further hypothesize that certain biochemical 
changes during disc degeneration, such as fragmentation of matrix compounds, are 
responsible for the innitiation of an inflammatory and catabolic cascade.  
 
5.3. Aims 
We are therefore interested  
- whether hyaluronic acid fragments (fHA) have the potential to stimulate the 
synthesis of pro-inflammatory and catabolic mediators in IVD cells in vitro. 
- which receptors are responsible for regulating IL-6 levels upon fHA 
treatment. Possible candidates are TLR2, TLR4, CD44 and RHAMM. 
- which transduction pathways are involved leading to IL-6 up-regulation by 
fHA. Possible candidates are NF-κB and MAP kinases (p38, ERK, JNK). 
- if bioactive compounds such as resveratrol, curcuma and triptolide exhibit 
anti-inflammatory and anti-catabolic effects on IVD cells. 
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RESEARCH ARTICLE Open Access
Hyaluronic acid fragments enhance the
inflammatory and catabolic response in human
intervertebral disc cells through modulation of
toll-like receptor 2 signalling pathways
Lilian Quero1,2, Marina Klawitter3, Anja Schmaus4, Melanie Rothley4, Jonathan Sleeman4,5, André N Tiaden3,
Juergen Klasen6, Norbert Boos1,2, Michael O Hottiger7, Karin Wuertz1,2,8,9† and Peter J Richards3,8*†
Abstract
Introduction: Intervertebral disc (IVD) degeneration is characterized by extracellular matrix breakdown and is
considered to be a primary cause of discogenic back pain. Although increases in pro-inflammatory cytokine levels
within degenerating discs are associated with discogenic back pain, the mechanisms leading to their
overproduction have not yet been elucidated. As fragmentation of matrix components occurs during IVD
degeneration, we assessed the potential involvement of hyaluronic acid fragments (fHAs) in the induction of
inflammatory and catabolic mediators.
Methods: Human IVD cells isolated from patient biopsies were stimulated with fHAs (6 to 12 disaccharides) and
their effect on cytokine and matrix degrading enzyme production was assessed using quantitative real-time
polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). The involvement of specific
cell surface receptors and signal transduction pathways in mediating the effects of fHAs was tested using small
interfering RNA (siRNA) approaches and kinase inhibition assays.
Results: Treatment of IVD cells with fHAs significantly increased mRNA expression levels of interleukin (IL)-1b, IL-6,
IL-8, cyclooxygenase (COX)-2, matrix metalloproteinase (MMP)-1 and -13. The stimulatory effects of fHAs on IL-6
protein production were significantly impaired when added to IVD cells in combination with either Toll-like
receptor (TLR)-2 siRNA or a TLR2 neutralizing antibody. Furthermore, the ability of fHAs to enhance IL-6 and MMP-3
protein production was found to be dependent on the mitogen-activated protein (MAP) kinase signaling pathway.
Conclusions: These findings suggest that fHAs may have the potential to mediate IVD degeneration and
discogenic back pain through activation of the TLR2 signaling pathway in resident IVD cells.
Introduction
Intervertebral disc (IVD) degeneration is considered to
be a major contributory factor to the development of
discogenic low back pain (LBP), a prevalent and costly
musculoskeletal disorder [1,2]. Efforts to develop more
effective therapies to combat this condition are ham-
pered by the lack of information relating to the patho-
physiological mechanisms responsible for instigating
IVD degeneration and the ensuing LBP. There is, how-
ever, some evidence suggesting that elevated levels of var-
ious pro-inflammatory cytokines within degenerated IVDs
may play a decisive role in mediating pain sensation
[3-6]. Therefore, a better appreciation of the processes
governing cytokine production within degenerated IVDs
may help in the development of more effective treatment
strategies to combat discogenic LBP.
Breakdown of the IVD extracellular matrix (ECM) is
driven by a collection of proteolytic enzymes of which
the matrix metalloproteinases (MMPs) and aggreca-
nases (members of the ADAMTS (A Disintegrin And
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Metalloproteinase with Thrombospondin Motifs) family)
have been the most extensively studied [7-10]. These
have the potential to degrade numerous matrix compo-
nents as well as to give rise to a variety of reactive frag-
ment species, which themselves may further act to
stimulate and activate IVD cells. This is made evident by
findings from our own studies, and from others, where
proteolytic fragments of fibronectin and type II collagen
have been shown to induce MMP expression in human
IVD cells [11-14]. In addition to proteins and proteogly-
cans, numerous glycosaminoglycans (GAGs) also exist
within the IVD, and include hyaluronic acid (HA), chon-
droitin sulfate and keratan sulfate, although only HA
exists in the form of a free GAG [15]. Among these, HA
has received significant attention due to the stimulatory
nature of its degradation products on various cell types.
HA is a polymer composed of repeating disaccharide
units comprised of D-glucuronic acid and D-N-
acetylglucosamine. Whilst existing as a high molecular
weight (HMW) polymer (>106 kDa) under normal con-
ditions, HA can become degraded in response to var-
ious pathogenic events resulting in the generation of
low molecular weight (LMW) fragments (fHAs) [16].
This may be brought about through the actions of var-
ious enzymes, such as hyaluronidases [17], as well as
by exposure to non-enzymatic mediators, including
reactive oxygen species (ROS) [18]. More specifically,
pro-inflammatory agents, such as IL-1b, have been
shown to induce the release and fragmentation of HA
from cartilage explants [19]. This may be of particular
relevance to the development of degenerative disc dis-
ease, where reductions in GAG content together with
increases in IL-1b are wholly evident in degenerated
IVDs [20,21]. Although there is currently no evidence
confirming the presence of fHAs within disc tissue, it
may be reasonable to assume that the sequence of cata-
bolic and inflammatory events within the degenerating
disc could provide an environment conducive to the
production of fHAs. However, the potential involve-
ment of such fragments in the pathogenesis of IVD
degeneration has not yet been considered. Certainly,
fHAs have the capacity to invoke both an inflammatory
response as well as induce synthesis of tissue degrading
enzymes when added to chondrocytes in vitro [22-25].
These effects are mediated through HA cell surface
receptors CD44 and/or toll-like receptor (TLR)-4, with
subsequent activation of NF-!B [24,25]. The receptor
for hyaluronan-mediated motility (RHAMM, CD168)
may also represent an additional means through which
fHAs could mediate their stimulatory effects [26].
However, no studies have yet sought to investigate the
influence of fHAs on the inflammatory and catabolic
response in human IVD cells, and to assess their possi-
ble mode of action.
In the current report, we have set out to investigate the
in vitro effects of fHAs on human IVD cells isolated from
the discs of patients undergoing spine surgery. Small
fHAs ranging in size from 12 to 24 mer were incubated
with IVD cells and their influence on inflammatory and
catabolic processes evaluated. Furthermore, studies were
conducted in an attempt to identify the signalling path-
ways responsible for mediating the effects of fHAs. Our
results clearly demonstrate that fHAs enhance both the
pro-inflammatory and catabolic response in IVD cells,
being mediated primarily through the TLR2 signaling
pathway. These findings may be considered of significant
clinical importance, based on the fact that increases in
pro-inflammatory cytokine and MMP production are
main features of IVD degeneration.
Materials and methods
Isolation and culture of IVD cells
Human IVD tissue was obtained from patients under-
going spinal surgery for symptomatic degenerative disc
disease, disc herniation or spinal trauma following
informed consent in accordance with the Ethics Com-
mittee of the Canton of Zurich (carried out at University
Hospital Balgrist, Zurich, Switzerland) (Table 1) and
Table 1 Details of patients used in the study.
Patient Pathology Severity Gradea Disc Level
1 DH 4 L4/5
2 SD 5 L4/5
3 DH 5 L4/5
4 DH 5 C5/6
5 DH 5 L5/S1
6 DH 4 L4/5
7 DH 3 L5/S1
8 DH 5 L5/S1
9 DH 4 L4/5
10 DH 4 L4/5
11 DH 5 L4/5
12 DH 4 L4/5
13 DH 3 L2/3
14 DH 4 L5/S1
15 DH 4 L5/S1
16 DH 5 L5/S1
17 DH 3 L5/S1
18 DH 5 L4/5
19 DH 4 L5/S1
20 DH 4 C6/7
21 DH 4 L4/5
22 DH 5 L5/S1
a The degree of IVD degeneration in patients was assessed prior to surgical
intervention by magnetic resonance imaging (MRI) using a 5-level grading
system based on Pfirrmann’s classification of disc degeneration.
C, cervical; DH, disc herniation; F, female; L, lumber; M, male; S, sacral; SD,
segment degeneration
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IVD cells isolated and cultured as previously described
[11]. Cells were used for experiments at passages 2 to 3.
Preparation of HA fragments
Hyaluronic acid oligomers of 6 to 12 disaccharide units
in length were prepared as previously described [27].
Ultrapure HMW HA (Healon 5), kindly provided by
Amo (Ettlingen, Germany), was dissolved at 5 mg/ml
in 0.3 M sodium phosphate buffer, pH 5.3, sonified and
subsequently enzymatically digested with 200 U/ml
bovine testis hyaluronidase (Sigma-Aldrich, Seelze,
Germany) for six hours at 37°C. The resulting
fragments were separated on a Bio Gel P10 column
(3.5 × 115 cm) (BioRad, Munich, Germany) and 3 ml
fractions collected. The concentration of HA in the
fractions was determined by measuring the absorbance
at 210 nm with reference to standards. The fractions
were tested for endotoxin contamination using the
Limulus Amebocyte Lysate (LAL)-assay kit (Lonza,
Verviers, Belgium) according to the manufacturer’s
instructions. In all cases, endotoxin levels were below
detection limits.
For determination of HA fragment size, fluorophore-
assisted carbohydrate electrophoresis (FACE) analysis of
7-amino-1,3-naphthalenedisulfonic acid (ANDS)-labeled
fragments was performed. Briefly, samples were dried
and resuspended in 5 µl 0.15 M ANDS (in 0.15% Acetic
Acid) and 5 µl 1 M NaCNBH4 (in DMSO) (both Sigma-
Aldrich). After 16 hours at 37°C the samples were dried
and resuspended in 20% glycerine. Samples were sepa-
rated on a 30% polyacrylamide gel at 15 mA. Bands
were visualized in the gel by UV illumination. The size
of the oligosaccharides in the fractions was determined
by comparing the bands with similarly labeled, commer-
cially available HA fragments of defined sizes (Sigma-
Aldrich) (Figure 1).
Figure 1 Preparation of fHAs. High molecular weight (HMW) hyaluronic acid (HA) was digested with bovine testis hyaluronidase. The resulting
fragments were separated on a Bio Gel P10 column. For determination of fragment size fluorophore-assisted carbohydrate electrophoresis
(FACE) analysis was performed. In this example, fractions 18, 23, 42, 48 and 64 derived from one HA-preparation were compared with a
commercially-available HA standard (Sigma-Aldrich). M, HA standard marker; ds, disaccharide units.
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Gene expression profile in IVD cells treated with fHAs
IVD cells (1 × 106) were cultured in 150 cm2 flasks and
starved in serum-free medium for 2 h prior to stimulation.
Cells were incubated in medium alone or medium supple-
mented with fHAs (5 or 20 µg/ml) for up to 18 hours.
Total RNA was isolated from IVD cells using the PureLink
RNA Mini kit (Life Technologies, Zug, Switzerland)
according to the manufacturer’s recommendation
(Life Technologies), then 1 μg total RNA was reverse-
transcribed using Superscript II (Life Technologies).
Quantification of mRNA expression was performed on the
StepOnePlus Real-Time PCR System (Life Technologies)
using the TaqMan Gene Expression Assays (Life Technol-
ogies) specific for IL-1b, IL-6, IL-8, TNF-a, MMP-1, -2, -3,
-9, -13, COX-2, ADAMTS4 and ADAMTS5 (Table 2).
Values were normalized to TATA-Box binding protein
(TBP) mRNA levels and presented as either 2-∆CT or as
fold change as compared to untreated cells according to
the 2-∆∆CT method where stated.
Stimulation of IL-6 production in IVD cells
IVD cells (1.3 x105) were cultured in 12-well plates and
starved in serum-free medium for 2 h prior to stimula-
tion. Cells were incubated in medium alone or medium
supplemented with fHAs (20 µg/ml), Pam3CysSerLys4
(Pam3CSK4) (25 ng/ml) (LabForce, Nunningen,
Switzerland), IL-1b (5 ng/ml) (Peprotech, London, UK) or
lipopolysaccharide (LPS) (25 ng/ml) (LuBioScience,
Luzern, Switzerland) for up to 18 hours. Culture superna-
tants were harvested for further analysis using a specific
IL-6 ELISA (BD Biosciences, Allschwil, Switzerland).
The effect of gene silencing on fHA-mediated IL-6
production in IVD cells
Specific knock down of TLR2, TLR4, CD44 and RHAMM
expression was performed with small interfering (si)RNA
oligos (Qiagen, Hombrechtikon, Switzerland). Human
IVD cells (1.3 × 105 cells) were transfected with 10 or 20
nM of siRNA specific for TLR2 (SI00050036), TLR4
(SI04951149), CD44 (SI00299705), or RHAMM (SI04
435347), or negative control siRNA (SI03650325) using
lipofectamine RNAiMAX (Life Technologies) in 12-well
plates. Following transfection, cells were incubated with
fresh growth medium (without antibiotics) and incubated
for 24 hours at 37°C, 5% CO2. Cells were then stimulated
with fHAs (20 μg/ml) for 18 hours and culture superna-
tants harvested for further analysis using a specific IL-6
ELISA (BD Biosciences).
The effect of TLR2 inhibition on fHA-mediated IL-6
production in IVD cells
IVD cells (1.3 × 105) were cultured in 12-well plates and
starved in serum-free medium for 2 h prior to stimulation.
Cells were then pre-incubated for one hour with either an
affinity purified polyclonal rat anti-human TLR2 neutraliz-
ing antibody (final concentration 5 µg/ml) (LabForce,
Switzerland) or an isotype matched IgG control (Lucerna-
Chem, Luzern, Switzerland). Cells were then stimulated
with fHAs (20 μg/ml) or Pam3CSK4 (25 ng/ml) for 18
hours and culture supernatants harvested for further ana-
lysis using a specific IL-6 ELISA (BD Biosciences).
The role of NF-!B in fHA-dependent IVD cell activation
IVD cells (3 × 105) were cultured in six-well plates and
starved in serum-free medium for 2 h prior to stimula-
tion. Cells were then treated for up to one hour with
either fHAs (20 μg/ml) or IL-1b (5 ng/ml). For the detec-
tion of NF-!B (p65) by immunofluorescence, cells were
fixed with ice cold methanol (-20°C) for 10 minutes at
selected time points, blocked for 10 minutes with PBS
containing 1% BSA (Sigma) and 0.1% Triton-X100
(Sigma), and incubated with polyclonal rabbit anti-NF-
!B (p65) (Santa Cruz Biotechnologies, Heidelberg,
Germany) (1:200) for one hour at room temperature. NF-
!B (p65) was detected using goat anti-rabbit Cy2 (Jackson
ImmunoResearch, Newmarket, Suffolk, UK) (1:200) and
visualized by fluorescence microscopy. For Western blot
analysis, cells were first washed with buffer containing 10
mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 1 mM
PMSF, 5 mM DTT with freshly added protease inhibitor
cocktail (Sigma-Aldrich) and then lysed with 0.1% NP-40
for five minutes on ice. Nuclear pellets were harvested
after centrifugation at 10,000 rpm for 5 minutes at 4°C,
and lysed for 20 minutes in buffer containing 20 mM
HEPES (pH 7.9), 1.5 mM MgCl2, 420 mM NaCl, 25% gly-
cerol, 1 mM PMSF and 5 mM DTT. Protein concentra-
tions were determined using the Bradford Assay (BioRad)
and equal amounts loaded onto 12% SDS-PAGE gels. Pro-
tein was subsequently electroblotted onto PVDF mem-
branes and incubated with nonfat dry milk (5%), 50 mM
Table 2 TaqMan gene expression assays used for
qRT-PCR.
Target gene Assay ID
TATA box binding protein (TBP) Hs00427620_m1
Interleukin 1 b (IL-1b) Hs00174097_m1
Interleukin 6 (IL-6) Hs00174131_m1
Interleukin 8 (IL-8) Hs00174103_m1
Tumor Necrosis Factor a (TNFa) Hs00174128_m1
Matrix metalloproteinase 1 (MMP-1) Hs00233958_m1
Matrix metalloproteinase 2 (MMP-2) Hs01548724_m1
Matrix metalloproteinase 3 (MMP-3) Hs00968308_m1
Matrix metalloproteinase 9 (MMP-9) Hs00957555_m1
Matrix metalloproteinase 13 (MMP-13) Hs00233992_m1
Cyclooxygenase 2 (COX-2) Hs00153133_m1
Aggrecanase 1 (ADAMTS4, AD4) Hs00943031_g1
Aggrecanase 2 (ADAMTS5, AD5) Hs00199841_m1
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Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20 (TBST)
for one hour at room temperature. Membranes were then
incubated for 2 hours at room temperature with either
anti- NF-!B (p65) (1:200) or anti-PARP1 (1:1,000) (both
from LabForce, Switzerland). After washing in TBST three
times for five minutes each, membranes were incubated
with an appropriate HRP-conjugated secondary antibody
for one hour at room temperature. Following a further
washing step, peroxidase activity was detected using
SuperSignal West Dura Chemiluminescent Substrate
(Thermo Scientific, Lausanne, Switzerland). NF-!B (p65)
binding activity was measured in nuclear extracts from
IVD cells using the NF-!B (p65) Transcription Factor
Assay according to the manufacturer’s recommendations
(Cayman, Tallinn, Estonia). All absorbance measurements
were carried out at 655 nm.
Role of MAP kinases in mediating the effects of fHAs in
IVD cells
Cultured IVD cells were treated for 15 minutes with
fHAs (20 μg/ml), IL-1b (5 ng/ml), LPS (25 ng/ml) or
left untreated and whole protein cell extracts isolated
following lysis in buffer containing 50 mM HEPES (pH
7.5), 450 mM NaCl, 15% glycerol, 2 mM EDTA, 1 mM
PMSF and a freshly added protease inhibitor cocktail
(Sigma-Aldrich). Protein was harvested following centri-
fugation at 14,000 rpm for 30 minutes and equal
amounts loaded onto 12% SDS-PAGE gels and trans-
ferred to PVDF. Membranes were then incubated for
two hours with either rabbit anti-p38 (1:1,000), rabbit
anti-phospho-p38 (Thr180/Tyr182) (1:1,000), rabbit
anti-p44/44 (1:1,000), rabbit anti-phospho-p44/42
(1:1,000), rabbit anti-SAPK/JNK (1:1,000) or rabbit anti-
phospho-SAPK/JNK (Thr183/Tyr185) (1:200) (all from
Cell Signaling Technology, Allschwil, Switzerland) and
further analysed as described above. The functional role
of MAP kinases in mediating the effects of fHAs was
investigated using MAP kinase inhibitors. IVD cells
were treated with fHA (20 μg/ml) alone (Control) or in
combination with MAP kinase inhibitors (10 μM) speci-
fic for p38 (SB203580), ERK 1/2 (PD98059) or SAPK/
JNK (SP600125) and culture supernatants harvested for
further analysis using ELISAs specific for IL-6 (BD Bios-
ciences) or MMP-3 (R and D Systems, Abingdon, UK)
according to the manufacturer’s protocol.
Statistical analysis
All statistical analyses were carried out using SPSS19.0
(SPSS Inc., Chicago, IL, USA). Data were first assessed
for normality of distribution using the Kolmogorov-
Smirnov test. Parametric analysis of normally distributed
data was performed using the two-tailed unpaired Stu-
dent’s t-test or one-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc tests for multiple group
comparisons. Non-parametric data were analyzed using
the Kruskal-Wallis one-way analysis of variance for mul-
tiple group comparisons followed by the Mann-Whitney
U test for comparisons between two groups. A P-value
of <0.05 was considered statistically significant. All data
were expressed as mean ± standard deviation (S.D.).
Results
Effect of fHAs on the expression of inflammatory and
catabolic genes in IVD cells
Initial experiments were undertaken in order to assess
the effects of fHAs on the expression of a range of
inflammatory and catabolic genes in cultured IVD cells.
Treatment of IVD cells was carried out for up to 18
hours using concentrations of fHAs based on previous
studies [24,28]. Stimulation of cells with fHAs at either
5 or 20 μg/ml resulted in significant alterations in sev-
eral of the genes analysed (Figure 2). The most notice-
able effects were observed in cells treated with the
higher dose of fHAs (20 μg/ml), where significant
increases in expression levels were measured for IL-1b
(P <0.01), IL-6 (P <0.05), IL-8 (P <0.01), MMP-1 (P
<0.01), MMP-13 (P <0.05) and COX-2 (P <0.01). All
subsequent experiments therefore involved the use of
fHAs at 20 μg/ml.
The stimulatory effect of fHAs on IVD cells is dependent
on functionally active TLR2
Of the genes identified as being regulated by fHAs, IL-6
was considered an appropriate candidate for further
investigations based on its roles as both a pro-inflamma-
tory cytokine and also as a mediator of pain [3].
Stimulation of IVD cells with fHAs induced a signifi-
cant increase in IL-6 protein production (3.5 ± 1.5 ng/ml;
P <0.01) as compared to untreated cells (Figure 3A), as
did other well-known instigators of IL-6 production,
including toll-like receptor activators Pam3CSK4 (6.0 ±
3 ng/ml) (Figure 3B) and LPS (10.8 ± 7.85 ng/ml)
(Figure 3C), as well as the pro-inflammatory cytokine
IL-1b (120 ± 36 ng/ml) (Figure 3D).
An siRNA approach was then used to target genes
encoding the cell surface receptors TLR2, TLR4, CD44
and RHAMM, with the aim of identifying potential recep-
tors involved in engaging fHAs. Knockdown efficiency
was confirmed in IVD cells after 24 hours using qRT-
PCR (Figure 4A). TLR2 and TLR4 were selected for
further evaluation of functional loss of receptor activity.
Confirmation of efficient and comparable TLR2 and
TLR4 loss-of-function was substantiated in siRNA-treated
cells through examination of their ability to express IL-6
following incubation with TLR ligands Pam3CSK4
(Figure 4B) and LPS (Figure 4C). fHA-dependent IL-6
production by IVD cells was also significantly reduced
following TLR2 loss-of-function (Figure 4D), although no
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significant reductions in IL-6 production were observed
in cells in which TLR4, CD44 or RHAMM had been
knocked down.
Further confirmation of TLR2’s involvement in the acti-
vation of IVD cells by fHAs was demonstrated in antibody-
mediated neutralization studies. Initial studies confirmed
the effectiveness of the polyclonal anti-TLR2 antibody to
neutralize TLR2 activity as demonstrated by its ability to
suppress Pam3CSK4-dependent IL-6 production as com-
pared to a non-specific IgG control antibody (Figure 5A).
Similarly, antibody-mediated TLR2 inactivation also signifi-
cantly reduced (P <0.05) the stimulatory effects of fHAs on
IL-6 production by IVD cells (Figure 5B).
The role of NF-!B in fHA-mediated IVD activation
Activation of NF-!B is considered to be a primary
means through which fHAs mediate their stimulatory
effects in chondrocytes [24,25]. We, therefore, carried
out a series of experiments to investigate whether fHAs
could also induce NF-!B activation in human IVD cells.
We were unable to observe any evidence of NF-!B
activation in IVD cells following stimulation with fHAs
(20 μg/ml). This was clearly demonstrated by the lack of
any increase in nuclear p65 as determined by both
immunofluorescence staining (Figure 6A) and also Wes-
tern blot analysis (Figure 6B) as compared to untreated
cells. Furthermore, nuclear extracts harvested from IVD
Figure 2 Gene expression profile in IVD cells treated with fHAs. Human IVD cells were incubated for 18 hours with hyaluronic acid
fragments (fHAs) at either 5 or 20 μg/ml (n = 4 to 6) and RNA harvested for analysis by qRT-PCR. Values were normalized to TATA-Box binding
protein (TBP) mRNA and expressed as 2-∆CT. Statistical analysis was performed using the Kruskal-Wallis one-way analysis of variance for multiple
group comparisons followed by the Mann-Whitney U test for comparisons between two groups, * P <0.05, ** P <0.01 as compared to untreated
IVD cells. IL, interleukin; TNF, tumor necrosis factor; MMP, matrix metalloproteinase; COX, cyclooxygenase; ADAMTS, A Disintegrin And
Metalloproteinase with Thrombospondin Motifs.
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cells treated with fHAs demonstrated no significant
increase in NF-!B (p65) DNA binding activity when
tested using a specific transcription factor assay (Figure
6C). This was in direct contrast to cells treated with IL-
1b, where obvious increases in nuclear p65 were evident
in all of the performed analyses.
Activation of IVD cells by fHAs is dependent on MAP
kinase signalling pathways
Based on the fact that TLR2 signalling also partly relies on
the MAP kinase pathway [29], we next investigated
whether fHAs had the capacity to activate various MAP
kinases in IVD cells. Western blot analysis revealed a
marked increase in the level of phosphorylated c-Jun-N-
terminal kinase/stress-activated protein kinase (JNK/
SAPK) (Figure 7A). In addition, we also saw a noticeable
increase in the level of phosphorylated extracellular signal-
regulated kinase (ERK) 1/2 (p44/p42) in cells treated with
fHAs (Figure 7B). However, by comparison, only marginal
increases in the level of p38 MAP kinase phosphorylation
were observed in response to fHAs (Figure 7C).
In order to further clarify the potential involvement of
MAP kinase activity in regulating fHA-dependent IVD
cell activation, we performed additional experiments uti-
lizing specific MAP kinase inhibitors. The stimulatory
effects of fHAs on IL-6 production by IVD cells were
significantly reduced following pre-exposure of the cells
to either ERK inhibitor PD98059 (P <0.05) or JNK inhi-
bitor SP600125 (P <0.01) (Figure 7D). The p38 MAP
kinase inhibitor, SB203580, had only a weak inhibitory
effect on fHA-dependent IL-6 production, which did not
reach statistical significance (P = 0.27). We also investi-
gated the ability of MAP kinase inhibitors to affect fHA-
induced MMP production in IVD cells. As with IL-6,
MMP-3 protein production was up-regulated by over
four-fold (P <0.01) in IVD cells treated with fHAs
(Figure 7E) and was significantly reduced following inhi-
bition of JNK activity (P <0.01).
Figure 3 Stimulation of IL-6 production in IVD cells. Human intervertebral disc (IVD) cells were incubated for 18 hours with either: hyaluronic
acid fragments (fHAs) (20 μg/ml) (n = 4) (A); Pam3CSK4 (25 ng/ml) (n = 4) (B); lipopolysaccharide (LPS) (25 ng/ml) (n = 5) (C); or interleukin (IL)-
1b (5 ng/ml) (n = 5) (D), and IL-6 protein levels determined in supernatants using a specific ELISA. In all cases, analyses were performed in
triplicate and values expressed as mean ± S.D. Statistical analysis was performed using the Student’s t-test, * P <0.05, ** P <0.01 as compared to
untreated IVD cells.
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Discussion
The primary source of discogenic back pain has been
debated over the years, although there is now a growing
body of evidence suggesting a close causal relationship
between pro-inflammatory cytokine expression and the
development of pain within the degenerated IVD
[3,10,30]. Certainly, pro-inflammatory mediators have
the capacity to provoke pain sensation [4-6], although it
remains unclear as to which processes are responsible
for initiating the ensuing cascade of cytokines in dis-
eased discs. Considering the fact that discogenic back
pain occurs primarily in degenerated discs, it is highly
likely that the processes governing disc degeneration
also play a role in instigating pro-inflammatory cytokine
production.
Degradation of the ECM through catabolic processes
can result in the generation of a variety of matrix pro-
tein fragments with the potential to influence cellular
behavior in numerous tissue types, usually with a detri-
mental outcome [9,11,12,31-33]. Furthermore, fragments
generated from HA have the potential to induce a num-
ber of pro-inflammatory responses as evidenced by their
ability to up-regulate chemokines, cytokines and matrix
degrading enzymes in several different cell types, includ-
ing chondrocytes [22-27,34-36]. In the present report,
we have extended these observations to include human
IVD cells, where fHA-mediated stimulation was shown
to significantly enhance the expression of pro-inflamma-
tory cytokines IL-1b, IL-6 and IL-8. Moreover, fHAs
were also found to stimulate the expression of certain
Figure 4 The effect of gene silencing on fHA-mediated IL-6 production in IVD cells. A) siRNA-mediated knockdown of genes Toll like
receptor (TLR)2, TLR4, CD44 and RHAMM was confirmed after 30 hours in intervertebral disc (IVD) cells by qRT-PCR (n = 4). In each case, gene
expression was calculated as fold change as compared to untreated cells. The use of a non-specific scrambled siRNA (siRNA (S)), confirmed
specificity of gene knockdown. B, C) Interleukin (IL)-6 protein production by Pam3CSK4- (25 ng/ml) (n = 4) (B) and lipopolysaccharide (LPS)- (25
ng/ml) (n = 3). (C) stimulated IVD cells following gene knockdown of TLR2 or TLR4 respectively, as determined by IL-6 ELISA. (D) hyaluronic acid
fragment (fHA)-treated (20 μg/ml) IVD cells following gene knockdown as determined by IL-6 ELISA (n = 4). IL-6 protein levels are represented as
a percentage of those measured for untreated cells. In all cases, analyses were performed in triplicate and values expressed as mean ± S.D.
Statistical analysis was performed using the Student’s t-test, * P <0.01.
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Figure 5 The effect of TLR2 inhibition on fHA-mediated IL-6 production in IVD cells. Interleukin (IL)-6 protein production by Pam3CSK4-
(25 ng/ml) (A) and hyaluronic acid fragment (fHA)-treated (20 μg/ml) (B) intervertebral disc (IVD) cells following antibody-mediated
neutralization of Toll like receptor (TLR)2 activity (n = 4). IL-6 protein levels are represented as a percentage of those measured for untreated
cells. In all cases, analyses were performed in triplicate and values expressed as mean ± S.D. Statistical analysis was performed using the
Student’s t-test, * P <0.05 as compared to cells treated with non-specific IgG control antibody.
Figure 6 The role of NF-!B in fHA-dependent IVD cell activation. (A) Immunofluorescence staining of intervertebral disc (IVD) cells for NF-!B
(p65) (green) following treatment with either hyaluronic acid fragments (fHAs) (20 μg/ml) or interleukin (IL)-1b (5 ng/ml) at selected time points.
Nuclear NF-!B (p65) is indicated by arrowheads. Untreated IVD cells served as a control. Scale bar = 50 μm. (B) Western blot analysis of nuclear
extracts from untreated IVD cells or cells treated for 1 hour with either fHAs (20 μg/ml) or IL-1b (5 ng/ml). Levels of PARP1 protein served as a
loading control. (C) NF-!B (p65) DNA binding activity in nuclear extracts from untreated IVD cells, or cells treated for one hour with IL-1b or
fHAs (20 μg/ml) (n = 3). In all cases, analyses were performed in triplicate and values expressed as mean ± S.D. Statistical analysis was performed
using the Student’s t-test, * P <0.01 as compared to untreated cells.
Quero et al. Arthritis Research & Therapy 2013, 15:R94
http://arthritis-research.com/content/15/4/R94
Page 9 of 13
  56 
matrix degrading enzymes, including MMP-1, MMP-3
and MMP-13, although significance was not always
attained due to the large variations between patient
samples. It is envisaged that larger population studies
may help to resolve this issue and thus allow for a more
accurate assessment of potential fHA-target genes. The
induction of such matrix degrading enzymes by fHAs
would undoubtedly contribute to IVD catabolism and
thus perpetuate the on-going destructive processes
within the actively degenerating disc. In addition to
increases in mRNA expression levels, we were also able
to detect enhanced levels of secreted IL-6 protein fol-
lowing fHA stimulation of IVD cells. This is considered
to be of particular importance when assessing the
Figure 7 Role of MAP kinases in mediating the effects of fHAs in IVD cells. Cultured intervertebral disc (IVD) cells were treated for 15
minutes with hyaluronic acid fragments (fHAs) (20 μg/ml), interleukin (IL)-1b (5 ng/ml), lipopolysaccharide (LPS) (25 ng/ml) or left untreated and
whole cell extracts harvested for Western blot analysis using antibodies specific to phosphorylated and non-phosphorylated SAPK/JNK (54/46)
(A), ERK 1/2 (44/42) (B) and p38 (C). (D, E) IVD cells were treated with fHA (20 μg/ml) alone (Control) or in combination with MAP kinase
inhibitors (10 μM) specific for p38 (SB203580), ERK 1/2 (PD98059) or SAPK/JNK (SP600125) and IL-6 (D) and matrix metalloproteinase (MMP)-3 (E)
protein levels determined by specific ELISA (n = 4). In all cases, analyses were carried out in triplicate and values expressed as mean ± S.D.
Statistical analysis was performed using Students t-test, * P <0.05, ** P <0.01 as compared to cells treated with fHAs alone (Control).
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relevance of fHAs in IVD degeneration in vivo, where
secreted cytokines are the main protagonists in driving
the pain sensation process [3,37].
The pro-inflammatory effects of LMW fHAs on
chondrocytes are generally thought to be dependent on
their interaction with TLR4 and CD44 [24,25]. In the
present report, we utilized both gene silencing and
antibody-directed inhibition approaches in an attempt
to identify potential signaling pathways responsible for
fHA-dependent IVD cell activation. Contrary to expec-
tations, functional loss of either TLR4 or CD44 did not
significantly influence fHA-induced IL-6 production in
IVD cells. Furthermore, loss-of-function studies invol-
ving RHAMM, another potential mediator of fHA-
dependent signaling, were also unable to demonstrate
any significant decreases in IL-6 secretion by fHA-
stimulated IVD cells. However, the stimulatory effects
of fHAs were significantly decreased in IVD cells in
which TLR2 expression had been effectively suppressed
following siRNA treatment. These observations were
further corroborated by studies in which TLR2 activity
was inhibited through the use of a specific neutralizing
antibody. To our knowledge, this is the first report
confirming the involvement of TLR2 in fHA-induced
cytokine production in human IVD cells.
The NF-!B signal transduction pathway has previously
been implicated as a primary means through which
fHAs mediate their effects [34,38]. More specifically,
NF-!B activation has been reported to mediate the sti-
mulatory effects of fHAs in chondrocytes [22,25]. In
addition to NF-!B, signaling pathways involving MAP
kinases have also been shown to play a functional role
in the transduction of fHA signals [22,34]. In the pre-
sent report, we were unable to demonstrate NF-!B acti-
vation in human IVD cells following treatment with
fHAs, although convincing data were obtained which
strongly implicated the MAP kinase pathway as being
an important regulator of fHA signaling. We could
demonstrate strong activation of MAP kinases ERK and
JNK in IVD cells following short-term stimulation with
fHAs, although p38 appeared to be less responsive to
the actions of fHAs. These findings may have important
ramifications in terms of identifying possible mechan-
isms through which fHAs induce both inflammatory
and catabolic responses in IVD cells. Certainly, many of
the genes up-regulated by fHAs in the current study
have previously been confirmed as MAP kinase target
genes in IVD cells [39-41]. Indeed, we were able to con-
firm activation of ERK and JNK but not p38 MAP
kinases as being necessary requirements for fHA-
mediated IL-6 production in IVD cells. Furthermore,
increases in MMP-3 protein production due to fHAs
also appeared to be dependent on JNK MAP kinase
activity. This may have significant implications when
considering therapeutic strategies for treating IVD
degeneration and inflammatory pain development, and
may, therefore, warrant further investigations into the
possible clinical benefits of using MAP kinase inhibition
for treating this debilitating disease.
Conclusions
In conclusion, the data provided in the current report pro-
vide convincing evidence that fHA-dependent stimulation
of human IVD cells is primarily regulated through TLR2-
mediated activation of the MAP kinase pathway. Further-
more, our findings offer new insights into the potential
molecular mechanisms governing IVD inflammatory pain
development in patients with IVD degeneration. Clearly,
therefore, further studies are now needed in order to con-
firm the presence and concentration of fHAs in tissue
samples, and thereby allow for an accurate assessment of
their true physiological role in IVD degeneration.
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Curcuma DMSO extracts and curcumin exhibit an
anti-inflammatory and anti-catabolic effect on
human intervertebral disc cells, possibly by
influencing TLR2 expression and JNK activity
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Abstract
Background: As proinflammatory cytokines seem to play a role in discogenic back pain, substances exhibiting
anti-inflammatory effects on intervertebral disc cells may be used as minimal-invasive therapeutics for intradiscal/
epidural injection. The purpose of this study was to investigate the anti-inflammatory and anti-catabolic potential of
curcuma, which has been used in the Indian Ayurvedic medicine to treat multiple ailments for a long time.
Methods: Human disc cells were treated with IL-1β to induce an inflammatory/catabolic cascade. Different extracts of
curcuma as well as curcumin (= a component selected based on results with curcuma extracts and HPLC/MS analysis)
were tested for their ability to reduce mRNA expression of proinflammatory cytokines and matrix degrading enzymes
after 6 hours (real-time RT-PCR), followed by analysis of typical inflammatory signaling mechanisms such as NF-κB
(Western Blot, Transcription Factor Assay), MAP kinases (Western Blot) and Toll-like receptors (real-time RT-PCR).
Quantitative data was statistically analyzed using a Mann Whitney U test with a significance level of p< 0.05 (two-tailed).
Results: Results indicate that the curcuma DMSO extract significantly reduced levels of IL-6, MMP1, MMP3 and MMP13.
The DMSO-soluble component curcumin, whose occurrence within the DMSO extract was verified by
HPLC/MS, reduced levels of IL-1β, IL-6, IL-8, MMP1, MMP3 and MMP13 and both caused an up-regulation of TNF-α.
Pathway analysis indicated that curcumin did not show involvement of NF-κB, but down-regulated TLR2 expression and
inhibited the MAP kinase JNK while activating p38 and ERK.
Conclusions: Based on its anti-inflammatory and anti-catabolic effects, intradiscal injection of curcumin may be an
attractive treatment alternative. However, whether the anti-inflammatory properties in vitro lead to analgesia in vivo will
need to be confirmed in an appropriate animal model.
Keywords: Human intervertebral disc cells, Curcumin, Curcuma, Proinflammatory cytokines, Matrix degrading enzymes,
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Background
Degeneration of the intervertebral disc is characterized
by enhanced proteolytic degradation of extracellular
matrix proteins as well as altered matrix protein synthe-
sis. This overall catabolic shift leads to changes in the tis-
sue structure that have been extensively described in the
literature [1-7]. Although large structural changes can be
observed during degeneration, this age-related process
does not necessarily cause pain symptoms.
There is certain evidence in the literature that in a
subgroup of patients, painful disc degeneration is
characterized by increased levels of proinflammatory
cytokines, e.g. interleukin 1β (IL-1β), interleukin 6
(IL-6), interleukin 8 (IL-8) and tumor necrosis factor
α (TNF-α) [6,8-11]. Although proinflammatory med-
iators seem to play a crucial role in intervertebral
disc diseases, little is known about inflammatory
pathways in intervertebral disc cells. Results from
studies on the pathogenesis of cartilage degeneration
indicate that proinflammatory processes are mostly
regulated by the transcription factor NF-κB [12],
whose activity is tightly regulated in vivo, e.g. by ac-
tivation of the so-called Toll-like receptors (TLRs)
[13]. Another important inflammatory pathway is the
MAP kinase pathway that consists of a family of pro-
tein kinases with the major members being p38, ERK
and JNK [14,15]. Due to the lack of knowledge con-
cerning the molecular events underlying discogenic
back pain, treatment of painful disc disease is cur-
rently limited, with typical options for the patient
being conservative treatment (e.g. physiotherapy) and
oral pain medication, both of which often only have
a temporary effect. Other options are various types
of surgical interventions, but these lead to high risks
for the patients and high costs for the health care
systems. Therefore, research in the most recent past
has concentrated on the development of minimal-in-
vasive, yet effective new treatment options, covering
approaches from cell and gene therapy to anti-
inflammatory substances for intradiscal injection.
Currently, corticosteroidal substances are frequently
used, which are known to have a significant risk for
side effects and may cause disc space infections [16].
Although research on biodrugs with regard to spinal
diseases is yet rare, these novel anti-inflammatory
candidates could potentially benefit patients with dis-
cogenic back pain.
Curcuma (Curcuma longa L., Zingiberaceae) is a per-
ennial herb that is cultivated in Asian countries. As a
powder, it has not only been used for cooking for centur-
ies, but also as a drug in the traditional Chinese and
Indian medicine, treating e.g. diabetic wounds, hepatic
disorders, rheumatism and sinusitis [17]. Numerous pub-
lications demonstrated an anti-inflammatory effect of
curcuma, with its effect probably being related to a class
of substances called curcuminoids [18].
Based on a thorough literature review, we hypothesize
that curcuma has the potential to interfere with catabolic
and inflammatory pathways. Hence, the aim of this study
was to analyze the effects of curcuma extracts as well as
of one selected component of curcuma on IL-1β
mediated cellular responses of human intervertebral disc
cells in vitro. Additionally, its mechanism of action was
investigated by testing for involvement of NF-κB, MAP
kinases (i.e. p38, ERK, JNK) and TLR2.
Methods
General experimental design
As an inflammatory environment is thought to be
present in (a subgroup of) patients with discogenic back
pain, human intervertebral disc cells (cultured in 2D)
were pretreated with recombinant IL-1β, thus increasing
the levels of proinflammatory cytokines and matrix de-
grading enzymes. Thereafter, different solvents (DMSO,
ethanol) were used to prepare sequential curcuma
extracts and tested for their ability to reduce inflamma-
tory and catabolic gene expression after 6 hours. The
presumably most abundant bioactive substance in the
most potent extract was chosen based on structure-
based solubility, information in the literature and identi-
fication using HPLC/MS analysis (i.e. curcumin) and
tested in the same setting, using various concentrations.
A mechanistic investigation, looking at involvement of
the NF-κB, MAP kinase and TLR2 pathway, was per-
formed for curcumin as well.
Human intervertebral disc cell culture
Human intervertebral disc tissue (nucleus pulposus and
annulus fibrosus) was removed from 27 patients under-
going spinal surgery for discectomy or interbody fusion
for degenerative disc disease or disc herniation (for
detailed information see Table 1). Informed consent was
obtained from all patients prior to surgery in accordance
with the institutional review board.
Intervertebral disc cells were released from the tissue
by enzymatic digestion with 0.2% collagenase NB4
(Serva, Germany) and 0.3% dispase II (Roche Diagnos-
tics, Switzerland) in PBS (37°C, 5% CO2) for approxi-
mately 4 hours. After digestion, the tissue suspension
was filtered (70 μm cell strainer, BD Biosciences, Belgium),
washed and cells were seeded and expanded in DMEM/
F12 (Sigma, Switzerland) supplemented with 10% FCS,
penicillin (50 units/ml), streptomycin (50 μg/ml) and
ampicillin (125 ng/ml) (all Invitrogen, Germany), with
medium changes once to twice a week and expansion
up to passage 2 or 3.
Klawitter et al. Journal of Inflammation 2012, 9:29 Page 2 of 14
http://www.journal-inflammation.com/content/9/1/29
  63 
 
Preparation of curcuma extracts
Organic curcuma from McCormick (Promena, Switzerland)
was used to prepare sequential DMSO and ethanol extracts.
Briefly, curcuma was dispersed in DMSO at a concentra-
tion of 320 mg/ml, incubated on the shaker at room
temperature for 10 min and centrifuged at 2000 rpm for
10 min before taking off the DMSO fraction. The
remaining pellet was then dispersed in 100% ethanol and
the procedure was repeated. After removal of the ethanol
fraction, the thereafter remaining pellet was discarded. For
each experiment, the fractions were prepared freshly in
order to avoid any damage due to freezing/thawing.
HPLC/MS analysis of the curcuma DMSO and EtOH
extracts
The DMSO and EtOH extracts of curcuma were analysed
by high performance liquid chromatography (1200 Series
HPLC, Agilent), coupled to a mass spectrometer (6130
series MS, Agilent). The chromatography of the curcuma
extracts was performed according to Wichitnithad et al.
[19], using a RP-C18 column (Agilent Eclipse Plus,
100 mm× 2.1 mm i.d., 1.8 μm). For identification of the
curcuminoids, measurements were carried out with a
multimode source (electrospray (ESI) ionization mode:
positive mode; drying gas flow: 12 l/min; drying gas
temperature: 350°C; nebulizer pressure: 50 psig; fragmentor
voltage: 70 V; capillary voltage: 4000 V). The quantification
of the most abundant curcuminoids was done at a wave-
length of 425 nm, with commercially available curcumin
(Sigma Aldrich) as an external standard.
Viability measurement
Cells seeded in 24 well plates were treated with different
concentrations of curcuma DMSO extract (25, 50, 100,
250, 500 or 1000 μg/ml), curcuma ethanol extract
(25, 50, 100, 250, 500 or 1000 μg/ml) or curcumin (1, 5,
10, 20, 50 or 100 μM - dissolved in DMSO). All experi-
ments were performed in triplicates on cells from 5 inde-
pendent biopsies. After 6, 18 and 30 hours, toxicity was
analyzed using the MTT assay: A fresh sterile solution of
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide] (Sigma, Switzerland) with a concentration
of 0.5 mg/ml in DMEM/F12 was prepared, 500 μl were
added to each well and incubated for 4 hours at 37°C.
MTT was discarded, cells were lysed with DMSO for
5 min at 37°C and absorbance was measured at 565 nm.
Absorbance of treated cells was calculated relative to ab-
sorbance of untreated control cells, which was set to 100%
(only changes in viability of >10% were considered). Con-
centrations that were non-toxic even at late time points
were chosen for subsequent experiments. Results of the
MTT assay were previously shown to be comparable to
other viability measurement techniques (DNA content by
Picogreen assay; cell counting) [20].
Gene expression analysis
Human intervertebral disc cells were serum starved for 2
hours and then exposed to 5 ng/ml IL-1β (Peprotech,
Great Britain) for 2 hours before adding 100 μg/ml cur-
cuma DMSO extract or 100 μg/ml curcuma EtOH
extract for 6 hours. Untreated control cells were included
to verify the inflammatory and catabolic response
induced by IL-1β treatment. As we were able to show
that the solvents did not influence cellular behavior (see
Additional file 1: Figure S1 and Additional file 2:
Figure S2), all groups were treated with the respective
volume (0.03%) of either DMSO or EtOH in all experi-
ments. Therefore, changes in gene expression are either
calculated relative to controls (+0.03% DMSO or EtOH)
or relative to IL-1β prestimulated cells (+0.03% DMSO
or EtOH). Based on the results with curcuma extracts
Table 1 Demographic data on surgical disc samples
(M=male; F = female)
Nr. Sex Age Level Pathology Grade Experiments
1 F 15 L5/S1 Herniation 4 G
2 M 35 L4/5 Herniation 4 G
3 M 46 L3/4 Herniation 3 G
4 M 60 L4/5 Herniation 4 G
5 F 56 L1/2 Herniation 5 G
6 F 48 L4/5 Herniation 4 G
7 M 59 L5/S1 DDD 4 G
8 M 39 L4/5 Herniation 3 G
9 M 60 L4/5 Herniation 3 G
10 F 51 L4/5 DDD 4 G
11 F 48 L4/5 DDD 3 G
12 M 59 L5/S1 Herniation 3 G
13 F 42 L4/5 Herniation 4 G
14 M 28 L5/S1 Herniation 3 V
15 F 71 L1/2 Herniation 5 V
16 F 46 L5/S1 Herniation 5 V
17 M 61 L4/5 Herniation 3 V
18 F 59 L4/5 Herniation 3 V
19 M 57 L4/5 Herniation 4 P
20 M 48 L4/5 Herniation 3 P
21 F 23 L5/S1 Herniation 3 P
22 F 43 L4/5 Herniation 4 P
23 M 49 L5/S1 Herniation 4 P
24 F 50 L5/S1 Herniation 3 P
25 F 45 L5/S1 Herniation 4 P
26 F 40 L4/5 Herniation 4 P
27 N 26 L4/5 Herniation 4 P
Grade = Pfirrmann Grading; Pathology: DDD=Degenerative disc disease
Experiments: V = Viability, G =Gene expression analysis, P = Pathway analysis.
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and data obtained by HPLC/MS analysis, a 25 mM stock
solution of curcumin (which is one of the major DMSO-
soluble, bioactive components of curcuma) was prepared
and cells were treated with final concentrations of 5, 10
or 20 μM curcumin for 6 hours after IL-1β prestimula-
tion. Taking the approximate percentage of curcumin in
curcuma powder (~2%) into account, the applied range
of curcumin (5–20 μM) was predicted to be similar to
the final concentration of curcumin when using the
above mentioned curcuma extracts (100 μg/ml). All gene
expression experiments were performed on cells from
five independent biopsies.
After treatment, cells were harvested by trypsin treat-
ment and total RNA was isolated using the PureLink RNA
Mini Kit (Ambion, Switzerland) according to the manufac-
turer’s instructions. cDNA was synthesized using TaqMan
Reverse Transcription Reagents (Applied Biosystems,
Switzerland) and gene expression of IL-1β, IL-6, IL-8,
TNF-α, MMP1, MMP3, MMP13, TLR2 and TBP (TATA
box binding protein=housekeeping gene) was analyzed.
Human specific probes and primers (Applied Biosystems,
Switzerland, see Table 2), TaqMan real-time RT-PCR Mix
(Applied Biosystems, Switzerland) and 10–30 ng of cDNA
(depending on the expression level of the respective gene)
were mixed and measured in duplicates using the StepOne
Plus Real-Time PCR System (Applied Biosystems,
Switzerland). The comparative ct method (= 2-ΔΔCt
method) [21] was used to quantify PCR data. In order to
calculate changes in gene expression induced by curcuma/
curcumin, gene expression in IL-1β-treated cells was set to
100% and gene expression of IL-1β/curcuma or IL-1β-/
curcumin-treated cells was calculated relative to IL-1β-
treated cells (containing the respective amount of either
DMSO or EtOH as well).
Western Blot for NF-κB (p65)
In order to investigate whether changes in NF-κB/p65
translocation occur after treatment with curcumin
(substance with most prominent effects, see results), disc
cell cultures were either kept untreated, treated with
5 ng/ml IL-1β alone or co-treated with 20 μM curcumin
for 60 min.
Nuclear extracts were prepared by washing trypsin-
harvested cells with 10 mM HEPES (pH 7.9), containing
1.5 mM MgCl2, 10 mM KCl, 1 mM PMSF, 5 mM DTT
and 0.1% protease inhibitors (pepstatin-A, leupeptin and
bestatin). Then, cells were lysed with 0.1% NP-40 for
5 min, centrifuged for 5 min at 10’000 rpm (4°C) and
supernatants were discarded. Nuclear pellets were
washed with 0.1% NP-40 and lysed for 20 min with
20 mM HEPES (pH 7.9), containing 1.5 mM MgCl2,
420 mM NaCl, 25% glycerol, 1 mM PMSF and 5 mM
DTT as well as protease inhibitors (see above). After cen-
trifugation, protein content was measured by Bradford
assay (Bio-rad, Germany).
Nuclear extracts of untreated, IL-1β-treated and IL-1β/
curcumin-treated cells were separated on a SDS-
polyacrylamid gel and transferred to a PVDF membrane
(Amersham, Switzerland). The membrane was incubated
with a p65 antibody (Santa Cruz, Germany) followed by
incubation with an appropriate HRP secondary antibody
before analyzing chemiluminescence. PARP (Poly [ADP-
ribose] polymerase) was used as a loading control. The
assay was performed on cells from three independent
biopsies.
Transcription factor assay for NF-κB (p65)
In order to detect specific NF-κB DNA binding activity
in nuclear extracts, the NF-κB (p65) Transcription Factor
Assay (Cayman, Estonia) was used according to the
protocol provided by the manufacturer. Briefly, a specific
double stranded DNA (dsDNA) sequence containing the
NF-κB response element was immobilized to the wells of
a 96 well plate. Nuclear extracts were prepared as
described above and added to the coated wells. NF-κB
contained in the added nuclear extract bound specifically
to the NF-κB response element and was detected by
addition of the provided specific primary antibody direc-
ted against NF-κB (p65). A secondary antibody conju-
gated with HRP was added, a colorimetric readout at
655 nm was performed and data was quantified as indi-
cated in the protocol. The assay was performed on cells
from two independent biopsies.
Western blot for MAP kinases (p38, ERK, JNK)
Whole cell extracts of untreated, IL-1β-treated and
IL-1β/curcumin-treated cells were prepared after 15 min
(using standard protocols) to investigate whether curcu-
min acts on typical MAP kinases. Protein content was
measured by Bradford assay and immunoblotting of whole
cell extracts was performed as described for p65, but
membranes were incubated with antibodies recognizing
Table 2 Primers/Probes used for real-time RT-PCR
(TaqManW Gene Expression Assays, Applied Biosystems)
Gene Primer sequence
number
Base
pairs
Interleukin-1β (IL-1β) Hs00174097_m1 94
Interleukin-6 (IL-6) Hs00174131_m1 95
Interleukin-8 (IL-8) Hs00174103_m1 101
Matrixmetalloproteinase-1 (MMP1) Hs00233958_m1 133
Matrixmetalloproteinase-3 (MMP3) Hs00968308_m1 98
Matrixmetalloproteinase-13 (MMP13) Hs00233992_m1 91
TATA box binding protein (TBP) Hs00427620_m1 91
Toll-like receptor 2 (TLR2) Hs00152932_m1 80
Tumor necrosis factor alpha (TNF-α) Hs00174128_m1 80
Data was obtained by real-time RT-PCR (ΔΔct method) (n = 10).
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Figure 1 Cytotoxicity of the curcuma DMSO extract (1a), curcuma ethanol extract (1b) and curcumin (1c) after 6, 18 and 30 hours. Data
was obtained by use of the MTT assay and is presented as Mean and SEM (n = 5). Asterisks indicate statistical significance (p < 0.05).
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either unphosphorylated or phosphorylated p38, ERK
(p42/44) or JNK (Cell Signaling, USA) before adding an
HRP-labeled rabbit secondary antibody and analyzing
chemiluminescence. Tubulin was used as a loading con-
trol. The assay was performed on samples from five in-
dependent experiments.
Statistical analysis
All quantitative data (cytotoxicity, gene expression) was
statistically analyzed using a Mann Whitney U test on
the SPSS statistics software and differences were consid-
ered statistically significant at p < 0.05 (two-tailed).
Results
Cytotoxicity of curcuma extracts and curcumin
Cytotoxicity of curcuma extracts (DMSO, ethanol) and
curcumin was determined after 6, 18 and 30 hours
(i.e. toxicity for short and long time points) using
the MTT assay. For the curcuma DMSO extract, cell
viability was constricted at concentrations of 500 μg/ml
(30 hours) and 1000 μg/ml (all time points) (Figure 1a).
A slight proliferative effect was observed for 100 μg/ml
(30 hours) and 250 μg/ml (18 hours). For the curcuma
ethanol extract, no cytotoxic effect could be observed at
any time point up to a concentration of 1000 μg/ml
(Figure 1b). For curcumin, cytotoxic effects could be
observed at concentrations of 50 μM (30 hours) and 100
μM (all time points) (Figure 1c).
Changes in gene expression with IL-1β prestimulation
With IL-1β treatment, we could observe a significant in-
crease in the mRNA levels of all genes of interest at the
time of analysis (6 hours). Data for all genes is shown in
Table 3 as mean, SEM and p-value (data based on ana-
lysis of cells from 10 independent biopsies).
Changes in gene expression with curcuma DMSO and
ethanol extracts
As shown in the Supplementary Material (Additional file 1:
Figure S1 and Additional file 2: Figure S2), neither DMSO
nor EtOH at the used concentration (0.03%) influenced the
expression of the inflammatory and catabolic target genes.
Treatment with the curcuma DMSO extract resulted
in a significant inhibition of MMP1, MMP3 and MMP13
after 6 hours, relative to IL-1β prestimulated cells (which
are also supplemented with the respective volume of
DMSO). While no changes occurred in the expression of
IL-1β and IL-8, a significant inhibition of IL-6 was
observed. However, we noticed a strong induction of
TNF-α expression at this early time point. Expression of
TLR2 was significantly reduced. For all results see
Figure 2a as well as Additional file 3: Table S3 for sum-
marized values.
Compared to IL-1β prestimulated cells, treatment with
the curcuma EtOH extract did not cause any changes in
gene expression after 6 hours for MMP1 and MMP3
while slightly decreasing MMP13 expression. Expression
of IL-1β, IL-6 and IL-8 also remained unchanged, but
TNF-α expression was increased. TLR2 expression was
not influenced. For all results see Figure 2b as well as
Additional file 3: Table S3 for summarized values.
Analysis of the curcuma DMSO and EtOH extracts
(HPLC/MS)
Based on the above shown results, the DMSO fraction
seemed to contain one or more anti-catabolic and anti-
inflammatory substances. Taking the solubility of the
various components of curcuma as well as the literature-
based preselection of anti-inflammatory components of
curcuma into account, the curcuminoid curcumin was
chosen to be the most promising candidate substance
with biological activity. In order to proof that curcumin
was indeed present in the DMSO extract, HPLC/MS ana-
lysis was performed on the stock extracts (320 mg/ml).
The results showed that predominantly curcumin
(6.32 mg/ml) (Peak 1) was present in the extract (reten-
tion time 16.9 min, (M+H)+ at m/z 369.1), followed
by its precursors demethoxycurcumin (retention
time 15.4 min, (M+H)+ at m/z 339.1) (Peak 2) and
bisdemethoxycurcumin (retention time 13.7 min, (M+H)+
at m/z 309.1) (Peak 3) and other unidentified compounds
with little absorbance (Figure 3).
As curcumin is also soluble in EtOH, we performed a
sequential extraction process described under Materials
and Methods in order to aggregate curcumin in the
DMSO extract. Both, the sequential EtOH extract
(stock extract = 320 mg/ml) as well as the pure curcu-
min stock solution in DMSO (25 mM) were also mea-
sured by HPLC/MS. While the curcuma DMSO extract
contained 6.32 mg/ml of curcumin, the sequential
Table 3 Effects of IL-1β stimulation on mRNA levels
of candidate genes after 6 hours
Gene Mean (Fold Change) SEM p-Value
IL-1β 246.34 48.12 <0.001
IL-6 2895.17 1571.28 <0.001
IL-8 241.89 56.71 <0.001
MMP1 166.05 31.06 <0.001
MMP3 260.58 70.75 <0.001
MMP13 119.06 29.49 <0.001
TNF-α 21.45 7.16 <0.001
TLR2 8.49 1.64 <0.001
Data was obtained by real-time RT-PCR (ΔΔct method) (n = 10).
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curcuma EtOH extract contained only 1.2 mg/ml
(Figure 4). Curcumin itself showed the highest value
and was in a similar range as the curcuma DMSO ex-
tract (8.80 mg/ml) (Figure 4).
Changes in gene expression with curcumin
Based on the above-mentioned findings, curcumin was
investigated at different concentrations (equalizing to the
approximate concentration of curcumin in the curcuma
extract) in more detail at the 6 hour time point. Treat-
ment with curcumin caused a significant reduction of
MMP1 (Figure 5a) and MMP3 (Figure 5b) at 10 μM and
20 μM. For MMP13, all concentrations of curcumin
caused a significant reduction (Figure 5c). Expression of
IL-1β (Figure 5d) and IL-6 (Figure 5e) was significantly
inhibited at both, 10 μM and 20 μM, while the lowest
Figure 2 Effects of the curcuma DMSO extract (2a) and curcuma ethanol extract (2b) on mRNA levels of candidate genes after 6 hours,
indicated as fold change relative to IL-1β-treatment (IL-1β treated cells also contain 0.03% of DMSO or EtOH respectively). Data was
obtained by real-time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 5). Asterisks indicate statistical significance (p < 0.05). Each
gene was normalized to its respective IL-1β treatment (IL-1β + solvent), which was always set to 100% (only one exemplary control bar is shown).
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concentration caused a slight increase of IL-6. IL-8 ex-
pression was also decreased at 20 μM (Figure 5f ). In con-
trast, TNF-α expression was significantly increased at all
three curcumin concentrations, with the most prominent
effects at 20 μM (Figure 5g). Furthermore, TNF-α ex-
pression was also increased upon curcumin treatment
alone (i.e. if no IL-1β pretreatment was performed), while
all other target genes remained unaltered under these
conditions (data not shown). TLR2 expression was sig-
nificantly reduced with each concentration (Figure 5h).
For summarized values see Additional file 4: Table S4.
Analysis of NF-κB
Immunoblotting of p65 in nuclear extracts of untreated,
IL-1β-treated and IL-1β/curcumin-treated cells revealed
that IL-1β-treatment caused nuclear translocation of p65
after 60 min. However, compared to IL-1β stimulated
samples, curcumin treatment did not reduce levels of the
target protein in nuclear extracts (equal protein loading
was confirmed by PARP detection) (Figure 6a). Using the
NF-κB/p65 transcription factor assay, we provide further
evidence that IL-1β strongly induced NF-κB DNA bind-
ing (similar to the positive control = Pos Ctrl), while cur-
cumin was not able to reduce levels after IL-1β
stimulation (Figure 6b). Internal assay controls (i.e. com-
petition and non-specific binding control) ensured valid-
ity of the test.
Analysis of MAP kinases (p38, ERK, JNK)
Effects of curcumin on MAP kinase activity were investi-
gated by detection of levels of phosphorylated and
unphosporylated p38 (Figure 7a), ERK (Figure 7b) and
JNK (Figure 7c) using immunoblotting technique of
whole cell extracts. Results demonstrate that IL-1β treat-
ment increased levels of phosporylated p38, ERK and
JNK after 15 min, which is indicative of activation of
these MAP kinases. Treatment with curcumin reduced
activity of JNK compared to IL-1β treatment (i.e. reduced
levels of p-JNK), but further increased levels of p-ERK
and p-p38 compared to IL-1β treatment. Levels of
unphosporylated p38, ERK and JNK were similar in all
groups. Equal protein loading was confirmed by tubulin
detection.
Discussion
Changes in gene expression
Curcuma is not only an ancient spice, but also a trad-
itional remedy that has been used in Indian and Chinese
medicine to treat indigestion and many other medical
issues. Since the 1970s, the anti-inflammatory com-
pounds called curcuminoids were discovered in the spice,
with one (and probably the most important component)
being curucmin [22]. Because of its anti-inflammatory
properties, curcuma and its components (especially cur-
cumin) have been investigated in osteoarthritis and
rheumatoid arthritis during the past one to two decades,
while only one paper has been published on the effects of
curcumin on intervertebral disc cells so far [23].
Our results clearly show that the different curcuma
extracts influenced cellular behavior in a different
manner. While the curcuma EtOH extract (which con-
tained only little amounts of curcumin, as shown by
HPLC/MS) had no effect and was thus considered to be
not suitable for further investigations, the curcuma DMSO
extract as well as the DMSO-soluble compound curcumin
(which was shown to be present in the DMSO extract by
Figure 3 Analysis of the composition of the curcuma DMSO
extract (black line) and the reference substance curcumin (grey
line, >94% purity with demethoxycurcumin and
bisdemethoxycurcumin as impurity) in DMSO by HPLC-DAD
(detection wavelength 425 nm). The three peaks were identified
as curcumin (1, retention time 16.9 min), demethoxycurcumin
(2, retention time 15.4 min) and bisdemethoxycurcumin (3, retention
time 13.7 min) by their (M+H)+ ions in the HPLC/MS analysis.
Figure 4 HPLC/MS measurement of the curcumin concentration
in curcuma DMSO and curcuma EtOH stock extracts (320 mg/ml),
prepared by the described sequential extraction procedure.
In addition, the curcumin stock solution (25 mM; in DMSO) was
quantified.
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Figure 5 (See legend on next page.)
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HPLC/MS) reduced levels of some disc-specific, major
proinflammatory cytokines and matrix degrading enzymes
in our in vitro experiments. We were able to demonstrate
that the observed effect was not due to the biologic activity
of the solvents DMSO and EtOH (Additional file 1:
Figure S1 and Additional file 2: Figure S2), although the
anti-inflammatory properties of DMSO have most recently
been described in human intestinal cells [24].
Specifically, we could demonstrate a reduction in gene
expression of IL-6, MMP1, MMP3 and MMP13 when
treating IL-1β prestimulated cells with the curcuma DMSO
extract. Additionally, IL-1β and IL-8 were reduced by cur-
cumin treatment after 6 hours. As effects were comparable
between the curcuma DMSO extract and curcumin and as
curcumin was detected at high concentrations in the
DMSO extract by HPLC/MS, we hypothesize that the
major bioactive substance in curcuma DMSO extracts
acting on human intervertebral disc cells could be
curcumin. Due to the beneficial effects of curcumin, this
natural compound may be of benefit for patients with
inflammation-related back pain, with the potential mode of
application being intradiscal injection. Albeit curcumin is
Figure 6 Effects of curcumin on nuclear translocation of p65/NF-κB, measured by immunoblotting of p65 (n= 3, nuclear extracts,
60 min). 6a: Nuclear translocation of p65, measured by immunoblotting (n=3, nuclear extracts, 60 min). One representative sample is shown and
PARP-1/2 is used as a loading control.
6b: NF-kB DNA binding activity, measured by NF-kB transcription factor assay (n=2, nuclear extracts, 60 min: without statistical evaluation). Note
that different internal controls (positive control, competition control and unspecific binding control) were used to validate the test.
(See figure on previous page.)
Figure 5 Effects of curcumin (5, 10 or 20 μM) on mRNA levels of candidate genes after 6 hours, indicated as fold change relative to
IL-1β-treatment: MMP1 (5a); MMP3 (5b); MMP13 (5c); Interleukin-1β (5d); Interleukin-6 (5e); Interleukin-8 (5f); TNF-α (5g); TLR2 (5h)
(IL-1β treated cells also contain 0.03% of DMSO). Data was obtained by real-time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM
(n = 5). Asterisks indicate statistical significance (p < 0.05). Each gene was normalized to its respective IL-1β treatment (IL-1β + DMSO), which was
always set to 100% (only one exemplary control bar is shown).
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well known for its low bioavailability in case of oral con-
sumption, in vivo concentrations after injections should not
be a limiting factor.
The observed gene expression results are similar to
effects that were observed when treating other cell types
with curcumin, e.g. leading to a reduction in IL-1β [25-28],
IL-6 [25,28-30], IL-8 [25,31], MMP1 [32], MMP3 [26,32,33]
and MMP13 [32,34]. For IL-6, we observed a slight increase
at the lowest concentrations (1.5 fold), but a decrease at
higher concentrations. This may be due to biphasic effects
of curcumin that are based on its dual function to either
scavenge or produce reactive oxygen species [35]. However,
the biphasic nature of curcumin cannot explain that higher
concentrations of curcumin strongly stimulated expression
of TNF-α in human intervertebral disc cells (both, without
pretreatment as well as after IL-1β prestimulation), which
is different from what is described in the literature
[25,28,36]. Based on the current study we do not know
whether this effect would also occur on the protein level
and in vivo. Therefore, further studies are thus required to
demonstrate safety and usefulness of curcumin in human
application.
So far, only one study investigated the effect of curcumin
on human intervertebral disc cells [23]. This study tested
curcumin for its effects on matrix protein gene expression,
but not on the expression of proinflammatory cytokines or
matrix degrading enzymes. Results of Yu et al.’s study indi-
cated that curcumin is also able to attenuate an IL-1
induced inhibition of SOX9 and collagen–II expression at
20 μg/ml (= 54.3 μM), which is higher than the concentra-
tions used in the present study and which was shown to be
a damaging concentration for other (disc-related) cell
types (e.g. C-28/I2= a chondrocyte cell line) [37]. Further-
more, it has to be noted that both, Yu’s as well as our study
were performed in a 2D culture system, which can cause
certain phenotypic changes of disc cells and may thus pos-
sibly influence cellular behavior to the tested treatment.
Pathway analysis
Curcumin seems to exhibit its anti-inflammatory and
anti-catabolic effects through versatile mechanisms. So
far, in different cell types, mainly inhibition of NF-κB,
MAP kinases and Toll-like receptors have been shown to
play a role [31,38-41].
NF-κB
Inhibition of the transcription factor NF-κB is the
best described mechanism of action of curcumin in
the literature [42]. A recent study in chondrocytes
showed that curcumin inhibits phosphorylation and
degradation of IκBα (= nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, alpha)
and thus translocation of the p65 subunit of NF-κB
to the nucleus, indicating that inhibition of the
NF-κB pathway takes place at a step before IκBα
phosphorylation [41]. In intestinal epithelial cells,
curcumin seems to exert its effects by blocking a sig-
nal leading to IKK (= IκB kinase) activity [31]. How-
ever, in our experimental setting, curcumin did not
seem to reduce IL-1β induced nuclear translocation
of NF-κB/p65 or NF-κB DNA binding, which is in
contrast to data obtained by Yu et al. on interverte-
bral disc cells [23].
Toll-like receptors
We were able to demonstrate a down-regulation of TLR2
mRNA expression after treating IL-1β prestimulated IVD
cells with curcumin, which confirms findings in other
cell types such as monocytic THP-1 cells, HL-60 pro-
myelocytic leukemia cells and primary peripheral blood
polymorphonuclear neutrophils [38]. However, in a
leukemia cell line, Reuter et al. showed an increase in
Figure 7 Effects of curcumin on MAP kinase activity, measured
by immunoblotting of p38/p-p38 (7a), ERK/p-ERK (7b) and JNK/
p-JNK (7c) (n = 5, whole cell extracts, 15 min). One representative
sample is shown and tubulin is used as a loading control.
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TLR2 due to curcumin, although most inflammatory
mediators were simultaneously down-regulated in this
study [25]. There is also some evidence in the literature
that curcumin can reduce expression levels of TLR4
[29,43]. Based on how little is known about TLRs and
curcumin so far, more research is needed to establish a
causal relationship between therapeutic efficacy of curcu-
min and TLR2 activity.
MAP kinases
The mitogen-activated protein (MAP) kinase signaling
pathways, including JNK, p38 and extracellular-signal
regulated kinase (ERK), play an important role in the
regulation of inflammatory responses [14]. As MAP
kinases are regulated by phosphorylation cascades, their
activity can be determined by detecting phosphorylation
levels. We found that curcumin was able to inhibit phos-
phorylation of JNK in IL-1β prestimulated IVD cells,
which is similar to primary chondrocytes [34,44]. Import-
antly, pharmacological inhibition of JNK (by SP600125)
has previously been shown to suppress MMP1, MMP3
and MMP13 mRNA expression in bovine and murine
IVD cells [45,46] (reviewed in [47]).
In contrast, phosphorylation of p38 and ERK was
induced upon curcumin treatment in IL-1β prestimu-
lated IVD cells as well as in curcumin-only treated IVD
cells, with a synergistic effect of IL-1β and curcumin
[48-50]. It may be possible that activation of p38 and
ERK led to the up-regulation of TNF-α expression
which was observed when IL-1β pretreated and un-
treated IVD cells were exposed to curcumin, but our
experimental design does not allow to establish a causal
relationship between MAP kinase activation and TNF-α
expression. Furthermore, activation of ERK and p38
does not only control inflammation, but also several
other cellular functions, such as cell cycle progression
for ERK (i.e. transition from the G1 to the S phase of
the cell cycle) [51] and cell growth and differentiation
for p38 [52], indicating that MAP kinase related cellular
control is of high complexity.
Conclusion
In conclusion, the results of this study demonstrate that
curcumin may become an attractive alternative for the
treatment of discogenic back pain when envisaging an
intradiscal injection method, which will circumvent the
low bioavailability of curcumin. Although we were able
to show in a previous study (using a similar experimental
set-up) that another anti-inflammatory substance (resver-
atrol), caused pain-reducing effects in a rodent model of
radiculopathic pain in vivo [53], the analgetic effect of
curcumin first needs to be confirmed before clinical trials
are reasonable.
Additional files
Additional file 1: Figure S1. Effects of 0.03% DMSO on mRNA levels of
candidate genes after 6 hours, indicated as fold change relative to
DMSO-free (i.e. untreated) controls (set to 1). Data was obtained by real-
time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 3).
Each gene was normalized to its respective DMSO-free control, which
was always set to 1 (only one exemplary untreated control bar is shown).
Additional file 2: Figure S2. Effects of 0.03% EtOH on mRNA levels of
candidate genes after 6 hours, indicated as fold change relative to EtOH-
free (i.e. untreated) controls (set to 1). Data was obtained by real-time RT-
PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 3). Each
gene was normalized to its respective EtOH-free control, which was
always set to 1 (only one exemplary untreated control bar is shown).
Additional file 3: Table S3. Summarized values of the graphical
illustration of the effects of the curcuma DMSO and EtOH extracts shown
in Figure 1. Quantitative values of the anti-catabolic and anti-
inflammatory effects of the curcuma DMSO and EtOH extracts on mRNA
levels of candidate genes after 6 hours (indicated as fold change relative
to IL-1β-prestimulation: 100%) are given only if a statistically significant
reduction occurred (p < 0.05). Note that IL-1β prestimulated cells also
contain 0.03% of DMSO or EtOH respectively. Data was obtained by real-
time RT-PCR (2-ΔΔCt method) and is presented as Mean and SEM (n = 5).
Additional file 4: Table S4. Summarized values of the graphical
illustration of the effects of curcumin shown in Figure 5. Quantitative
values of the anti-catabolic and anti-inflammatory effects of curcumin on
mRNA levels of candidate genes after 6 hours (indicated as fold change
relative to IL-1β-prestimulation: 100%) are given only if a statistically
significant reduction occurred (p < 0.05). Note that IL-1β prestimulated
cells also contain 0.03% of DMSO. Data was obtained by real-time RT-PCR
(2-ΔΔCt method) and is presented as Mean and SEM (n = 5).
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Abstract
Background: MMP28 (epilysin) is a recently discovered member of the MMP (matrix metalloproteinase) family that
is, amongst others, expressed in osteoarthritic cartilage and intervertebral disc (IVD) tissue. In this study the
hypothesis that increased expression of MMP28 correlates with higher grades of degeneration and is stimulated by
the presence of proinflammatory molecules was tested. Gene expression levels of MMP28 were investigated in
traumatic and degenerative human IVD tissue and correlated to the type of disease and the degree of
degeneration (Thompson grade). Quantification of MMP28 gene expression in human IVD tissue or in isolated cells
after stimulation with the inflammatory mediators lipopolysaccharide (LPS), interleukin (IL)-1b, tumor necrosis factor
(TNF)-a or the histondeacetylase inhibitor trichostatin A was performed by real-time RT PCR.
Results: While MMP28 expression was increased in individual cases with trauma or disc degeneration, there was
no significant correlation between the grade of disease and MMP28 expression. Stimulation with LPS, IL-1b, TNF-a
or trichostatin A did not alter MMP28 gene expression at any investigated time point or any concentration.
Conclusions: Our results demonstrate that gene expression of MMP28 in the IVD is not regulated by inflammatory
mechanisms, is donor-dependent and cannot be positively or negatively linked to the grade of degeneration and
only weakly to the occurrence of trauma. New hypotheses and future studies are needed to find the role of
MMP28 in the intervertebral disc.
Keywords: MMP28, Epilysin, Matrix metalloproteinase, Intervertebral disc, Inflammation
Background
Proteins of the matrix metalloproteinase (MMP) family
play an essential role in tissue homeostasis by initiating
breakdown and reorganization of the extracellular matrix.
While being tightly regulated in normal physiological
processes (e.g. via tissue inhibitors of metalloproteases
TIMPs), dysregulation of MMPs has been implicated in
many diseases. During intervertebral disc (IVD) degen-
eration, the expression and activity of a number of
MMPs is increased, including MMPs 1, 3, 7, 9 and 13 [1].
Proinflammatory cytokines such as IL-1b and TNF-a as
well as bacterial endotoxins (e.g. lipopolysaccharide LPS)
can stimulate expression of various MMPs (e.g. MMPs 1,
3, 9 and 13) in the IVD, as well as in cartilage [2-10].
During the recent past, five new members in the
MMP family have been identified: MMP24 to MMP28.
MMP28, also known as epilysin and most closely related
to MMP19, is a soluble MMP that contains an activa-
tion sequence recognized by the furin endoprotease
following the pro-domain [11]. It is a well-conserved
MMP, with great similarity (97%) in the catalytic
domain between human and mouse and overall 85%
identical amino acids [12]. MMP28 is strongly expressed
in testis, as well as in bone, kidneys, lung, heart, colon,
intestines, brain, skin and carcinomas [12-17]. It is also
expressed in cartilage, synovium and IVDs, with lower
expression in bovine discs compared to bovine cartilage
[18-22]. Interestingly, MMP28 expression seemed to be
* Correspondence: Karin.wuertz@cabmm.uzh.ch
1Spine Research Group, Competence Center for Applied Biotechnology and
Molecular Medicine, University of Zurich, Zurich, Switzerland
Full list of author information is available at the end of the article
Klawitter et al. Journal of Negative Results in BioMedicine 2011, 10:9
http://www.jnrbm.com/content/10/1/9
© 2011 Klawitter et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
  76 
 
increased in osteoarthritis and degenerated IVD com-
pared to healthy tissue, indicating that it may play an
important role during these disease processes [18-21].
Despite increasing interest in the role of MMP28 in
vivo, little is known about its substrates. Recombinant
MMP28 has been reported to degrade casein in vitro
and is thought to cleave several neural proteins such as
neurite outgrowth inhibitor A ( = Nogo-A), neural cell
adhesion molecule ( = NCAM-1) and neuregulin 1 ( =
NRG1) [17,23,24]. However, with regard to musculoske-
letally relevant proteins, no information on potential
substrates is currently available.
As symptomatic degenerated IVDs are characterized
by increased levels of certain proinflammatory mediators
[10,25-27], which are know to regulate several MMPs
[1], we hypothesized that MMP28 expression could be
increased in an inflammatory context. Therefore, the
aim of this study was to determine the expression level
of MMP28 in traumatic or degenerated discs (with dif-
ferent degrees of degeneration) and to investigate the
effects of different concentrations of the proinflamma-
tory mediators IL-1b, TNF-a or LPS on its expression
in human IVD cells at various time points. Additionally,
the effect of the histondeacetylase (HDAC) inhibitor tri-
chostatin A was investigated, as it has been shown to be
an up-regulator of MMP28 expression in HeLa cells
[28].
Materials and methods
MMP28 expression in human IVD biopsies
Thirteen tissue samples from eight patients who had been
diagnosed with symptomatic degenerative disc disease or
spinal trauma were included in this part of the study.
Based on magnetic resonance imaging (MRI) findings, the
degree of IVD degeneration was evaluated according to the
Thompson grading system prior to the surgical interven-
tion (for detailed information see Table 1) [29]. Informed
consent was obtained from all patients according to the
local ethical regulations. Frozen biopsies were pulverized,
the IVD fragment powder was dissolved in 1 ml of TriFast
RNA isolation reagent (PeqLAB) and total RNA was iso-
lated according to the manufacturer’s instructions. cDNA
was prepared from total RNA using VILO cDNA Synthesis
Kit (Invitrogen). For Real-Time (RT)-PCR, cDNA template
(5 μl) was mixed with the qPCR reaction solution (IQ
SYBR Green Supermix, Bio Rad) and expression of
GAPDH and MMP28 was measured:
GAPDH: Forward-TGGACTCCACGACGTACTCA
GAPDH: Reverse-GGAAGCTTGTCATCAATGGAA
MMP28: Forward-GCCGTGCAGAGCCTGTAT
MMP28: Reverse-GAGTCCCAGGTCTCAAAGTCA
Furthermore, MMP13 was measured as a control gene:
MMP13: Forward-CCAGTCTCCGAGGAGAAACA
MMP13: Reverse-AAAAACAGCTCCGCATCAAC
Primers were used at a concentration of 0.25 nΜ, reac-
tions were carried out in triplicates and the specificity of
the amplification products was controlled with a melting
curve analysis of each reaction. The 2-∆Ct method was
used to calculate gene expression levels of MMP28 and
MMP13. To assure consistent PCR quality, a functional
cDNA quality control was used. Samples that produced
Ct values for GAPDH greater than 26 were not included
in the analysis. Instead PCR was repeated with a new
sample with identical Thompson grade.
Isolation, culture and stimulation of IVD cells
Twenty patients who had been diagnosed with sympto-
matic disc disease or disc herniation (for detailed
Table 1 Clinical and demographic data of the study
population used for ex vivo gene expression analysis
(age, sex, diagnosis, Thompson grade [29], vertebral
level)
Sample Sex Age Diagnosis Grade Level Region
1 M 31 DDD II L5/S1 NP
2a F 39 Trauma II C4/5 AF
2b F 39 Trauma II C4/5 NP
3a F 57 Trauma II Th10/11 AF
3b F 57 Trauma II Th10/11 NP
4a F 70 Trauma II Th12/L1 AF
4b F 70 Trauma II Th12/L1 NP
5a M 29 Trauma III L1/2 AF
5b M 29 Trauma III L1/2 NP
6a F 34 DDD III L4/5 AF
6b F 34 DDD III L4/5 NP
7a M 41 DDD III C4/5 AF
7b M 41 DDD III C4/5 NP
8 M 46 DDD III L5/6 NP
9a M 25 DDD IV L5/S1 AF
9b M 25 DDD IV L5/S1 NP
10 M 44 DDD IV L5/S1 AF+NP
11 M 50 DDD IV L5/S1 AF+NP
12 M 55 Spondylodesis IV C3/4 AF+NP
13a F 58 Spondylodesis IV C5/6 AF
13b F 58 Spondylodesis IV C5/6 NP
14 M 37 DDD V L5/S1 AF+NP
15a F 41 DDD V L3/4 AF
15b F 41 DDD V L3/4 NP
16a M 67 DDD V L5/S1 AF
16b M 67 DDD V L5/S1 NP
17a M 72 DDD V L4/5 AF
17b M 72 DDD V L4/5 NP
M = male, F = female, NP = nucleus pulposus, AF = annulus fibrosus. DDD =
degenerative disc disease, C = cervical, Th = thoracic, L = lumbar, S = sacral
(degeneration grade according to Thompson)
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information see Table 2) and had undergone operative
treatment were included in this cell culture study.
Informed consent was obtained from all patients accord-
ing to the local ethical regulations. Disc tissue was
minced and treated with 0.3% collagenase NB4 (Serva)
and 0.2% dispase II (Roche Diagnostics) in phosphate
buffered saline (PBS) for approximately 6 hours at 37°C.
After digestion, the cell suspension was filtered using a
70 μm cell strainer (BD Bioscience, Switzerland), centri-
fuged at 1000 g for 5 min and the cell pellet was washed
with and then resuspended in DMEM/F12 (Sigma). Cells
were expanded in a 2D culture containing DMEM/F12
(Sigma) with 10% FCS (Tecomedical), penicillin (50 U/
mL), streptomycin (50 μg/mL), and ampicillin (125 ng/
mL) (Gibco), with medium changes twice a week. When
an 80% confluence level was reached, expanded cells in
passage 2 or 3 were rendered serum free for 2 hours and,
in a first set of experiments, incubated with LPS, IL-1b
and TNF-a in a time-dependent (n = 5) and dose-depen-
dent manner (n = 5). For the dose dependency experi-
ment, cells were treated for 18 hours with different
concentrations of LPS (0.01 μg/ml, 0.1 μg/ml, 1.0 μg/ml,
2.0 μg/ml), IL-1b (0.1 ng/ml, 1 ng/ml, 5 ng/ml, 10 ng/ml)
or TNF-a (0.1 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml). For
the time course experiment, cells were incubated with one
chosen concentration of LPS (1 μg/ml), IL-1b (5 ng/ml) or
TNF-a (100 ng/ml) for 2, 6 or 18 hours in serum-free
medium. In a second set of experiments, disc cells as well
as HeLa cells (positive control) were incubated with differ-
ent concentrations of the HDAC inhibitor trichostatin A
(1 nM, 10 nM, 100 nM, 1000 nM) (Sigma-Aldrich) for 18
hours (n = 3). As trichostatin A is dissolved in EtOH, a
respective EtOH control was included in these experi-
ments. All concentrations of all chemicals were shown to
be non-toxic in advance using the MTT assay (data not
shown).
MMP28 mRNA detection in isolated human IVD cells after
stimulation
After stimulation, cells were trypsinized and total RNA
was isolated according to the manufacturer’s recommen-
dation (PureLink RNA Mini Kit, Invitrogen). For each
sample, 1 μg of total RNA was reverse transcribed to
cDNA (Reverse Transcription Reagents, Applied Biosys-
tems) and then used for real-time RT-PCR measurements
using TaqMan Gene Expression assays (Applied Biosys-
tems) for detection of MMP28 (Hs00425233_m1) as well
as of TATA-box binding protein TBP (internal control)
(Hs00427620_m1). As a positive control, expression of
MMP13 was also measured (Hs00233992_m1) on samples
stimulated with IL-1b (10 ng/ml), LPS (2.0 μg/ml) or
TNF-a (100 ng/ml) for 18 hours.
Gene expression was first normalized to the house-
keeping gene before comparing expression of treated
cells to untreated control or the respective solvents con-
trol if applicable (2-∆∆Ct method). Only changes > 2-fold
were considered to be relevant.
Statistical analysis
To compare gene expression levels between the study
groups, the Wilcoxon signed-rank test was used to
determine significance between the groups. The statisti-
cal software package SPSS was used and the significance
level was set to p < 0.05
Results
MMP28 gene expression pattern in human disc tissue
Analysis of MMP28 gene expression in disc biopsies,
which was grouped according to the degree of IVD
degeneration (Thompson grade), is shown in Figure 1a:
MMP28 was expressed in most of the analyzed disc sam-
ples and higher expression levels were found in samples
removed because of spine trauma (Thomson grade II =
normal adult discs with no disc degeneration). Expression
levels were low or practically absent in samples with
Thompson grade III (i.e. mild disc degeneration), but
increased slightly with increasing disc degeneration, with
high donor-donor variation. No consistent statistically
Table 2 Clinical and demographic data of the study
population used for in vitro cell culture experiments
(age, sex, diagnosis, Pfirrmann grade [38], vertebral
level)
Sample Age Sex Diagnosis Grade Level
1 59 F Disc Herniation 4 L4/5
2 61 M Disc Herniation 4 L3/4
3 50 M Disc Herniation 3 L5/S1
4 46 F Disc Herniation 5 L5/S1
5 51 M Symptomatic Disc Disease 3 L4/5
6 50 F Disc Herniation 3 L3/4
7 51 F Disc Herniation 3 L4/5
8 47 M Disc Herniation 5 L4/5
9 42 M Disc Herniation 4 L4/5
10 80 M Disc Herniation 4 L2/3
11 50 M Disc Herniation 4 L4/5
12 48 F Symptomatic Disc Disease 3 L4/5
13 61 F Disc Herniation 4 L4/5
14 37 F Disc Herniation 4 L4/5
15 66 M Disc Herniation 3 L5/S1
16 70 F Disc Herniation 4 L5/S1
17 40 F Disc Herniation 4 L4/5
18 55 F Disc Herniation 3 L4/5
19 26 M Disc Herniation 4 L5/S1
20 57 M Disc Herniation 4 L4/5
M = male, F = female, L = lumbar, S = sacral (grading according to Pfirrmann)
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significant correlation between MMP28 expression and
Thompson grades or disease could be found (Figure 1a).
As a control gene, MMP13 expression was analyzed in
the same samples, and it showed a strong increase in
expression in samples with Thompson grade V degenera-
tion (Figure 1b), as previously described in the literature
[30,31].
Regulation of MMP28 gene expression
No changes in MMP28 expression could be observed
when cells were treated with different concentrations of
LPS (Figure 2a), IL-1b (Figure 2b) or TNF-a (Figure 2c)
for 18 hours, no matter which concentration was used.
As changes in gene expression may strongly depend on
the chosen time point, one concentration that is typi-
cally used in the literature was chosen for each inflam-
matory mediator and cellular behavior was investigated
after 2, 6 or 18 hours of treatment. However, even at
different time points, MMP28 expression was not regu-
lated by LPS (1 μg/ml) (Figure 3a), IL-1b (5 ng/ml)
(Figure 3b) or TNF-a (100 ng/ml) (Figure 3c). In order
to verify the general responsiveness of disc cells to the
chosen treatment conditions, we also measured changes
in MMP13 expression. We found that after 18 hour,
treatment with IL-1b (100 ng/ml) resulted in a 146.4 ±
28.0 fold increase of MMP13 expression. Similarly, LPS
(2.0 μg/ml) caused an 11.1 ± 2.2 fold increase and TNF-
a (100 ng/ml) a 134.0 ± 31.5 fold increase in MMP13
mRNA levels (Mean ± SEM, all p < 0.001)(data not
shown).
Trichostatin A (a HDAC inhibitor) did not cause any
changes in MMP28 expression in human IVD cells at
any concentration (18 hours only) (Figure 4a). However,
in HeLa cells, which were used as a positive control,
Trichostatin A caused a significant 2.1 ± 0.1 fold induc-
tion of MMP28 expression at 1000 nM (p < 0.001)(data
not shown).
Discussion
Our results indicate that MMP28 is expressed by human
intervertebral disc cells in vivo and in vitro, with high
donor-donor variations in vivo but did not depend on
the level of disc degeneration as measured by Thomp-
son grade score. Additionally, we were able to demon-
strate that inflammatory cues (LPS, IL-1b and TNF-a)
did not regulate the expression of MMP28 in vitro, indi-
cating that inflammatory processes during IVD disease
do not seem to regulate MMP28 expression in vivo.
In our study, MMP28 was expressed in most disc sam-
ples with overall more pronounced expression in virtually
non-degenerated (grade II), traumatic tissue (removed for
the need of spinal fusion after trauma) and severely degen-
erated IVD tissue. However, for both, non-degenerated tis-
sue and the severe degeneration group, high donor-donor
variation was observed. Differences in expression levels in
similarly degenerated discs suggest that individual pro-
cesses during degeneration rather than the degeneration
stage itself causes an up-regulation of MMP28. In a study
done by Gruber et al., MMP28 was measured on the gene
expression level using Affymetrix gene array as well as on
the protein level using immunohistochemistry on discs
with Thompson grade I to IV [19]. Protein detection of
MMP28 expression was also anticipated in our study, but
commercially available antibodies proved to be unspecific
when performing immunoblotting experiments (data not
shown). Comparable to our study, Gruber et al. demon-
strated that gene expression of MMP28-precursor (gene
identification number AF219624.1) tended to be highest in
Thompson grade I and II trauma discs and also elevated
in severely degenerated and herniated discs, again without
any statistical correlation. Therefore, it is still unclear to
Figure 1 Ex vivo human IVD tissue gene expression of a)
MMP28 and b) MMP13 ( = positive control) in degenerated or
traumatic samples with Thompson grading II-V (patients: n =
17, samples: n = 28). Data is presented as individual measurement
values; * if p < 0.05 between indicated groups.
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date whether and how disc diseases can influence MMP28
expression levels. However, increased levels of MMP28
could be detected in cartilage from osteoarthritis and
rheumatoid arthritis patients, suggesting that this novel
MMP plays a certain, not completely understood role in
some musculoskeletal diseases [18,20,21]. So far, it is not
clear why some trauma patients showed high MMP28
expression, but it has been described that certain MMPs
such as MMP1 may also increase in disc tissue after trau-
matic incidences [31,32]. The molecular mechanisms
underlying the peculiar expression of MMP28 during
trauma and certain cases of more severe degeneration is
not clear yet and will have to be analyzed further. During
degeneration and trauma, specific molecular events may
take place, such as apoptotic or inflammatory processes,
changes in matrix protein composition (e.g. increase in
collagen type I) and alterations in the mechanical environ-
ment [32-36], all of which may explain MMP28 regulation.
Aside from MMP28, we also measured MMP13 expres-
sion, whose levels have been described in the literature to
be elevated with degeneration [30,31]. In our samples, we
also found a significant and relatively high increase of
MMP13 expression in the grade V degeneration group,
compared to all lower grades of degeneration, thus con-
firming previously published data.
However, when testing whether inflammation regulates
MMP28 expression, we could not find any changes in
MMP28 mRNA levels after treatment with LPS, IL-1b or
TNF-a, although inflammatory mediators regulate many
other MMPs (e.g. MMP1, MMP3, MMP9, MMP13), as
shown in the literature [7-10]. Indeed, when measuring
changes in MMP13 expression in our samples, we were
able to detect a significant increase after stimulation with
all three agents (LPS, IL-1b or TNF-a). This clearly indi-
cates that the absence of MMP28 regulation observed in
this study is not due to lack of sensitivity of our model
system. As effects on gene expression after stimulation
can depend strongly on the used concentrations as well
as on the chosen time point for analysis, variations in
dose and sampling points were considered in this study,
yet no effects were observed under any condition. In
human keratinocytes, TNF-a induced MMP28 at least to
a minor degree (up to 8 fold), while multiple other
growth factors (bFGF, EGF, GM-CSF, HGF, KGF, PDGF,
TGF-b1, VEGF, IGF-1) and cytokines (IFN-g, IL-1b) did
not influence its expression levels at all [37]. All this data
indicates that compared to other MMPs, MMP28 seems
to be rather unresponsive to external inflammatory sti-
muli in disc cells, although being expressed in degenera-
tive diseases that are characterized by inflammation.
Figure 2 Regulation of MMP28 gene expression in human IVD cells treated with different concentrations of LPS (a), IL-1b (b) or TNF-a
(c) for 18 hours (n = 5 each). Data is presented as mean ± SEM; * if p < 0.05 between indicated groups.
Figure 3 Regulation of MMP28 gene expression in human IVD cells treated with 1 μg/ml LPS (a), 5 ng/ml IL-1b (b) or 10 ng/ml TNF-a
(c) for 2, 6 or 18 hours (n = 5 each). Data is presented as mean ± SEM; * if p < 0.05 between indicated groups.
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It should however be noted that, in this part of the study,
no distinction was made between annulus fibrosus and
nucleus pulposus cells as a clear separation of the two
zones is not possible in later stage degenerated disc tissue
(whereas a separation was possible in less degraded tissue
in the first part). Considering the fact that no effect was
observed in this mixed cell population, it is however unli-
kely that a significant alteration would have been
observed if distinct cell types had been used.
As TNF-a was not able to induce MMP28 in human
IVD cells, we investigated the potential of trichostatin A, a
HDAC inhibitor, which was previously shown to strongly
regulate MMP28 in HeLa cells. It is assumed that HDAC
inhibitors induce MMP28 promoter by acetylation of spe-
cificity protein 1 (SP1), which can alter protein-protein
interactions and can modify the SP1 containing protein
complexes that act at the GC/GT-boxes [28]. However, in
our experiments, trichostatin A did not have any effect on
the expression levels of MMP28 in disc cells, but the sti-
mulatory effect in HeLa cells could be confirmed in our
experimental setting. So far, no other studies have been
performed concerning the responsiveness of MMP28 to
HDAC inhibitors. Therefore, it is unknown whether most
other cell types would show a behavior similar to HeLa
cells (regulation) or to IVD cells (no regulation).
Conclusions
In conclusion, findings of this study provide evidence
that MMP28 expression in human IVD tissue is higher
in certain cases but the causal relationship between disc
diseases and MMP28 expression is unclear to date. In
contrast to many other MMPs, MMP28 is not regulated
by various inflammatory mediators (IL-1b, TNF-a, LPS)
or the HDAC inhibitor trichostatin A. Future studies
will be necessary to identify the role of MMP28 in the
IVD more conclusively.
Abbreviations
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Abstract
Introduction Increased levels of proinflammatory cyto-
kines seem to play a pivotal role in the development of
back pain in a subpopulation of patients with degenera-
tive intervertebral disc (IVD) disease. As current treat-
ment options are mostly limited to surgical interventions
or conservative treatment, anti-inflammatory substances
might offer a novel, more target-orientated therapeutic
approach. Triptolide (TPL), a natural substance found in
the Chinese medicinal herb Tripterygium wilfordii Hook,
has been demonstrated to possess anti-inflammatory
effects in various cells, but no studies exist so far for the
IVD. Therefore, the aim of this study was to determine
the effects of TPL on human IVD cells by analyzing
changes in gene expression and underlying molecular
mechanisms.
Materials and methods In order to investigate the anti-
inflammatory, anabolic and anti-catabolic effect of TPL,
dose-dependency experiments (n = 5) and time course
experiments (n = 5) were performed on IL-1b presti-
mulated human IVD cells and changes in gene expres-
sion of IL-6/-8, TNF-a, PGE2S, MMP1/2/3/13, aggrecan
and collagen-I/-II were analyzed by real-time RT-PCR.
The molecular mechanisms underlying the effects
observed upon TPL treatment were investigated by
analyzing involvement of Toll-like receptors TLR2/4
(real-time RT-PCR, n = 5), NF-jB, MAP kinases p38,
ERK and JNK (immunoblotting and immunocytochem-
istry, n = 4) as well as RNA polymerase II (immuno-
blotting, n = 3).
Results Results showed that 50 nM TPL exhibited an
anti-inflammatory, anti-catabolic and anabolic effect on
the mRNA level for IL-6/-8, PGE2S, MMP1/2/3/13,
aggrecan, collagen-II and TLR2/4, with most pronounced
changes after 18 h for proinflammatory cytokines and
MMPs or 30 h for TLRs and matrix proteins. However,
we also observed an up-regulation of TNF-a at higher
concentrations. The effects of TPL did not seem to be
mediated via an inhibition of NF-jB or a decrease of
RNA polymerase II levels, but TPL influenced activity
of MAP kinases p38 and ERK (but not JNK) and
expression of TLR2/4.
Conclusions In conclusion, TPL may possess promising
potential for the treatment of inflammation-related disco-
genic back pain in vitro, but its analgetic effect will need to
be confirmed in an appropriate in vivo animal model.
Keywords Intervertebral disc ! Triptolide ! Gene
expression ! Immunoblotting ! Signaling pathway
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Introduction
Tripterygium wilfordii Hook F, a vine native to several
Asian countries, has been widely used in the traditional
Chinese medicine. Triptolide (TPL), a diterpenoid triep-
oxide, was identified as its major active component. It has
been demonstrated to possess strong immunosuppressive
and anti-inflammatory effects [1, 2]. TPL has been used in
treating inflammatory joint diseases [3, 4], but could
potentially also be applied in other inflammation-related
diseases. As TPL has been additionally shown to possess
anti-proliferative and pro-apoptotic activity in various
types of cancer cells, it is considered a possible new can-
didate in the group of new cancer therapeutics [5].
Current literature on the intervertebral disc (IVD) pro-
vides clear evidence for the relevance of inflammatory
mediators in the development of back pain. Nucleus pul-
posus (NP) tissue has long been known to induce radicu-
lopathic pain, due to chemical irritation of dorsal root
ganglion nerves induced by proinflammatory cytokines
present in this tissue [6–10]. Similarly, degenerative disc
disease (leading to so-called discogenic back pain) seems
to correlate with increased levels of proinflammatory
cytokines such as interleukin 1b (IL-1b), interleukin 6 (IL-6),
interleukin 8 (IL-8) and tumor necrosis factor a (TNF-a)
[11–15]. Although basic knowledge on the increased
expression of inflammatory mediators in certain cases of
back pain (i.e. discogenic back pain, NP mediated back
pain) exists, the molecular mechanisms underlying these
processes are not yet elucidated. However, molecular bio-
logical research of the past decades indicates that the MAP
kinase pathways as well as the transcription factor nuclear
factor-jB (NF-jB) are the major mechanisms regulating
inflammatory responses in vivo and in vitro. Additionally,
TPL has been described to not only influence NF-jB [16–
20] and MAP kinases [17, 18, 21], but also to reduce levels
of RNA polymerase II (=enzyme that is essential in the
process of transcription) in cancer cells [5], thus possibly
explaining the broad spectrum of genes whose expression
is influenced upon TPL treatment.
In order to suppress inflammation, corticosteroidal
substances are frequently used, which are, however, known
to have a significant risk for side effects. There is thus
increased interest in alternative substances that possess a
strong anti-inflammatory and anti-catabolic potential. In
the present study, we examined the effects of TPL on the
inflammatory and catabolic response of human IVD cells
that were prestimulated with recombinant IL-1b to simu-
late an inflammatory situation. We also analyzed the
molecular mechanisms mediating the inhibition of cytokine
expression by investigating the role of the transcription
factor nuclear factor kappa B (NF-jB), the Toll-like
receptors TLR2 and TLR4, the mitogen-activated protein
(MAP) kinases including p38, ERK (=extracellular signal-
regulated kinase) and JNK (=c-Jun N-terminal kinase) as
well as the involvement of RNA polymerase II.
Materials and methods
Materials
Materials used in this study are specified in Table 1.
Human intervertebral disc cell culture
Human IVD tissue was removed from patients undergoing
spinal surgery for discectomy or interbody fusion for
degenerative disc disease or disc herniation (for detailed
information see Table 2) after obtaining informed consent
in accordance with the local ethical guidelines.
Table 1 Detailed information about materials used in this study
Material Supplier
Ampicillin Gibco
BSA Sigma-Aldrich
Bradford reagent Bio-Rad
Collagenase NB4 Serva
Dispase II Roche
DMSO Sigma
ERK/p-ERK antibodies Cell Signaling
F-12/DMEM medium Sigma-Aldrich
Fetal calf serum (FCS) Tecomedical
HRP-mouse antibody Amersham
HRP-rabbit antibody Sigma
Hyperfilm ECL Amersham
Hybond-P PVDF Amersham
IL-1b recombinant Peprotech
JNK/p-JNK antibodies Cell Signaling
MTT Sigma-Aldrich
p38/p-p38 antibodies Cell Signaling
p65 antibody Santa Cruz
PARP1 antibody Santa Cruz
PCR Master Mix Applied Biosystems
Penicillin Gibco
PureLink RNA Kit Invitrogen
Reverse transcription reagents Applied Biosystems
RNA polymerase II antibody Santa Cruz
Streptomycin Gibco
SuperSignal West Dura Socochim
Triptolide Sigma
Trypsin Invitrogen
Tubulin antibody Cell Signaling
Eur Spine J (2012) 21 (Suppl 6):S850–S859 S851
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IVD tissue was enzymatically digested (0.2% collage-
nase NB4, 0.3% dispase II) for 4–8 h and cells were
thereafter cultured in DMEM/F12 supplemented with 10%
FCS, penicillin (50 units/ml), streptomycin (50 lg/ml) and
ampicillin (125 ng/ml) up to passage 2–3.
Viability measurement
Cellular viability after treatment with different concentra-
tions of TPL (6, 18 and 30 h) was analyzed using the MTT
assay as previously described, which has also been shown
to be comparable to other viability/toxicity measurements
(Picogreen assay, cell counting) [22]. Non-toxic concen-
trations were chosen for subsequent experiments.
Gene expression analysis
In order to investigate the effects of TPL on the expression
of inflammatory mediators (IL-6, IL-8, TNF-a, PGE2S =
prostaglandin E2 synthase), matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), Toll-like receptors
(TLR2, TLR4) and anabolic genes (aggrecan collagen-I,
collagen-II), dose-dependency (0.5, 5, 50 nM—all 18 h)
and time course experiments (6, 18, 30 h—all 50 nM) were
performed. Cells were serum starved for 2 h and then
exposed to 5 ng/ml IL-1b for 2 h before treating cells with
different concentration of TPL for 18 h. The most active
concentration was chosen for further time course experi-
ments. Untreated control cells as well as DMSO treated cells
(=solvent) were included in each experiment. After treat-
ment, cells were harvested by trypsin, RNA was isolated,
reverse transcribed and gene expression was measured on
the StepOne Plus PCR machine (Applied Biosystems) using
real-time RT-PCR as previously described. Briefly, human
specific probes and primers (see Table 3), TaqMan real-time
RT-PCR Mix and cDNA were mixed, measured in dupli-
cates and data was analyzed by using the comparative ct
method (2!DDCt method, housekeeping gene = Tata Box
binding protein = TBP). The assay was performed on
samples from five independent experiments.
Table 2 Demographic data on
surgical disc samples used in
this study
M male, F female, grade
classification of intervertebral
disc degeneration by Pfirrmann
grade
Number Age Sex Pathology Grade Level
1 60 M Disc herniation 3 L4/5
2 51 F Sympt. disc disease 4 L5/S1
3 42 F Disc herniation 4 L4/5
4 50 M Disc herniation 4 L4/5
5 47 M Disc herniation 4 L4/5
6 46 F Disc herniation 3 L5/S1
7 54 M Disc herniation 4 L4/5
8 27 F Disc herniation 3 L4/5
9 26 F Disc herniation 3 L4/5
10 43 M Disc herniation 4 L4/5
11 43 F Disc herniation 4 L4/5
12 50 F Disc herniation 3 L5/S1
13 49 M Disc herniation 4 L5/S1
14 26 M Disc herniation 4 L5/S1
15 45 F Disc herniation 4 L5/S1
16 40 F Disc herniation 4 L4/5
17 57 M Disc herniation 4 L4/5
18 44 F Disc herniation 3 L5/S1
19 60 M Disc herniation 4 L4/5
20 47 M Disc herniation 4 L4/5
21 36 M Disc herniation 3 C5/6
22 53 M Disc herniation 4 L4/5
23 48 F Disc herniation 4 L4/5
24 48 F Disc herniation 3 L4/5
25 42 F Disc herniation 4 L4/5
26 60 M Sympt. disc disease 3 L4/5
27 46 F Disc herniation 4 L5/S1
28 27 F Disc herniation 4 L4/5
29 42 M Disc herniation 3 L4/5
S852 Eur Spine J (2012) 21 (Suppl 6):S850–S859
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Pathway analysis (NF-jB, MAP kinases)
In order to investigate potentially involved pathways,
immunoblotting was performed for p65 (subunit of NF-jB)
as well as for the phosphorylated (=activated) and unphos-
phorylated MAP kinases p38, ERK and JNK. Briefly, cells
were stimulated with IL-1b or co-stimulated with IL-1b and
50 nM of TPL (the most potent concentration in gene
expression experiments) for 15 min (MAP kinases) or
60 min (NF-jB). Unstimulated control cells were included
as well.
For NF-jB immunoblotting, nuclear extracts were
prepared according to standard protocols, protein content
was measured by Bradford assay, nuclear extracts were
fractioned by SDS-PAGE, proteins were transferred onto
membranes and first incubated with a p65 antibody and
then with the appropriate secondary HRP-labeled anti-
body before analyzing chemiluminescence. In order to
confirm NF-jB immunoblotting results, nuclear trans-
location of p65 was additionally examined by immu-
nocytochemistry in methanol-fixed cells using standard
techniques.
For MAP kinase immunoblotting, whole cell extracts
were prepared as previously described, protein content
was measured by Bradford assay, whole cell extracts
were fractioned by SDS-PAGE, proteins were transferred
onto membranes and first incubated with antibodies rec-
ognizing phosphorylated or unphosphorylated p38, ERK
(=p42/44) or JNK antibody and then with the appropriate
secondary HRP-labeled antibody before analyzing chemilu-
minescence.
PARP1 and tubulin were used as loading controls for
p65 and MAP kinase immunoblotting, respectively. Each
assay was performed on samples from four independent
experiments.
Analysis of RNA polymerase II protein expression
level
The effect of TPL on RNA polymerase II expression was
investigated by immunoblotting of whole cell extracts that
were obtained from cells stimulated with either IL-1b alone
or IL-1b prestimulated cells with 50 nM of TPL for 6, 18
or 30 h (see ‘‘Gene expression analysis’’), using a specific
antibody recognizing human RNA polymerase II. Tubulin
was used as a loading control and the assay was performed
on samples from three independent experiments.
Statistical analysis
Statistical analysis was performed by Mann–Whitney
U Test (two-tailed) using the SPSS software. A signifi-
cance level of P\ 0.05 was considered statistically
significant.
Results
Viability
TPL exhibited a cytotoxic effect at concentrations of
250 nM and higher already within 18 h (data not shown).
For further experiments, non-toxic concentrations of 0.5, 5
and 50 nM were chosen, which did not exhibit any statis-
tically significant cytotoxic effect within the time frame of
the subsequent experiments (up to 30 h).
Gene expression
Confirming our data from previous studies, pre-treatment
with IL-1b stimulated expression of IL-6, IL-8, TNF-a,
Table 3 Primers/probes used
for real-time RT-PCR
(TaqMan! Gene Expression
Assays, Applied Biosystems)
Gene Primer sequence number Base pairs
Aggrecan Hs00202971_m1 93
Collagen-I Hs00164004_m1 66
Collagen-II Hs00264051_m1 124
Interleukin-6 (IL-6) Hs00174131_m1 95
Interleukin-8 (IL-8) Hs00174103_m1 101
Matrixmetalloproteinase-1 (MMP1) Hs00233958_m1 133
Matrixmetalloproteinase-2 (MMP2) Hs00174131_m1 96
Matrixmetalloproteinase-3 (MMP3) Hs01548724_m1 98
Matrixmetalloproteinase-13 (MMP13) Hs00233992_m1 91
Prostaglandin E2 Synthase (PGE2S) Hs00228159_m1 66
Tata Box binding protein (TBP) Hs00427620_m1 91
Toll-like receptor 2 (TLR2) Hs00152932_m1 80
Toll-like receptor 4 (TLR4) Hs00152939_m1 89
Tumor necrosis factor a (TNF-a) Hs00174128_m1 80
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MMP1, MMP2, MMP3, MMP13 as well as TLR2 and
reduced expression of aggrecan, collagen-I and collagen-II
(for detailed results, see Table 4), but did not influence
expression of PGE2S and TLR4.
In the first set of experiments, IL-1b prestimulated cells
were treated with different concentrations of TPL (0.5, 5,
50 nM) for 18 h. We observed a dose-dependent inhibition
of the expression of inflammatory mediators (IL-6, IL-8,
PGE2S), matrix degrading enzymes (MMP1, MMP2,
MMP3, MMP13) and Toll-like receptors (TLR2, TLR4).
For aggrecan, a 1.9-fold increase was observed with 50 nM
after 18 h, while no changes occurred with the lower
concentrations. Collagen-I and collagen-II were either not
altered or slightly decreased after 18 h. For all results,
see Fig. 1a–d. TNF-a expression was increased at
concentrations of 5 nM (2.8-fold) and 50 nM (21.2-fold)
(data not shown).
For the second set of experiments, IL-1b prestimulated
cells were treated with 50 nM TPL for 6, 18 or 30 h (time
course experiments). Results show that TPL exhibits its
anti-inflammatory, anti-catabolic and anabolic effects
already after 6 h with regard to IL-6, IL-8, MMP1, MMP3,
MMP13, aggrecan and TLR2, but its effects were more
pronounced after longer incubation periods (18 and 30 h),
including an increase of collagen-II (Fig. 2a–d). The most
distinct reduction in gene expression was observed at 18 h
for IL-6 (100 ? 4.1%), MMP1 (100 ? 11.1%), MMP3
(100 ? 15.7%), MMP13 (100 ? 13.3%) and TLR4 (100 ?
18.2%), but effects were also significant for IL-8 (100 ?
36.5%), MMP2 (100 ? 42.2%), PGE2S (100 ? 26.4%)
Table 4 Effects of IL-1b
stimulation on mRNA levels of
candidate genes after 6, 18 and
30 h, indicated as fold change
relative to no treatment (mean,
SEM, P values)
Data was obtained by real-time
RT-PCR (2!DDCt method)
(n = 5). PGE2S and TLR4 were
not significantly regulated by
IL-1b stimulation (values not
shown)
Gene Time point (h) Mean fold change SEM P value
Aggrecan 6 -1.4 0.3 0.001
18 -1.8 0.5 0.001
30 -2.7 0.5 \0.0001
Collagen-I 6 -1.0 0.2 0.001
18 -1.3 0.5 0.015
30 -2.1 0.2 \0.0001
Collagen-II 6 -2.1 0.2 \0.0001
18 -8.9 3.2 \0.0001
30 -7.2 1.1 \0.0001
IL-6 6 432.7 74.3 \0.0001
18 6236.1 2601.3 \0.0001
30 7350.5 2557.3 \0.0001
IL-8 6 558.4 175.2 \0.0001
18 1102.5 291.3 \0.0001
30 1983.8 649.3 \0.0001
MMP1 6 449.1 163.9 \0.0001
18 1576.5 470.9 \0.001
30 2032.6 631.9 \0.0001
MMP2 6 0.7 0.3 0.419
18 2.1 0.5 \0.0001
30 3.4 0.3 \0.0001
MMP3 6 327.7 124.9 \0.0001
18 1143.5 240.7 \0.0001
30 1768.8 636.0 \0.0001
MMP13 6 79.1 20.6 \0.0001
18 114.6 30.2 \0.0001
30 297.3 140.0 \0.0001
TNF-a 6 78.5 16.4 \0.0001
18 41.1 14.4 \0.0001
30 46.0 11.3 \0.0001
TLR2 6 16.5 1.9 \0.0001
18 13.5 1.2 \0.0001
30 13.4 2.1 \0.0001
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and TLR2 (100 ? 30.1%). We observed a time-dependent
up-regulation of aggrecan with a significantly increase after
18 h (1.8-fold), but the effect was more pronounced after
30 h (2.7-fold). Similarly, collagen-II expression was sig-
nificantly induced after 30 h (3.1-fold), while collagen-I
expression was not altered at any time point. While matrix
proteins were most regulated after 30 h, effects declined
for several genes at this time point already. Nevertheless,
the inhibitory effect remained significant for IL-6, MMP1,
MMP2, MMP13, PGE2S, TLR2 and TLR4 (Fig. 2a–d). In
accordance with results of the dose-dependency experi-
ments, TNF-a expression was up-regulated, especially after
30 h (6 h: 4.8-fold; 18 h: 101.0-fold; 30 h: 987.3-fold)
(data not shown).
NF-jB and MAP kinase pathway
Immunoblotting for p65 indicates that IL-1b prestimulation
caused nuclear translocation of p65, which is the first step
of NF-jB activation. However, treating IL-1b prestimu-
lated cells with 50 nM TPL was not able to prevent or
reverse nuclear translocation of NF-jB. Figure 3a shows
that the p65 band of TPL treated samples is not reduced
compared to IL-1b stimulated samples, while untreated
cells show a much smaller amount of target protein as
detected by immunoblotting of nuclear extracts. Equal
protein loading was confirmed by PARP1 detection. This
pattern could be confirmed by immunocytochemistry as
shown in Fig. 3b.
Immunoblotting for MAP kinases indicated that IL-1b
prestimulation caused phosphorylation of p38, ERK and
JNK, which is indicative of their activation. TPL treat-
ment (50 nM) strongly reduced levels of phosphorylated
p38 (Fig. 3c) and slightly reduced levels of phospory-
lated ERK (Fig. 3d), but not of JNK (Fig. 3e) compared
to IL-1b stimulated samples. As expected, levels of un-
phosporylated p38, ERK and JNK were similar in all
groups. Equal protein loading was confirmed by tubulin
detection.
RNA polymerase II protein expression level
Immunoblotting for RNA polymerase II indicates that
50 nM TPL did not influence its expression levels at any
investigated time point (6, 18, 30 h), compared to IL-1b
stimulated samples or untreated samples (Fig. 4).
dc
a b
Fig. 1 Effects of different concentrations of TPL (0.5, 5, 50 nM—
18 h) on mRNA levels of candidate genes, indicated as fold change
relative to IL-1b-prestimulation (set to 100%): a inflammatory
mediators (IL-6, IL-8, PGE2S), b matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), c matrix proteins (aggrecan,
collagen-I, collagen-II) and d Toll-like receptors (TLR2, TLR4). Data
was obtained by real-time RT-PCR (2!DDCt method) and is presented
as Mean and SEM (n = 5). Asterisks indicate statistical significance
(P\ 0.05); an asterisk in brackets indicates barely significant (IL-8:
P = 0.051)
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ba
c
Fig. 2 Effects of TPL (50 nM) on mRNA levels of candidate genes
after different time points (6, 18, 30 h), indicated as fold change
relative to IL-1b-prestimulation (set to 100%): a Inflammatory
mediators (IL-6, IL-8, PGE2S), b matrix degrading enzymes
(MMP1, MMP2, MMP3, MMP13), c matrix proteins (aggrecan,
collagen-I, collagen-II) and d Toll-like receptors (TLR2, TLR4). Data
was obtained by real-time RT-PCR (2!DDCt method) and is presented
as Mean and SEM (n = 6). Asterisks indicate statistical significance
(P\ 0.05)
Fig. 3 Effects of TPL (50 nM) on the induction/activity of NF-jB
and MAP kinases, detected by immunoblotting (IB) and immunocy-
tochemistry (IC). NF-jB induction was detected by a IB of nuclear
extracts (n = 4, 60 min) and b IC (n = 4, 60 min). MAP kinase
activity was detected by IB of whole cell extracts (n = 4, 15 min) for
c p38, d ERK and e JNK. One representative sample is shown. For IB,
PARP1 or tubulin was used as a loading control. For IC, Hoechst
counterstaining of cell nuclei was performed
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Discussion
Tripterygium wilfordii Hook has its therapeutic origin in
the traditional Chinese medicine (TCM), which—during
the past years—has been recognized by researchers world-
wide as an important and extensive source for revealing
novel lead molecules for modern drug discovery. However,
typical TCM preparations usually combine multiple herbs
(or other natural substances) with the respective variability
in composition (e.g. due to harvesting periods) and can thus
not be regarded as standardized products. In order to create
patentable and marketable products for conventional
Western medicine, the active component has to be identi-
fied and its molecular mechanism of action should be
elucidated. TPL has been identified as one of the major
bioactive components of Tripterygium wilfordii Hook. The
therapeutic potential of TPL or Tripterygium wilfordii
Hook is currently investigated at the stage of clinical trials
for the treatment of polycystic kidney disease, glomerulo-
sclerosis, nephropathy, spondylitis and rheumatoid arthritis
(http://clinicaltrials.gov). On a laboratory stage, the anti-
inflammatory and anti-catabolic effects of TPL are cur-
rently being investigated in even more cell and tissue types,
thus trying to broaden its therapeutic use. However, to the
authors’ knowledge, no studies have been performed with
regard to IVD diseases yet.
Results from this study on human IVD cells indicate that
TPL can effectively reduce mRNA levels of major
inflammatory mediators (IL-6, IL-8, PGES2) and matrix
degrading enzymes (MMP1, MMP2, MMP3, MMP13),
with highest effects after 18 h. However, mRNA expres-
sion of TNF-a was up-regulated upon TPL treatment.
Additionally, 50 nM TPL significantly induced levels of
relevant matrix proteins (aggrecan, collagen-II), especially
after 30 h. Why lower concentrations of TPL seemed to
inhibit collagen-II expression at earlier time points (18 h)
is currently not clear. While matrix proteins responded
strongly to TPL treatment after 30 h, effects were not as
pronounced anymore at this time point for most inflam-
matory and catabolic genes, indicating that TPL may
possess a limited bioactivity time frame. However, usage
of a slow release system may overcome this restriction.
Pathway analysis provides evidence that this effect may be
(at least partially) mediated by the MAP kinases p38 and
ERK (whose activity we saw to be influenced by TPL),
while the transcription factor NF-jB, the MAP kinase JNK
or the RNA polymerase II did not seem to be involved in
signal transduction. Additionally, expression of Toll-like
receptors TLR2 and TLR4 was reduced by TPL treatment.
The observed inhibition of mRNA for the major matrix
degrading enzymes and the induction of matrix proteins in
human IVD cells suggests that TPL can block tissue degra-
dation andmay thus potentially slow down or prevent further
disc degeneration. A comparable anti-catabolic potential of
TPL has been described in other cell types before, e.g. TPL
was shown to inhibit expression of proMMPs 1 and 3 in
human synovial fibroblasts [23] and expression of MMP3,
MMP13 and ADAMTS4 in human OA chondrocytes [24].
In the present in vitro study, TPL was able to inhibit
inflammatory responses in human IVD cells, which is
similar to macrophages (inhibition of PGE2, IL-1a, IL-b
and IL-6 expression) [23] and various kinds of fibroblasts
(inhibition of PGE2, COX-2, IL-6 and IL-8 expression)
[20, 25–27]. Although to the author’s knowledge only few
studies exist to date that investigated the anti-inflammatory
in vitro effect of TPL in chondrocytes [24], its effects were
tested in a collagen-induced arthritis mouse model in vivo.
Results indicate that TPL can reduce inflammatory
responses and cartilage damage in the joint tissues by
inhibiting expression of MMP3, MMP13, PGE2, COX-2,
IL-1b, IL-6, TNF-a [16–18]. While we can confirm the
inhibition of MMP3, MMP13 and IL-6 in human IVD cells
in vitro, expression of TNF-a was induced in our system
and will thus be subject to further scrutiny in next exper-
iments. The increased level of TNF-a may not only be
critical for any in vivo application, but may have also
influenced our results if transferred to the protein level as it
may be responsible for the sustained and unaltered NF-jB
activation. Activation of NF-jB has been described to
cause an anti-apoptotic effect, thus possibly masking any
toxic effect of TPL [28]. However, in order to verify
whether this is the case, experiments with NF-jB inhibition
(e.g. using Ad5-I kappa B alpha Delta N; MG132 [28]) will
need to be performed in the future. This will be important
as in tumor cells, TPL could in contrast block TNF-a-
induced activation of NF-jB, resulting in enhanced apop-
tosis induced by TNF-a [29].
Based on the obtained results, the next step will be to
investigate the anti-inflammatory and analgetic behavior of
TPL in vivo, using a well-established rodent model of
radiculopathic pain [30]. As bioavailability and diffusion
rates in vivo are unclear, the in vitro data obtained in this
study can only provide a first basis to choose appropriate in
vivo application modes.
Fig. 4 Effects of TPL (50 nM) on the expression levels of RNA
polymerase II, detected by immunoblotting of whole cell extracts
(n = 3) (6, 18, 30 h). One representative sample is shown. Tubulin
was used as a loading control
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Based on the promising gene expression results, we
further sought to investigate the underlying molecular
mechanism. Findings in the literature indicate that the NF-
jB pathway is one of the molecular mechanisms underly-
ing the cellular responses observed after TPL treatment
[16–20]. However, the effects of TPL seem to be mediated
by a complex interplay of various signaling mechanisms,
including the MAP kinases p38 [17], ERK [21] or JNK [17,
18] as well as the transcription factor AP-1 [19]. We were
able to show that in IVD cells, TPL may work in part by
interfering with phosphorylation of the MAP kinases p38/
ERK and by regulating expression of TLR2/4, but probably
not by inhibiting NF-jB or JNK activity, although this is
described for multiple other cell types [16–20], indicating
that the involved signaling pathways are cell-specific. In
addition, we investigated whether TPL is able to influence
protein levels of RNA polymerase II as this has been
described to be a major mechanism of action of TPL in
cancer cells most recently [5]. However, in human disc
cells, TPL did not reduce RNA polymerase II levels as
shown by immunoblotting, indicating once more that TPL
acts cell-specifically on certain mechanisms/pathways.
Clinical relevance
TPL seems to be a promising candidate to treat certain
cases of discogenic or NP mediated back pain, in which
increased levels of proinflammatory cytokines are respon-
sible for pain sensation. The in vitro cell culture results
clearly showed that TPL could effectively inhibit several
proinflammatory cytokines and matrix degrading enzymes,
which are thought to play a major role during symptomatic
disc degeneration. Simultaneously, TPL induced expres-
sion of disc-specific matrix proteins. However, in vivo
experiments will be needed to verify that TPL is an
attractive, new therapeutic agent for degenerative disc
disease by preventing further degradation of the tissue and
exhibiting an analgetic effect due to inhibition of proin-
flammatory cytokines.
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57ucleus pulposus (NP) tissue has long been known to be a potent inducer of pain ( e.g. , in radiculopa-thy). Scientifi c evidence indicated that this effect is 
due to proinfl ammatory cytokines present in this tissue.  1  –  5  
Degenerative disc disease (leading to so-called discogenic 
back pain) also seems to correlate with increased levels of 
proinfl ammatory cytokines.  6  –  12  The treatment of NP-medi-
ated pain such as radiculopathic pain and discogenic pain 
is still a matter of debate, indicating that current treatment 
options are not ideal. This is most likely because of the fact 
that current therapeutic strategies do not account for the 
biological mechanisms of pain development. There is a clear 
need for the development of novel therapeutic procedures 
that have the ability to interfere with the biological mecha-
nisms of NP-mediated pain, that is, with increased expres-
sion of pain-mediating proinfl ammatory cytokines. Inject-
able anti-infl ammatory substances that specifi cally target 
the metabolism of intervertebral disc (IVD) cells may serve 
as new and useful minimal-invasive treatment options,
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either for radiculopathic pain or discogenic back pain. The 
substance of choice should ideally also exhibit a strong 
anti-catabolic effect, thus limiting further degeneration of 
the IVD. 
 There is a growing interest in natural bioactive com-
pounds that may have a pronounced anti-infl ammatory effect 
and could thus possibly replace corticosteroids. Resveratrol 
(3,5,4’-trihydroxy-trans-stilbene ) is a polyphenolic phyto-
alexin found in red wine that has previously been shown to 
demonstrate anti-infl ammatory, anticancer, immunomodula-
tory, cardioprotective, antioxidative, and chemopreventive 
capabilities in various cell and tissue types  13  –  20  . However, it 
is unclear whether resveratrol also has an anti-infl ammatory 
effect on IVD cells. 
 The most commonly regulated pathways/receptors in 
infl ammation are the transcription factor nuclear factor 
 κ B (NF- κ B), the mitogen-activated protein (MAP) kinase
family (p38 MAP kinase [p38], extracellular-signal regu-
lated kinase [ERK], c-Jun N-terminal kinase [JNK]), and 
the toll-like receptors (TLRs). Anti-infl ammatory substanc-
es may reduce proinfl ammatory cytokines on the messen-
ger RNA (mRNA) and/or protein level by inhibiting one or 
several of these (and/or possibly also alternative) signaling 
pathways. 
 On the basis of the obvious needs for more defi ned, bio-
logical treatment options for NP-mediated pain, we aimed to 
investigate the promising candidate resveratrol  in vitro and  in 
vivo . The detailed aims of this study were the following: 
 1.  To analyze the anti-infl ammatory and anticatabolic 
potential of resveratrol in an  in vitro IVD cell culture 
model. 
 2.  To identify the signal transduction mechanisms 
underlying the observed effects in vitro. 
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 3.  To examine the analgetic potential of resveratrol to 
reduce NP-mediated pain, using an in vivo rodent 
animal model of radiculopathic pain. 
2FGH&IJG6!2GKL2F&HMNL!2
2+0%;#7:9<2:$C2G$1#E,C#%<2
 Detailed information on all chemicals and (primary and sec-
ondary) antibodies used in this study is given in  Table 1 . 
2JOL2+%992J<,9:1#,$2:$C2+A91A.%2
 IVD tissue samples were obtained during spinal surgery ( Table 2 ) 
after informed consent was granted by the patients. The study 
was approved by the institutional review board. Disc cells were 
isolated from the biopsies by enzymatic digestion with 0.3% col-
lagenase NB4 and 0.2% dispase II in phosphate buffered saline 
(PBS) for approximately 6 hours at 37 ° C. Primary IVD cells were 
cultured in growth medium (Dulbecco’s Modifi ed Eagle’s Me-
dium and Ham’s F-12 Nutrient Mixture [DMEM-F12], 10% 
fetal calf serum [FCS], 50 U/mL penicillin, 50  μ g/mL streptomy-
cin, 125 ng/mL ampicillin ) and passaged by trypsin treatment at 
approximately 80% confl uency (up to three passages). Biopsies 
were separated into NP and annulus fi brosus (AF) on the basis 
of the macroscopic appearance of the disc. Great care was taken 
that NP tissue was processed for further analysis. 
2+%992O#:E#9#1-2G<<:-2
 Nontoxic concentrations of resveratrol that were used in 
cell culture experiments were determined by the MTT assay. 
Briefl y, cells were cultured in 24-well plates and treated with 
11 different concentrations of resveratrol (between 1000  μ M 
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Na-Deoxycholate for 1 hour, followed by trichloracetic acid 
over night at 4 ° C. The pellet was resuspended in RIPA buffer 
and protein content was measured using Bradford reagent 
before analysis by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and immunoblotting. Briefl y, 
samples were denatured and loaded onto a polyacrylamide gel. 
After separation by electrophoresis, proteins were transferred 
to a PVDF membrane, blocked in tris-buffered saline tween-20 
(TBS-T) with 5% milk-powder (1 hour) and then incubated 
with a specifi c antibody for IL-6, IL-8, MMP1, MMP3 and 
MMP13 (candidates were chosen on the basis of highest effects 
seen on the mRNA level) at the appropriate dilution for 2 hours. 
After washing, membranes were incubated with the respective 
secondary antibody at the appropriate concentration for 1 hour 
at room temperature. SuperSignal West Dura was used for de-
tection of chemiluminescence on Hyperfi lm. The assay was per-
formed on supernatants from three independent experiments. 
/E487)@+4,/.-A/!CCA5.:/'C/FA:GA*8.*'7/'4/HIFJ"/E5.+G+.)/
 Expanded cells in passage 2 or 3 were rendered serum free for 
2 hours, preincubated with IL-1 β (5 ng/mL) and thereafter 
resveratrol alone (50  μ M) or in combination with the SIRT1 
inhibitor sirtinol (1, 5 or 10  μ M) was added and cells were 
incubated for additional 18 hours. Untreated control cells 
as well as ethanol (EtOH) treated cells were included in the 
experimental setup. After stimulation, gene expression was 
analyzed as described earlier. The assay was performed in du-
plicates and the results are provided as mean values with stan-
dard error of the mean from six independent experiments. 
/I99?4'5).'5-A9+:.*)KL8:AB/MNK/κ/L/E5.+G8.+'4/E::8)/
 The effect of resveratrol on the IL-1 β –induced nuclear trans-
location of p65 was examined by immunocytochemistry for 
p65 (RelA), the large subunit of NF- κ B. IVD cells were seeded 
on chamber slides and were grouped into no treatment, IL-1 β 
treatment (5 ng/mL) or IL-1 β (5 ng/mL)  + resveratrol treat-
ment (50  μ M). Treatment was performed for 5, 15, 30, 60, 
or 120 minutes or 18 hours before fi xing cells for 10 minutes 
in ice-cold methanol. After washing, cells were blocked with 
1% bovine serum albumin (BSA) and 0.1% Triton-X in PBS 
for 60 minutes, incubated with p65 antibody for 60 minutes, 
washed, incubated with the respective secondary fl uorescence-
labeled antibody for 45 minutes, embedded in Mowiol 4–88 
and microscopically analyzed. The assay was performed on 
cells from two independent donors. 
/(%O/84B/PEQ/R+48:A/S!FRT/(#UT/VMRW/E487):+:/
!"#$!κ!%!&'()*!
 To further investigate the infl uence of resveratrol on the NF-
 κ B pathway, IVD cells were grouped into no treatment, IL-1 β 
treatment (5 ng/mL) or IL-1 β (5 ng/mL)  + resveratrol treat-
ment (50  μ M). After 60 minutes, nuclear extracts were pre-
pared according to standard protocols. Protein content was 
measured by Bradford assay, nuclear extracts were fractioned 
by SDS-PAGE, proteins were transferred onto membranes 
and fi rst incubated with a p65 antibody and then with the 
and 0  μ M, 1:2 dilution each time) for 18 hours before adding 
a fresh, sterile solution of MTT (3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide) with a concentration of 
0.5 mg/mL in DMEM/F12. After 2 to 3 hours at 37 ° C, MTT 
was discarded, cells were lysed with DMSO for 10 minutes 
and absorbance was measured at 565 nm. Absorbance of res-
veratrol treated cells was calculated relative to absorbance of 
untreated control cells. The assay was performed in triplicates 
and the results are provided as mean values with standard er-
ror of the mean from six independent experiments. 
/E487)@+4,/.-A/!CCA5.:/'C/FA:GA*8.*'7/'4/.-A/XA4A/
!Y(*A::+'4/3AGA7/
 Expanded cells in passage 2 or 3 were rendered serum free 
for 2 hours and then preincubated with IL-1 β (5 ng/mL) for 
2 hours to induce an infl ammatory and catabolic response. 
Thereafter, resveratrol (in EtOH, 5  μ M or 50  μ M) was added 
and cells were incubated for additional 18 hours. Untreated 
control cells as well as EtOH-treated cells were included in the 
experimental setup. After incubation, mRNA was isolated, 1 
 μ g was reverse transcribed to complementary DNA and gene 
expression of IL-1 β , IL-6, IL-8, MMP1, MMP3, MMP13 and 
the toll-like receptor TLR2 was measured (primer details are 
given in  Table 3 ). After normalizing to the housekeeping gene 
(TBP), which was chosen on the basis of unresponsiveness to 
the applied treatment, expression of resveratrol treated cells 
was compared with untreated control or EtOH-treated cells 
using the 2  −  ∆ ∆ Ct method  21  . The assay was performed in du-
plicates and the results are provided as mean values with stan-
dard error of the mean from six independent experiments. 
/E487)@+4,/.-A/!CCA5.:/'C/FA:GA*8.*'7/'4/.-A/Q*'.A+4/
!Y(*A::+'4/3AGA7/
 Cells were treated as described above for gene expression 
analysis and conditioned media was harvested after 18 hours. 
Protein was precipitated from the medium by incubation with 
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L5-L6 facetectomy on the left side, but no other procedures 
were performed. All animals underwent behavioral testing at 
days 0 (baseline), 2, 7, 14, and 21 by evaluating the hind paw 
withdrawal response to von Frey hair stimulation of the plan-
tar surface of the footpad. Briefl y, von Frey fi laments with a 
calibrated force between 1 and 29 g were sequentially applied 
twice to the paw surface. The determined withdrawal force 
was verifi ed with a negative test of next lower fi lament as 
well as by confi rming the initial response after a time lag of 5 
minutes. Lower withdrawal thresholds are considered a sign 
of mechanical hypersensitivity, which is correlated to pain be-
havior in this animal model. 
1!090#;0#6981E$98,;#;1
 All quantitative cell culture data were expressed as means 
and standard error of the mean (SEM). Statistical analysis 
was performed by Mann-Whitney  U test (two-tailed) us-
ing the SPSS software. A signifi cance level of  P  < 0.05 was 
considered statistically signifi cant. For the animal study, be-
havioral data were also statistically evaluated by analysis of 
variance (ANOVA) with both nonparametric and multiple 
comparisons by Bonferroni correction test among the three 
treatment groups. 
1F&!?5G!1
1*%881H#9D#8#0,1
 As shown in  Figure 1 , resveratrol did not show any cytotoxic 
effect after 18 hours at concentrations  ≤ 250  μ M. 
1&CC%60;1+C1F%;I%-90-+81+$10/%1J%$%1&K"-%;;#+$15%I%81
 As expected, prestimulation with IL-1 β caused a strong up-
regulation of IL-1 β , IL-6, IL-8, MMP1, MMP3, MMP13 
appropriate secondary antibody before analyzing chemilu-
minescence. Poly (ADP-ribose) polymerase-1/2 (PARP-1/2) 
was used as the loading control. The assay was performed on 
samples from three independent experiments. 
!"#$!%&'()*)!+,-./!01%/!23%4!
 To investigate whether resveratrol acts on typical MAP kinas-
es, IVD cells were grouped into no treatment, IL-1 β treatment 
(5 ng/mL) or IL-1 β (5 ng/mL)  + resveratrol treatment (50 
 μ M). After 15 minutes, whole cell extracts were prepared ac-
cording to standard protocols. Whole cell extracts were used 
as stated earlier, but incubated with either unphosphorylated 
or phosphorylated antibodies recognizing p38, ERK (p42/44) 
or JNK before adding an HRP-labeled rabbit secondary anti-
body and analyzing chemiluminescence. Tubulin was used as 
a loading control. The assay was performed on samples from 
three independent experiments. 
1&8%60-+"/+-%0#61L+D#8#0,1!/#C01E;;9,1C+-1MNO1κ1P1
 Effects of resveratrol on NF- κ B activity were further confi rmed 
by performing electrophoretic mobility shift assay (EMSA) for 
NF- κ B on nuclear extracts from IVD cells, which were grouped 
into no treatment, IL-1 β treatment (5 ng/mL) or IL-1 β (5 ng/
mL)  + resveratrol treatment (50  μ M) (at 60 minutes). By sub-
jecting samples to electrophoretic mobility shift analysis, the 
binding of NF- κ B to DNA can be visualized. Briefl y, nuclear 
extracts were incubated with binding buffer for 10 minutes be-
fore adding biotin-labeled NF- κ B probe, followed by incuba-
tion at 15 ° C for 30 minutes. Samples were electrophoretically 
separated on a 6% polyacrylamide gel, transferred onto a ny-
lon membrane, and then fi xed by UV cross-linking. Specifi city 
of the complex was confi rmed with a competition assay by ad-
dition of a non–biotin-labeled cold probe as recommended by 
the manufacturer (signal removed). The assay was performed 
on samples from two independent experiments. 
15'!6&781E$#:981&K"%-#:%$0;1+$1Q9#$1P%/9I#+-1
 All animal experiments were carried out under the control of 
the Animal Care and Use Committee in accordance with local 
guidelines for the animal experiments and government law 
concerning the protection and control of animals. 
 Female Sprague-Dawley rats (n  = 18, 200–250 g) (Japan 
SLC, Shizuoka, Japan) were anesthetized by intraperitoneal 
injection of 30 mg/kg sodium pentobarbital, placed in a prone 
position and surgical intervention was performed by use of a 
stereo operating microscope and microsurgical instruments. 
Briefl y, an incision was made to the spinal midline, fascia 
and multifi dus muscle were resected, and the left L5 nerve 
root and dorsal root ganglion (DRG) were exposed by L5-L6 
facetectomy on the left side, with great care taken to avoid 
trauma to the tissue. Autologous NP was harvested from the 
tail and applied to the DRG in 12 animals. In addition, ei-
ther resveratrol (0.1 mL of 50  μ M solution in saline [NPR 
group]) or saline (0.1 mL [NPS group]) were injected into 
the underlayer of the epineurium just distal to the NP in 6 
animals each before closing the incisions. In the Sham group 
(n  = 6), the left L5 nerve root and DRG were exposed by 
5N#.@-%1 '>5 58'#9'+,:+)-5 %#5 &):5 .;:):)<%.5 ,:5 /)='+,:'5 .)&.'&:+,:%)&#"5
8'#9'+,:+)-5>,=5&)5.;:):)<%.5'??'.:5,:5.)&.'&:+,:%)&#55≤5@AB55μ5CD5E*:5
!,#5#%F&%!5.,&:-;5.;:):)<%.5,:5ABB55μ5C5G5!55=5B"BB@H5,&=5IBBB55μ5C5G5!55=5
B"BBJH5,?:'+5IK5>)*+#"5L,:,5!'+'5)E:,%&'=5E;5*#'5)?5:>'5CMM5,##,;5,&=5
%#5$+'#'&:'=5,#5C',&5,&=526C5 G&5 5=5 NH"51#:'+%#O#5 %&=%.,:'5 #:,:%#:%.,-5
#%F&%!5.,&.'5G5!55<5B"BAH"5
!"#$%&''()*+,,---./011 /&2%32//---$405-67
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IL-8, MMP1, MMP3, and MMP13 ( Figure 3 ). The general 
observation was that treatment with IL-1 β –induced protein 
levels of all candidates compared with untreated control cells 
(lanes 1 and 2), but that 50  μ M resveratrol was able to ef-
fectively reduce IL-1 β –induced levels in all donors (lane 3). 
For the investigated matrix degrading enzymes, it should be 
noted that both, proform and active form, were reduced with 
resveratrol treatment. 
/!CCA5.:/'C/EA:FA*8.*'7/'4/GHI/κ/J/K5.+F+.)/
 Treatment of IL-1 β prestimulated cells with 50  μ M resveratrol 
did not prevent or reverse nuclear translocation of the NF- κ B 
subunit p65 at any time point. In resveratrol treated cells, the 
specifi c p65 antibody detected p65 in the nucleus (just as in the 
cells treated with IL-1 β only, which serves as a positive control 
and TLR2 ( Table 4 ). Resveratrol exhibited minor or no ef-
fects at the lower concentration (5  μ M) ( Figure 2 ). However, 
at the higher concentration (50  μ M), resveratrol caused a 
signifi cant inhibition of the IL-1 β –mediated infl ammatory 
and catabolic response. After setting IL-1 β –induced gene 
expression to 100% for each gene, resveratrol was able to 
reduce expression of proinfl ammatory cytokines (IL-6 by 
76%, IL-8 by 55%), matrix metalloproteinases (MMP1 by 
51%, MMP3 by 48%, MMP13 by 45%) and TLR2 by 18% 
( Figure 2 ). 
/!CCA5.:/'C/EA:FA*8.*'7/'4/.-A/L*'.A+4/!M(*A::+'4/3AFA7/
 The anti-infl ammatory and anticatabolic effect of the high-
est concentration of resveratrol that was observed on the 
mRNA level could be confi rmed on the protein level for IL-6, 
3H+,?*A/1=33>'#?'+,1+)-3'@A%2%1#3,&3,&1%B%&!3,//,1)+C3,&D3,&1%.,1,2)-%.3'EE'.13)&31A'3/>=83-'?'-"38E1'+36F3A)*+#G3H533μ3I3+'#?'+,1+)-3+'D*.'D3/>=83
-'?'-#3)E3$+)%&!3,//,1)+C3.C1)J%&'#3:KBL3M3!33<35"5556N3,&D3:KBF3M3!33<35"5556N3M3K3NG3O)--B-%J'3+'.'$1)+3OK>43M3!33=35"55PN3MKNG3,&D3/,1+%@BD'Q+,D%&Q3
'&RC/'#3IIS63M3!33<35"5556N3M3J3NG3IISP3M3!33=35"55PN3M3J3N3,&D3IIS6P3M3!33=35"5TLN3M3J3N3.)/$,+'D3!%1A3:KB63β3U$+'#1%/*-,1'D3.'--#G32*13A,D3&)3'EB
E'.13)&3/>=83-'?'-#3)E3:KB63β3M&)13#A)!&N"3V,1,3!'+'3)21,%&'D32C3+',-B1%/'3>OBS;>3M43!∆3∆3;13/'1A)DN3,&D3%#3$+'#'&1'D3,#3I',&3,&D39<I3M&33=3LN"3
8#1'+%#J#3%&D%.,1'3#1,1%#1%.,-3#%Q&%"3.,&.'3M3!33<35"5HN"3
/NKJ3!/O=//P.+9?78.+'4/6+.-/Q3I"/β/Q4B?5A:/84/Q4!/8998.'*)/84B/&8.8D'7+5/EA:('4:A=/P.+9?78.+'4/6+.-/
R/4,S93/EA5'9D+484./Q3I"/β/Q45*A8:AB/9EGK/3AFA7:/'C/Q3I"/β/T/Q3IUT/Q7I%T/VVL"T/VVL#T/
VVL"#T/84B/N3E1=/N-+:/N8D7A/P?998*+@A:/VA84:T/P!VT/84B//!/W87?A:/C'*/877/XA4A:/'C/
Q4.A*A:.=/Y8.8/6A*A/ZD.8+4AB/D)/EA87IN+9A/ENIL&E/[1/!∆/∆/&./VA.-'B\/[4//=/U\/
XA4A VA84/[H'7B/&-84,A\ P!V "!"
:&1'+-'*J%&B63β3M:KB63β3N F"LL P"54 5"55P
:&1'+-'*J%&BL3M:KBLN TT"PW 65"FF 3<35"556
:&1'+-'*J%&BF3M:KBFN 66"W5 P"H6 3<35"556
O)--B-%J'3+'.'$1)+343MOK>4N P"TT 5"WF 5"55P
I,1+%@/'1,--)$+)1'%&,#'B63MIIS6N PX"T5 66"66 3<35"556
I,1+%@/'1,--)$+)1'%&,#'BP3MIISPN X5"F6 4X"5T 3<35"556
I,1+%@/'1,--)$+)1'%&,#'B6P3MIIS6PN 6P"4F 4"6X 3<35"556
!"#$%&''()*+,,---./012 /&3%43//---$502-67
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levels of phosphorylated and unphosporylated p38, ERK 
and JNK in whole-cell extracts by immunoblotting ( Figure 
6 ). Results demonstrate that IL-1 β treatment increased lev-
els of phosporylated p38, ERK, and JNK after 15 minutes, 
which is indicative of activation of these three MAP ki-
nases. However, treatment with 50  μ M resveratrol did not 
infl uence activity of any of the three MAP kinases. Levels 
of unphosporylated p38, ERK, and JNK were similar in all 
groups. 5
2&DD%71<2,D2F%<G%.:1.,92,$2H:#$2I%0:G#,.2#$2:$2
J$#;:92K,C%92
 Animal behavior in response to nonnoxious mechanical stimu-
lation with von Frey fi laments was compared with the sham 
group, which (as expected) showed a rather stable mechanical 
withdrawal. Withdrawal thresholds in the control group were 
overall close to the preoperative baseline over the entire course 
of the experiment, indicating that the surgical intervention alone 
did not cause any change in pain behavior. The additional two 
groups (treatment with NP tissue  + saline  = NPS, treatment 
with NP tissue  + resveratrol  = NPR) were compared with the 
sham group for all time points. Results indicate that in the NPS 
group, the mechanical withdrawal thresholds were signifi cantly 
decreased for each time point compared with the baseline val-
ues of the sham group up to day 14, indicating that pain was 
evoked by application of NP tissue to the DRG. In the NPR 
group that was cotreated with resveratrol, animal behavior was 
very similar to the sham group. Thresholds in the NPR group 
were signifi cantly higher than in the NPS group on day 2 ( P  < 
0.0001), day 7 ( P  = 0.037) and day 14 ( P  = 0.0044). However, 
of NF- κ B induction), while untreated cells show cytoplasmic 
location of p65 (which is indicative of nonactive NF- κ B) ( Fig-
ure 4 A ) . This fi nding was confi rmed by p65 immunoblotting of 
nuclear extracts ( Figure 4 B): Western blots clearly show that the 
p65 band in the nuclear extract of resveratrol treated samples 
is not reduced compared with IL-1 β –stimulated samples, while 
untreated cells show a much smaller amount of target protein. 
EMSA experiments, revealed no decrease or elimination of the 
NF- κ B DNA-binding activity in resveratrol treated cells com-
pared with IL-1 β prestimulated cells ( Figure 4 C), confi rming 
results obtained by Western blot and immunocytochemistry. 
Specifi city of the EMSA assay was confi rmed by using a cold 
probe in one lane (negative control), which has no visible band. 5
2&DD%71<2,D2F%<G%.:1.,92,$2!LFM'2J71#G#1-2
 To test whether resveratrol exhibits its effects by activating 
SIRT1, resveratrol-treated cells were cotreated with sirtinol, a 
SIRT1 inhibitor. Cotreatment of resveratrol and sirtinol did not 
overall abolish inhibition of gene expression observed by resvera-
trol treatment alone ( Figure 5 ). Only for MMP1, cotreatment of 
resveratrol and sirtinol resulted in an increase in gene expression 
compared with resveratrol treatment alone (5  μ M:  P  = 0.019; 
10  μ M:  P  = 0.013). In contrast, MMP3 and MMP13 expression 
was even further reduced upon sirtinol cotreatment compared 
with resveratrol treatment alone (MMP13 at 5  μ M:  P  = 0.003; 
MMP13 at 10  μ M:  P  = 0.006; MMP3 at 10  μ M:  P  < 0.0001). 5
2&DD%71<2,D2F%<G%.:1.,92,$2KJH2N#$:<%2J71#G#1-2
 Involvement of typical MAP kinases in the effects observed 
by resveratrol treatment was investigated by detecting 
5O#/A.%2 (?5 58'#9'+,:+)-5 ';<%=%:#5 ,&5 ,&:%>
%&!5,//,:)+?5 ,&@5 ,&:%.,:,=)-%.5 'AA'.:5
)&5 :<'5 $+):'%&5 -'9'-"51A:'+5 BC5 <)*+#D5 EF5
5μ5G5+'#9'+,:+)-5+'@*.'@5$+):'%&5-'9'-#5)A5
3H>I5JJKD53H>C5JIKD5GGLB5J+KD5GGLM5JPKD5
,&@5GGLBM5 J&KD5 .)/$,+'@5 !%:<5 3H>B5β5N
$+'#:%/*-,:'@5 .'--#"5O,:,5!'+'5 )=:,%&'@5
=?5 %//*&)=-)::%&P5 )A5 $+):'%&5 #,/$-'#5
';:+,.:'@5 A+)/5 :<'5 .)&@%:%)&'@5/'@%*/5
J&55=5MK5,&@5)&'5+'$+'#'&:,:%9'5#,/$-'5%#5
#<)!&"5
!"#$%&''()*+,,---./012 /&3%23//---$405-67
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$HI3J%&@%.,1%?'3)G3%&,.1%?'3=BC3κ37KL3!A%-'3:MC63β3C,-)&'3,&@3:MC63β3+3+'#?'+,1+)-31+',1'@3#,/$-'#3#A)!3&*.-',+3-).,-%F,1%)&3)G3$HI3J%&@%.,1%?'3)G3=BC3κ373
%&@*.1%)&K"3N,1,3!'+'3)21,%&'@32E3%//*&).E1).A'/%#1+E3G)+3$HI3J&33=34K3,&@3)&'3+'$+'#'&1,1%?'3#,/$-'3%#3#A)!&"3D,+13G3#A)!#3%&.+',#'@3-'?'-#3
)G3$HI3%&3&*.-',+3'O1+,.1#3*$)&3#1%/*-,1%)&3!%1A3:MC63β3J%&@%.,1%?'3)G3=BC3κ373%&@*.1%)&K3.)/$,+'@3!%1A3*&1+',1'@3.)&1+)-3.'--#L32*131A%#3'GG'.1#3!,#3
&)13,2)-%#A'@32E3+'#?'+,1+)-L31A'+'G)+'3.)&!3+/%&P3@,1,3#A)!&3%&3D,+13F"3N,1,3!'+'3)21,%&'@32E3$HI3%//*&)2-)11%&P3)G3&*.-',+3'O1+,.1#3J&33=3QK3
,&@3)&'3+'$+'#'&1,1%?'3#,/$-'3%#3#A)!&"3D8>DC6R43%#3*#'@3,#3,3-),@%&P3.)&1+)-"3:&3D,+13&L31A'3$+'#'&.'3)G3=BC3κ373N=832%&@%&P3.,&32'3)2#'+?'@3
%&32)1AL3:MC63β3C,-)&'3,&@3:MC63β3+3+'#?'+,1+)-C1+',1'@3#,/$-'#3J%&@%.,1%?'3)G3=BC3κ373%&@*.1%)&KL32*13&)13%&3*&1+',1'@3.)&1+)-3#,/$-'#3J%&@%.,1%?'3)G3
%&,.1%?'3=BC3κ37K"3S+',1/'&13!%1A3,3$+)?%@'@3.)-@3$+)2'3,2)-%#A'@31A'3#%P&,-L31A*#3.)&!3+/%&P3#$'.%!3.%1E3)G31A'3,##,E"3N,1,3!'+'3)21,%&'@32E3$HI3
'-'.1+)$A)+'1%.3/)2%-%1E3#A%G13,##,E3J<T98K3)G3&*.-',+3'O1+,.1#3J&33=34K3,&@3)&'3+'$+'#'&1,1%?'3#,/$-'3%#3#A)!&"3
at day 21, there was no signifi cant difference anymore between 
the thresholds of the NPR and NPS ( Figure 7 ). 3
/HIJ&=JJIKL/
/F3.+MI3!/7887.'*)/73A/F3.+47.7C'6+4/N'.@3.+76/
'B/O@9P@*7.*'6/
 Results from our cell culture experiments provide clear evi-
dence that resveratrol can effectively reduce mRNA levels of 
major proinfl ammatory cytokines (IL-6, IL-8), TLR2, and 
matrix degrading enzymes (MMP1, MMP3, MMP13), which 
have previously been shown to be involved in disc degenera-
tion and pain induction. This effect could be confi rmed on the 
protein expression level for IL-6, IL-8, MMP1, MMP3, and 
MMP13. Very few donors seemed to be unresponsive to res-
veratrol treatment, indicating that genetic differences may pos-
sibly infl uence treatment outcomes. Data from these patients 
were excluded from the analysis as these cells simultaneously 
responded in an excessive manner to IL-1 β treatment. No de-
mographic differences of these patients could be identifi ed. 
The observed inhibition of the expression of certain genes is 
similar to what was observed in chondrocytes.  20  ,  22  However, 
resveratrol also regulated expression of IL-1 β in chondro-
cytes,  23  whereas IL-1 β was not regulated in our experiments 
on human IVD cells. 
 In a study performed by Li  et al  24  , resveratrol has additional-
ly been shown to increase proteoglycan synthesis and to rescue 
IL-1 β –induced proteoglycan loss in bovine IVD cells, therefore 
providing further evidence that resveratrol may be an innovative 
treatment of NP-mediated back and leg pain. Li et al24 cultured 
their bovine disc cells in both two dimensions and alginate, 
but we concentrated on a two- dimensional culture approach. 
Although this is a limitation of the present study as phenotypic 
shifts during monolayer culture may affect the results, this ap-
proach enabled us to perform the subsequent detailed signal 
transduction analysis (with the goal to further elucidate the mo-
lecular mechanisms underlying the anti-infl ammatory and anti-
catabolic effects of resveratrol) in the same system. 
/N7.-Q7)/F376)9+9/RLDM/κ/GS/
 The activation of the transcription factor NF- κ B leads to an up-
regulation of proinfl ammatory cytokines and matrix degrading 
enzymes. We therefore investigated whether resveratrol exhibits 
its effects via inhibition of NF- κ B. In addition, we investigated 
!"#$%&''()*+,,---./01% /&2%32//---$401-56
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was shown to inhibit expression of certain TLRs for example 
in HEK293 and RAW264.7 cells,  25  ,  26  only a minor reduction of 
TLR2 was observed in IVD cells. We also found that resveratrol 
regulation of TLR2, as activation of TLR2 is known to trigger 
several crucial intracellular signaling responses including acti-
vation of the transcription factor NF- κ B. Although resveratrol 
5E#.@-%1F>558'#9'+,:+)-5;)'#5&):5#''/5:)5,.:5,#5,5238<=>,.:%9,:)+"54):+',:/'&:5)?53@>5β5$+'#:%/*-,:';5.'--#5!%:A5+'#9'+,:+)-5BCD55μ5EF5,&;5:A'5238<=5%&>
A%G%:)+5#%+:%&)-5B=H5CH5)+5=D55μ5EF5;%;5&):5,G)-%#A5:A'5'??'.:#5)G#'+9';5GI5+'#9'+,:+)-5:+',:/'&:5,-)&'5B+';*.';5/8715'J$+'##%)&5)?53@>KH53@>LH5EEM=H5
EEMNH5EEM=NF5,?:'+5=L5A)*+#H5!%:A5:A'5'J.'$:%)&5)?5,5$,+:%,-5+'9'+#,-5)?5EEM=5'J$+'##%)&5,:5C55μ5E5B5!55=5D"D=OF5,&;5=D55μ5E5B5!55=5D"D=NF"56J$+'#>
#%)&5)?5EEMN5,&;5EEM=N5!,#5?*+:A'+5+';*.';5)&5:+',:/'&:5!%:A5C55μ5E5#%+:%&)-5BEEM=NP55!55=5D"DDNF5,&;5=D55μ5E5#%+:%&)-5BEEMNP55!55=5D"DDKQ5
EEM=NP55!55<5D"DDD=F"5M,+:5G5#A)!#5$+)%&!5,//,:)+I5.I:)R%&'#H5M,+:5H5#A)!#5EEM#"5S,:,5!'+'5)G:,%&';5GI5+',->:%/'58<>M485BT5!∆5∆54:5/':A);F5,&;5
%#5$+'#'&:';5,#5E',&5,&;526E5B&55=5KF"58A)/G%5%&;%.,:'5#:,:%#:%.,-5#%U&%"5.,&.'5G':!''&53@>=5β5$+'#:%/*-,:%)&5,&;5+'#9'+,:+)-5:+',:/'&:Q5,#:'+%#R#5
%&;%.,:'5#:,:%#:%.,-5#%U&%"5.,&.'5G':!''&5+'#9'+,:+)-5:+',:/'&:5,&;5+'#9'+,:+)-55+5#%+:%&)-5:+',:/'&:5B5!55<5D"DCF"5
5E#.@-%1 I>5 58'#9'+,:+)-5 ;)'#5 &):5
#''/5 :)5 ,.:5 )&5 :A'5 E1M5 V%&,#'5
$,:A!,I"51-:A)*UA5 :+',:/'&:5!%:A5
3@>=5β5 %&;*.';5 -'9'-#5)?5$A)#$)+I>
-,:';5$NLH568VH5,&;5W7V5.)/$,+';5
!%:A5*&:+',:';5.)&:+)-5.'--#H5 :+',:>
/'&:5!%:A5 CD5 5μ5E5 +'#9'+,:+)-5!,#5
&):5,G-'5 :)5,::'&*,:'5,.:%9,:%)&5)?5
,&I5)?5:A'5/'/G'+#5)?5:A'5E1M5R%>
&,#'5?,/%-I5BK1P5$>$NLH5K0P5$>68VH5
K4P5$>W7VF"5@'9'-#5)?5*&$A)#$)+I>
-,:';5$NL5BGFH568V5BHFH5,&;5W7V5B*F5
,+'5#%/%-,+5%&5,--5U+)*$#"5S,:,5!'+'5
)G:,%&';5 GI5 %//*&)G-)::%&U5 )?5
!A)-'>.'--5'J:+,.:#5B&55=5NF5,&;5)&'5
+'$+'#'&:,:%9'5#,/$-'5%#5#A)!&"5<*>
G*-%&5%#5*#';5,#5:A'5-),;%&U5.)&:+)-5
%&5,--5G-):#"5
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in multiple studies on various cell types (p38,  38  –  40  ERK,  38  ,  40  ,  41  
JNK  38  ,  42  ), we could not confi rm this mode of action in human 
IVD cells. 
/D3+876/E.>A)/
 We used an  in vivo animal model in which NP-mediated pain is 
simulated by the application of NP tissue to the DRG, thus rep-
resenting typical radiculopathic pain. Similar to previous stud-
ies,  43  –  46  NP tissue induced behavior related to nociceptive pain 
in our animal experiments. Resveratrol treatment was able to 
prevent this threshold reduction and thus the pain-related be-
havior to a certain degree for 14 days. However, there was no 
signifi cant difference of the thresholds between resveratrol and 
saline after NP treatment after 21 days. A more pronounced and 
long-lasting effect of resveratrol may be obtained by varying its 
concentration or the type of administration. As induction of no-
ciceptive pain in this model is thought to be due to the release of, 
for example, TNF- α , interleukins, and serotonin,  5  ,  8  ,  44  we specu-
late that resveratrol may possibly reduce pain behavior  in vivo 
by reducing or inhibiting cytokines that are released from the NP 
tissue, similar to the mechanism observed in our  in vitro cell cul-
ture study. Despite these promising fi ndings, further experimen-
tal studies, for example, the use of controlled drug release sys-
tems or a large animal model are needed before resveratrol can 
be considered for clinical use. One limitation of this study is that 
the  in vivo animal model did not ideally match the stepwise ap-
proach of our  in vitro model.  In vivo , IL-1 β and resveratrol were 
applied simultaneously, whereas a stepwise approach with IL-1 β 
pretreatment was performed in the  in vitro part. Although pre-
treatment better simulates the disease process, this would lead to 
a second surgery, thus increasing stress and pain for the animals 
and the risk of surgery-related issues. As the investigation of pain 
behavior in rodents is challenging and prone to any interference, 
we chose to perform the less invasive (simultaneous) approach. 
was not able to attenuate the nuclear translocation of p65 as 
shown by Western blot on nuclear extracts and immunocyto-
chemistry and also did not decrease the NF- κ B DNA-binding 
activity as shown by EMSA. Our study indicates that resveratrol 
does not seem to act on the NF- κ B pathway in human IVD cells, 
although this has been observed in multiple other cell types  19  ,  27  –  30  . 
/F7.-G7)/D376)9+9/HEIJK"L/
 As resveratrol is considered to be a potent SIRT1 activator  31  
and as SIRT1 is known to inhibit the transcriptional activity of 
NF- κ B, resveratrol is thought to exhibit its anti-infl ammatory 
effect via this pathway.  32  –  36  We performed experiments to test 
for involvement of the SIRT1 pathway in resveratrol-treated 
human IVD cells by costimulating cells with resveratrol and 
the SIRT1 inhibitor sirtinol. Sirtinol was not able to attenuate 
the anti-infl ammatory and anticatabolic effect of resveratrol in 
IVD cells (except partially for the gene MMP1), thus indicat-
ing that resveratrol does not seem to exhibit its effect via the 
SIRT1 pathway. Instead of attenuating the anticatabolic effect 
of resveratrol, treatment with the SIRT1 inhibitor resulted in 
even further reduced mRNA levels of MMP3 and MMP13. 
A most recent study by Rothgiesser  et al  37  indicates that, de-
pending on the lysine position in p65, acetylation can cause an 
increase or a decrease of gene expression. 
/F7.-G7)/D376)9+9/HMDF/N+379@9L/
 Although resveratrol has been described as an inhibitor of the 
activity of one or several members of the MAP kinase family 
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Abstract BACKGROUND CONTEXT: Bupivacaine is commonly used as an adjunct during provocative
discography and is administered intradiscally in patients with discogenic back pain. Recent studies
demonstrated that bupivacaine is cytotoxic for articular chondrocytes in vitro at clinically used
concentrations (0.25%–0.5%).
PURPOSE: To analyze a concentration-dependent effect of bupivacaine on cell viability and gene
expression of human intervertebral disc (IVD) cells in an in vitro model.
STUDY DESIGN: In vitro cell culture study.
PATIENT SAMPLE: Disc cells were isolated from human disc biopsies from 11 patients under-
going surgery because of degenerative disc disease or disc herniation.
OUTCOME MEASURES: Cell viability and gene expression after exposure to bupivacaine.
METHODS: Human IVD cells were treated with different concentrations of bupivacaine for 2 (n55)
or 18 hours (n55) and analyzed for cell viability and proliferation (3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide assay). Additionally, cells were prestimulated with interleukin-1 beta
(IL-1b) (5 ng/mL) to increase the levels of proinflammatory cytokines and matrix-degrading enzymes
and thereafter treated with 0.75 mmol bupivacaine (as determined in the cell viability test) for 2 (n55)
or 18 hours (n55). Prestimulated cells with or without bupivacaine treatment were analyzed for gene
expression of IL-1b, IL-6, IL-8, tumor necrosis factor-a (TNF-a), cyclooxygenase-2 (COX-2), matrix
metalloproteinase-3 (MMP3), MMP9, MMP13, and a disintegrin and metalloproteinase with throm-
bospondin motifs 4 (ADAMTS4) using real-time reverse transcription-polymerase chain reaction. Sta-
tistical analysis was performed by using the Mann-Whitney U test with a significance level of p!.05.
RESULTS: After 18 hours, bupivacaine exhibited either a cytotoxic or a proliferative effect on
human IVD cells, depending on the concentration. Similar but lower effects could be observed
already after 2 hours. With a concentration of 0.75 mmol (proliferative effect), bupivacaine signif-
icantly decreased messenger RNA levels of TNF-a, COX-2, MMP13, and ADAMTS4 after 18
hours. In contrast, expression of IL-6, IL-8, and MMP9 did not differ; expression of IL-1b and
MMP3 was stimulated with 0.75 mmol. After 2 hours, we observed a reduction in the expression
of COX-2, MMP3, MMP13, and ADAMTS4, without any effect regarding IL-1b.
CONCLUSIONS: Application of bupivacaine in clinically relevant concentrations was toxic for
IVD cells in vitro. A low concentration stimulated cell proliferation and reduced gene expression
of certain matrix-degrading enzymes and proinflammatory cytokines. If these results can be corrob-
orated in tissue explant models or animal studies, caution regarding provocative discography with
bupivacaine is prompted. ! 2011 Elsevier Inc. All rights reserved.
Keywords: Human intervertebral disc cells; Bupivacaine; Cytotoxicity; Gene expression; Provocative discography
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Introduction
Spinal injections are frequently used for the diagnosis
and treatment of patients with low back and leg pain. A va-
riety of different drugs such as local anesthetics or cortico-
steroids are used, and the choice of technique depends on
whether the aim is to eliminate or to diagnose the spinal
pain [1].
Various reports on the intradiscal injection of bupiva-
caine with the aim to eliminate or reduce pain can be found
in the literature, with different success rates in various stud-
ies [2–4]. In patients with one-level internal disc disruption
or nonsequestered nuclear prolapse, intradiscal injection of
0.5% bupivacaine was previously tested, but only 9% of the
treated patients showed clinical improvement [2]. In con-
trast, in another study including patients with chronic low
back pain, intradiscal administration of 0.5% bupivacaine
resulted in immediate improvement in 83% of the patients.
This improvement was maintained for 2 weeks in 67% of
patients but only in 17% of patients after 1 month [3]. Intra-
discal injection of 50% dextrose and 0.25% bupivacaine in
patients with severe degenerative disc disease resulted in
sustained improvement in 43.4% of patients, although it
is unclear which of the two components was primarily re-
sponsible for this clinical effect [4]. The pain relieving
mechanism of local anesthetics such as bupivacaine can
be twofold: It can inhibit sensitization of nerve endings,
which is thought to be the main mechanism underlying pain
relief. This is based on the inhibition of certain voltage-
gated ion channels (sodium and potassium), therefore re-
ducing the action potential in the neural cell [5,6]. Latest
studies indicate that it may also reduce production of proin-
flammatory cytokines [7–10]. It could, for example, be
demonstrated that bupivacaine leads to a cytokine reduction
in macrophages (interleukin-1 beta [IL-1b], IL-6, tumor
necrosis factor-a [TNF-a]) [7] and rat fibroblasts (IL-2,
IL-4, and their receptors) [10] and to an inhibition of
carrageenan-evoked systemic cytokine production in rats
[9]. Carrageenans are a family of linear sulfated polysac-
charides, which are extracted from red seaweeds and have
an ability to form gels. A group of local anesthetics (lido-
caine, bupivacaine, and amethocaine) were additionally
shown to inhibit secretion of IL-8 and IL-1b in HT-29
and Caco-2 cell lines (intestinal epithelial cells) and par-
tially in freshly isolated epithelial cells in a concentration-
dependent manner [8].
For diagnosis of discogenic back pain, provocative dis-
cography is commonly used, in which spinal pain can be
provoked by the injection of contrast medium. The mecha-
nism of pain provocation during discography is largely un-
known, but it is hypothesized that pathological metabolites
are extruded from the disc and irritate nerve fibers in the
outer annulus fibrosus, thus causing pain [11]. After con-
trast medium injection, local anesthetics such as bupiva-
caine at a concentration of 0.25% or 0.5% are commonly
used to reduce the pain [12,13]. Provocative discography
remains a topic of debate. Recently, Carragee et al. [14]
demonstrated that provocative discography seems to result
in an accelerated disc degeneration/herniation and a loss in
disc height/signal after 10 years. The procedure was per-
formed using a 22-gauge to 25-gauge needle, but no men-
tion is made concerning the use of a contrast medium
and/or a local anesthetic. The negative effects of discogra-
phy could be based on tissue rupture at the injection side
because of the needle, on the contrast medium that is used
to provoke the pain, or on the local anesthetic that is
commonly injected at the end of the procedure.
Negative effects of bupivacaine have been reported, es-
pecially with regard to its toxicity. Recent in vitro studies
on articular chondrocytes elucidated that bupivacaine was
cytotoxic at the clinically applied concentrations [15–17].
It could be demonstrated by Chu et al. [15] that exposing
human articular chondrocytes for 15 minutes to 0.25%
bupivacaine resulted in 41% reduced viability, whereas
0.125% seemed to have no cytotoxic effect. Cytotoxicity
of 0.25% bupivacaine on chondrocytes could be confirmed
under in vivo conditions as well, using continuous infusion
into the shoulder of rabbits [18]. So far, the response of in-
tervertebral disc (IVD) cells to bupivacaine treatment is not
well explored. Only one study published in October 2009
exists so far, which indicates that bupivacaine may possess
strong cytotoxicity for disc cells as well, similar to articular
chondrocytes [19].
The objective of this study, therefore, was to analyze the
potential concentration-dependent cytotoxic effect of dif-
ferent concentrations of bupivacaine on human IVD cells.
An additional objective was to determine the effects of
bupivacaine on proinflammatory cytokines and matrix-
degrading enzymes.
Methods
Cell isolation and culture
Intervertebral disc tissue was obtained from a total of 11
patients (Table 1). All patients underwent a discectomy for
disc herniation or interbody fusion for degenerative disc
disease. The material was obtained from a spinal service
of a University Hospital.
In most samples, a differentiation of the nucleus pulpo-
sus and annulus fibrosus tissue was not possible because of
degeneration. Therefore, a mixed cell population (nuclear
chondrocytes and annular fibroblasts) was used. Cells were
isolated by overnight digestion with 0.2% collagenase NB4
(Serva, Switzerland) and 0.3% dispase II (Roche Diagnos-
tics, Switzerland) in phosphate-buffered saline (37!C, 5%
carbon dioxide). Digested tissue was filtered (70 mm cell
strainer, BD Bioscience, Switzerland) and washed with
Dulbecco’s Modified Eagle’s Medium: Ham’s Nutrient
Mixture F-12 (DMEM/F12) medium (Sigma, Switzerland).
Cells were expanded up to two passages in a monolayer us-
ing DMEM/F12 medium, containing 10% fetal calf serum,
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penicillin (50 units/mL), streptomycin (50 mg/mL), and
ampicillin (125 ng/mL) (Invitrogen, Switzerland) with
medium changes once to twice a week.
Informed consent was obtained from all tissue donors
before the procedure according to the requirement of the
local institutional review board.
Cytotoxicity
Bupivacaine was dissolved in water to obtain a concen-
tration of 150 mmol (stock), autoclaved, and diluted in
DMEM/F12 medium containing 10% fetal calf serum, pen-
icillin (50 units/mL), streptomycin (50 mg/mL), and ampi-
cillin (125 ng/mL) to obtain concentrations of 0.1, 0.5, 1,
5, 7.5 (0.25%), and 15 mmol (0.5%).
Cells were seeded in 24-well plates with exactly the
same cell density for all samples of one donor (approxi-
mately 50,000 cells/well for each donor) and expanded
for a few days before adding 1,000 mL of bupivacaine me-
dium in triplicates for each donor (of every concentration
mentioned above). After 2 (n55) and 18 hours (n55), cells
were analyzed for cell proliferation and viability using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assay: A fresh sterile solution of MTT (Sigma,
Switzerland) with a concentration of 0.5 mg/mL in the
DMEM/F12 medium was prepared, 500 mL was added to
each well and incubated for 3 hours at 37!C. MTT was dis-
carded, cells were lysed with dimethyl sulfoxide for 10
minutes at 37!C, and absorbance was measured at 565
nm. Absorbance of bupivacaine-treated cells was calculated
relative to absorbance of untreated control cells, which is
set to 100%.
Gene expression
Expanded cells were maintained under serum-free condi-
tions for 2 hours. Thereafter, 5 ng/mL of IL-1b (Peprotech,
Switzerland) was added to all but one sample of each donor
to induce an inflammatory response and to increase the levels
of matrix-degrading enzymes, representing the putative
situation in painful degenerated IVDs. Two hours later, bupi-
vacaine stock was added to one pretreated sample per donor
to obtain a concentration of 0.75 mmol. After 2 (n55) or 18
hours (n55), cells from all three conditions (untreated con-
trol cells, IL-1b prestimulation, IL-1b prestimulationþ
0.75 mmol) were harvested by trypsin treatment, and total
RNA was isolated using the GenElute Mammalian total
RNA Miniprep Kit (Sigma, Switzerland) according to the
manufacturer’s instructions. Complementary DNA was
synthesized using TaqMan Reverse Transcription Reagents
(Applied Biosystems, Switzerland), and gene expression of
IL-1b, IL-6, IL-8, TNF-a, cyclooxygenase-2 (COX-2),
matrixmetalloproteinase-3 (MMP3),MMP9,MMP13, a dis-
integrin and metalloproteinase with thrombospondin motifs
(ADAMTS4), and TATA-box binding protein (a housekeep-
ing gene: shown to be not regulated on treatment) was
analyzed. Human specific probes and primers (Applied
Biosystems, Switzerland, see Table 2), TaqMan real-time
RT-PCR Mix (Applied Biosystems, Switzerland), and 10 ng
of complementary DNA was mixed and measured in
duplicates using the RG-3000A PCR machine (Corbett
Research [now Qiagen], Switzerland). The comparative
Ct method was used to calculate changes in gene expression
of each measurement, first normalized versus the expression
of TATA-box binding protein (DCt) and thereafter versus the
untreated control or versus IL-1b (DDCt). To calculate the
change as a result of IL-1b stimulation, the DDCt value was
calculated between IL-1b–treated cells and control cells. To
calculate the change as a result of bupivacaine treatment, the
DDCt value was calculated between bupivacaine-treated cells
and IL-1b–treated cells. Results are indicated as a fold change
in messenger RNA (mRNA), relative to untreated controls or
IL-1b–treated cells, which is set to 1% or 100%, respectively.
Statistical analysis
The Mann-Whitney U test was used for analyzing statis-
tical significance. The significance level was set as 0.05,
two-tailed. Results in all figures are indicated as mean6
standard error of the mean.
Table 1
Patient data
No. Sex Age (y) Pathology Grade Disc level
1 M 29 Sequestration III L5/S1
2 F 66 Protrusion IV L4/L5
3 M 61 Sequestration IV L3/L4
4 F 50 Protrusion II L3/L4
5 F 29 Sequestration IV L4/L5
6 M 55 Sequestration IV L4/L5
7 M 41 Unknown Unknown Unknown
8 M 48 Extrusion IV L4/L5
9 M 72 Sequestration III L3/L4
10 M 34 Sequestration III L4/L5
11 M 36 Extrusion IV L4/L5
M, male; F, female; Grade, Pfirrmann grade for degeneration.
Cells from several donors were used for more than one method or time
point.
Table 2
Primers/probes used for real-time reverse transcription-polymerase chain
reaction
Gene
Primer sequence
number Base pairs
TATA-box binding protein HS 00427620_m1 91
Interleukin-1b HS 00174097_m1 94
Interleukin-6 HS 00174131_m1 95
Interleukin-8 HS 00174103_m1 101
Tumor necrosis factor-a HS 00174128_m1 80
Cyclooxgenase-2 HS 00153133_m1 75
Matrix metalloproteinase-3 HS 00968308_m1 98
Matrix metalloproteinase-9 HS 00957555_m1 79
Matrix metalloproteinase-13 HS 00233992_m1 91
Aggrecanase-1 (ADAMTS4) HS 00943031_g1 91
ADAMTS4, a disintegrin and metalloproteinase with thrombospondin
motifs.
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Results
Cytotoxicity
For cytotoxicity, cells under untreated control conditions
were set to 100%. Values lesser than 100% represent cell
death caused by bupivacaine, and values greater than
100% represent stimulated proliferation as a result of the
treatment.
After 2 hours
When applying bupivacaine doses of 5 mmol and higher,
a statistically significant toxic effect could be observed,
with severe cell death happening at the clinically used con-
centrations of 7.5 and 15 mmol (0.25% and 0.5%), respec-
tively (p!.0001 for both). A very slight but significant
stimulation could be observed at 1 mmol (p!.0001)
(Fig. 1, Left).
After 18 hours
When applying bupivacaine doses of 5 mmol (0.1%) and
higher, a statistically significant toxic effect could be ob-
served (p!.0001 for all). A cytotoxic effect (approximately
50%) could be observed already at 3 mmol (data not shown
in Fig. 1, Right). Concentrations of 5 mmol and higher,
which are clinically used, impaired cell viability with the
cell death ratio reaching almost 100%. When using concen-
trations between 0.1 and 1 mmol, a significant stimulation
of cell proliferation up to 170% could be observed (0.1
mM, p5.003; 0.5 mM, p!.0001; 1 mM, p5.003).
Effect on gene expression
Prestimulation with IL-1b
Cells were prestimulated with IL-1b for 2 hours (which
is commonly used to induce the expression of proinflamma-
tory cytokines and matrix-degrading enzymes in vitro) be-
fore starting another incubation period for 2 or 18 hours.
The effects of prestimulation with IL-1b are compared with
untreated control cells at the same time point, whose
expression is set to one.
After 2 hours. Prestimulation with IL-1b resulted in a sig-
nificant increase in the mRNA levels of ADAMTS4,
MMP13, and COX-2, IL-8 (all !50-fold and p!.015)
and IL-1b, MMP3, IL-6, and TNF-a (all O50-fold and
p!.015) (Fig. 2A, B).
After 18 hours. Prestimulation with IL-1b resulted in
a significant increase in the mRNA levels of ADAMTS4,
MMP9, (all !50-fold and p!.02) and MMP13, IL-6,
IL-8, and MMP3 (all O50-fold and p!.0001). No
statistically relevant effect could be observed for TNF-
a (p5.42) because of high variation between the donors
(Fig. 2C, D).
Effect on mRNA levels of proinflammatory cytokines and
matrix-degrading enzymes
After prestimulation, cells were treated with bupivacaine
with a concentration of 0.75 mmol, under which prolifera-
tion was stimulated (see Fig. 1, Left, Right), and mRNA
levels of proinflammatory cytokines and matrix-degrading
enzymes were measured. The mRNA levels of prestimu-
lated cells were set to 100%, and changes after bupivacaine
treatment were depicted accordingly: Values lesser than
100% represent a decrease and values greater than 100%
represent a stimulation of gene expression, as shown in
Fig. 3.
After 2 hours. Comparedwith IL-1b prestimulation (100%),
bupivacaine caused a significant reduction of most of the
measured matrix-degrading enzymes (MMP3 to 60% with
p!.0001, MMP13 to 57% with p!.0001, and ADAMTS4
to 62% with p5.02) except for MMP9, which was not
regulated (Fig. 3A). Bupivacaine treatment also resulted in
decreasedCOX-2 expression (to 56%with p5.001), whereas
the remaining proinflammatory cytokines TNF-a, IL-1b, and
Fig. 1. Cytotoxicity of different concentrations of bupivacaine after (Left) 2 hours or (Right) 18 hours of treatment, measured by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide assay and calculated relative to untreated control conditions (100%). Data are indicated as mean6standard error
of the mean. *p!.05 compared with untreated controls with n55 in each group.
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IL-8 were not influenced; IL-6 was increased, but only
slightly (130%), and this effect was not significant
(p5.106) (Fig. 3B).
After 18 hours. Bupivacaine caused a significant decrease
of MMP13 (to 25% with p!.0001) and ADAMTS4 (to
37% with p!.0001) compared with IL-1b prestimulation
(100%). However, a minor increase of MMP3 could be
observed as well (to 154% with p5.015) (Fig. 3C), and
no statistically relevant effect was observed for MMP9. Bu-
pivacaine treatment also resulted in a significant reduction
of COX-2 (to 46% with p5.015) and TNF-a (to 55% with
p5.015) compared with prestimulation, whereas no effect
was seen for IL-6 and IL-8. On the other hand, bupivacaine
treatment resulted in fourfold increased mRNA levels of
IL-1b (to 418% with p!.0001) (Fig. 3D).
Discussion
Results from this study show that the local anesthetic
bupivacaine, which is often used as an adjunct during pro-
vocative discography, strongly influences the viability and
gene expression of human IVD cells in a concentration-
dependent manner.
Cell viability
Cell viability measurement using the MTT assay clearly
demonstrated that in vitro, concentrations typically used in
a clinical setting (0.5%515 mmol and 0.25%57.5 mmol)
resulted in severe cell death after both 2 and 18 hours of
treatment. Although some crystallization occurred during
incubation at the highest concentration (probably because
of chemical incompatibility with the medium [20]), other
concentrations also resulted in severe inhibition of cell vi-
ability, without showing any crystallization in this in vitro
experiment. To further support our findings, MTT data were
confirmed by two alternative cytotoxicity measurement
methods for selected concentrations (0.75 mmol5nontoxic
and 3 mmol5toxic) (picogreen assay and trypan blue; data
not shown). The observed cytotoxicity (that was compara-
ble in all measurements) is similar to that of a recently pub-
lished article that demonstrated severe cell death of human
and rabbit IVD cells caused by 0.25% or 0.5% bupivacaine
Fig. 2. Effects after IL-1b prestimulation. Gene expression after prestimulation with IL-1b was measured using real-time reverse transcription polymerase
chain reaction for the (A, B) 2-hour group and (C, D) 18-hour group and compared with untreated control conditions (set to one). A, C show genes that are
regulated less than 50-fold, and B, D show genes that are regulated more than 50-fold. Data are indicated as mean6standard error of the mean. *p!.05
compared with untreated controls with n55 in each group. ADAMTS4, a disintegrin and metalloproteinase with thrombospondin motifs; MMP13, matrix
metalloproteinase-13; COX-2, cyclooxgenase-2; IL-8, interleukin-8; MMP9, matrix metalloproteinase-9; IL-1b, interleukin-1b; TNF-a, tumor necrosis
factor-a; MMP3, matrix metalloproteinase-3; IL-6, interleukin-6.
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as early as 60 minutes, with the main mechanism being ne-
crosis [19]. More evidence for the toxic effect of bupiva-
caine comes from studies on chondrocytes, in which
0.25% bupivacaine resulted in 41% reduced viability after
15 minutes already, whereas a concentration of 0.125%
was not cytotoxic [15]. The findings of our study and the
studies mentioned above provide critical new information
relating to current concerns on the clinical use of bupiva-
caine. From Lee’s study, it becomes evident that both
nucleus pulposus and annulus fibrosus cells showed in-
creased cell death after bupivacaine treatment [19]. In our
study, cells from the entire disc were used as degeneration
was progressed so far that distinguishing between the two
regions was not possible anymore. Based on the studies
done on IVD cells so far, it is unclear whether the cells
from degenerated discs are more susceptible than the cells
from healthy discs. However, studies on chondrocytes indi-
cate that an intact articular surface has a chondroprotective
effect [16], thus providing evidence that diseased tissue
shows increased drug susceptibility.
Interestingly, cytotoxicity was replaced by stimulation
of cell proliferation at lower concentrations (0.1–1.0
mmol), especially after 18 hours. The minor effects after
2 hours are understandable, as cell growth requires ade-
quate times. To the authors’ knowledge, this is the first
study demonstrating that bupivacaine can exhibit either
a cytotoxic or a proliferative effect in IVD cells, depending
on the concentration used. A proliferative effect of bupiva-
caine at concentrations lower than 0.1 mmol could also be
observed in keratinocytes, whereas high concentrations
showed severe toxicity in this cell type as well [21]. The
proliferative effect could be a beneficial aspect for the treat-
ment of degenerated disc disease. As the IVD is character-
ized by low cell numbers [22] with reduced functionality
(which may lead to typical signs of degenerative disc
disease), a proliferative side effect of an intradiscally ap-
plied drug could possibly help counteracting the process
of degeneration.
The major issue of cell viability measurements in an in
vitro cell culture model is the questionable direct
Fig. 3. Effects of bupivacaine treatment. Gene expression after treatment with bupivacaine (0.75 mmol) was measured using real-time reverse transcription
polymerase chain reaction after (A, B) 2 hours and (C, D) 18 hours and compared with IL-1b–pretreated conditions (set to 100%). A, C show proinflam-
matory cytokines, and B, D show matrix-degrading enzymes. Data are indicated as mean6standard error of the mean. *p!.05 compared with IL-1b–pre-
treated cells with n55 in each group. ADAMTS4, a disintegrin and metalloproteinase with thrombospondin motifs; MMP9, matrix metalloproteinase-9;
TNF-a, tumor necrosis factor-a; IL-1b, interleukin-1b; COX-2, cyclooxgenase-2; MMP13, matrix metalloproteinase-13; IL-6, interleukin-6; IL-8,
interleukin-8; MMP3, matrix metalloproteinase-3.
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transferability to the in vivo situation. The reason is that it
is unclear how quickly the drug is cleared from the tissue
because of diffusion and bulk flow of fluids. Additionally,
the volume of the disc will cause a certain dilution, and
the extracellular matrix, which was missing in our cell
culture study, may have a strong influence on the bioavail-
ability. However, there is certain evidence from the latest
research indicating that data from in vitro cell culture stud-
ies can be confirmed in tissue explant studies, in which
cells are at least protected by the native matrix. So far un-
published data on organ culture testing of bupivacaine were
presented at the 2010 International Society for the Study of
the Lumbar Spine Meeting, showing that the cytotoxic
effect previously observed on isolated cells could also be
observed in excised mouse disc tissue [23]. The cell and tis-
sue culture studies performed in the most recent past clearly
provide enough relevant data indicating that the next logi-
cal step would be to follow up with an in vivo animal study,
the most valuable system for drug testing.
For this study, we used a self-made sterile stock solution
of bupivacaine rather than a commercially available solu-
tion, which has advantages and disadvantages. With our re-
sources, we are not able to ascertain that in the process of
preparing the sterile bupivacaine stock solution, no toxic
byproducts have arisen. However, one of the most relevant
anesthesiology textbooks clearly states that amide-based
anesthetics such as bupivacaine are not very susceptible
to heat and can thus be heat sterilized [24]. As a major
advantage compared with commercially available bupiva-
caine solutions, no pH adjustment was necessary in this
stock that was always used fresh, therefore minimizing
any pH-related cytotoxic side effects that could arise in
commercial preparations (pH 4.0–4.4).
Gene expression
We hypothesized that bupivacaine may also have an
effect on inflammatory and catabolic mediators at nontoxic
concentrations. So far, there is no information about the
inflammatory or catabolic response of disc cells to bupiva-
caine treatment, and studies on other types of cells or
tissues are rare and very contradictive [7,25–29]. In our
study, we used IL-1b prestimulation to simulate the situa-
tion during IVD disease, as IL-1b is known to cause
reliable catabolic and inflammatory effects. Although treat-
ment with IL-1b is commonly used for this purpose, it can
only simulate certain aspects of the inflammatory situation
in the IVD in vivo. Treating prestimulated cells with a non-
toxic concentration of bupivacaine resulted in a partial re-
duction of TNF-a and COX-2 expression, thus indicating
its anti-inflammatory effect. Importantly, it also signifi-
cantly reduced the expression of several relevant matrix-
degrading enzymes in the disc, even at 2 hours. Although
the observed effects may be clinically interesting, it is pos-
sible that repetitive injection would be necessary. However,
repetitive disc puncture may entail negative side effects that
need to be investigated before announcing a novel thera-
peutic value of bupivacaine. The positive effect of bupiva-
caine with regard to mRNA levels is further limited because
of a slight increase in the expression of MMP3 and a strong
increase in the expression of IL-1b (both after 18 hours).
This negative effect was not present after 2 hours, but it
is unclear how the expression of these genes would change
with more time, whether changes would be translated onto
the protein level, and for how long bupivacaine would influ-
ence cells in vivo at all. If the upregulation of IL-1b and
MMP3 would be maintained long enough in vivo, induction
of degradation and inflammation would be a matter of con-
cern. Therefore, the expression pattern of IL-1b and MMP3
will have to be investigated in more detail.
Clinical relevance
If toxicity results obtained in this in vitro cell culture
study can be corroborated in vivo (eg, using an animal
model), caution will be necessary when applying bupiva-
caine as an adjunct during provocative discography with
the currently used concentration.
Lower concentrations, which stimulated cell prolifera-
tion and reduced gene expression of certain matrix-
degrading enzymes and proinflammatory cytokines, may
be therapeutically beneficial, but more data are required
to assure clinical purpose and safety.
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7. UNPUBLISHED DATA 
7.1. AGE as a pro-inflammatory and catabolic mediator on IVD 
cells in vitro 
AGE and its receptor RAGE are found to be increased during IVD degeneration [46, 47]. 
AGE is a non-enzymatically modificated tissue protein produced by the reaction of 
glucose with protein amino groups. These products are implicated in diseases such as 
diabetes. A study by Yoshida et al. [2009] could demonstrate a catabolic effect of AGE 
in combination with IL-1β. IL-1β decreased aggrecan mRNA level in bovine IVDs only 
in combination with AGE which was recovered by blocking RAGE activity [254].  
We were interested in whether the accumulation of AGE can lead to a pro-inflammatory 
and catabolic stimulus in IVD cells in vitro. When investigating cell viability upon 
treatment with AGE or CML, no toxic effect was observed in the tested concentration 
range of 2.5 to 600 µg/ml after 18 hours (Figure 1A). On the contrary, it caused a minor 
proliferative effect. However, the stimulation of IVD cells with 200 µg/ml AGE and 
CML for 18 hours increased mRNA level of TNF-α, IL-8 and MMP13 (Figure 1B), but 
this was not statistical significant due to high patient-variation, i.e. only few donors were 
responsive to the stimulus. No effect was seen for all patients on investigated genes AD5, 
MMP1, MMP2, MMP13 and IL-6 (data not shown). For further investigations, different 
time points and concentrations have to be included. 
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Figure 1A-B. Viability assay of AGE and CML on IVD cells (A) (n=3, Mean ± SEM). 
Gene expression levels of IVD cells treated with 200 µg/ml AGE and CML for 18 hours 
(B) (n=8, Mean ± SEM). Cells treated with BSA served as a control (ctrlAGE as well as 
ctrlCML). Statistical analysis was perfomed using student’s t-test with a significant level 
of p<0.05. 
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7.1.1. Methods 
AGE was prepared by dissolving of 100 mg of BSA (Sigma) and 750 mg D-Ribose 
(Sigma) in 50 ml PBS, pH 7.4 and incubated for 5 weeks at 37°C and 5% CO2 and 
dialysed to PBS. CML was generated by 100 mg BSA and 100 mg glycoaldehyde dimer 
(Fluka), but only incubated for 3 days and also dialysed to PBS. BSA alone served as a 
control. IVD cells were cultured in 2D monolayer in 150 ccm flasks. Before starting the 
experiment, cells were rendered serum free for 2 hours and then treated for 18 hours with 
200 µg/ml AGE, CML or BSA alone as a control. For gene expression analysis, cells 
were harvested using trypsin treatment and mRNA was isolated using the mRNA 
Purification Kit according to the manufacturer’s recommendation (Invitrogen). 
Thereafter, 1 µg of mRNA was reverse transcribed to cDNA (TaqMan, Applied 
Biosystems) and then used for real-time RT-PCR measurements using TaqMan Gene 
Expression assays (Applied Biosystems) for detection of cytokines (IL-6, IL-8, TNF-α), 
matrix degrading enzymes (MMP1, MMP3, MMP13) and aggreccanases AD4 and AD5. 
Gene expression was first normalized to the housekeeping gene TATA-Box binding 
Protein (TBP) before comparing expression of treated cells to untreated control (2-ΔΔCt 
method). Statistical analysis was performed using the student’s t-test, with a significance 
level of p < 0.05. 
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7.2. Comparison of cytokine level of biopsies from disc 
herniation and trauma patients and from cells when cultured  
As cytokines play a major role in pain development, we were interested in differences of 
cytokine levels from biopsies of herniated disc tissue to trauma patients. Therefore 
mRNA was isolated directly from biopsies. Gene expression level was measured by real-
time RT-PCR and compared to the lowest expressed which was in both cases 
TNF−α followed by IL-6 and IL-1β (Figure 2). A huge increase we detected for IL-8 (45 
time higher) in trauma patients compared to disc herniation patients, obviously giving 
IL-8 a tremendous role in acute tissue injury. 
 
 
 
 
  
 
 
Figure 2. Comparison of mRNA cytokine levels from biopsies of herniated disc (n=5, 
left) and trauma patient (n=8, right). Gene expression was first normalized to the 
housekeeping gene TATA-Box binding Protein (TBP) before comparing expression to 
lowest expressed cytokine (TNF-α) which was set as 1 (Mean ± SEM). 
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Further we were interested in whether the cytokine level changes in IVD cells during 
culturing. Therefore, cells from biopsies of herniated disc were additionally expanded in 
a 2D monolayer culture system up to passage 1 and passage 3 where the experiments are 
generally conducted. First of all, measurement of mRNA level of cultured IVD cells 
revealed that IL-8 was no longer the highest expressed cytokine like in biopsy but shifted 
to IL-6, more dominant in passage 3 (Figure 3). 
 
 
 
 
 
Figure 3. Gene expression profile of cytokines TNF-α, IL-1β, IL-6 and IL-8 in passage 1 
(left) and passage 3 (right) of 2D monolayer cultured IVD cells from biopsies of 
herniated disc (n=5). Gene expression was first normalized to the housekeeping gene 
TATA-Box binding Protein (TBP) before comparing expression to lowest expressed 
cytokine (TNF-α) (Mean ± SEM). 
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When we compared gene expression level of cultured IVD cells to basal level of biopsy, 
we observation a huge drop of IL-8 mRNA expression (-1500 fold) which was not so 
dominant for IL-6 (-20 fold). IL-1β and TNF-α mRNA level decreases as well 
dramatically when IVD cells are cultured (Figure 4). 
 
 
 
Figure 4. Change of mRNA level of cytokine TNF-α, IL-1β, IL-6 and IL-8 in 2D 
monolayer cultured IVD cells compared to cells from biopsy. Gene expression was first 
normalized to the housekeeping gene TATA-Box binding Protein (TBP) before 
comparing expression to biopsy which which was set as 1 (n=5, Mean ± SEM). Student’s 
t-test was considered statistically significant at a level of p<0.05. 
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Due to the interesting observation that the mRNA cytokine level drops drastically when 
cells from IVD biopsies are in culture, we wanted to find optimal conditions for culturing 
IVD cells which is comparable to the biopsy environment concerning cytokine 
expression level. For testing different culture conditions, cells were isolated from 
biopsies and cultured either in 2D monolayer system or 3D (alginate beads) under normal 
condition (DMEM/F12, 10% FCS, 1% antibiotics, 37°C, 5% CO2) or in a 
“microenvironment” (low glucose DMEM/F12, 10% FCS, 1% antibiotics, 37°C, 400 
mOsm, pH 6.5) (Figure 5). mRNA was isolated either directly from biopsy or from cells 
expanded in the different culture conditions and cytokine gene expression was compared 
after two weeks of culturing. 
 
 
 
Figure 5. Schematic representation of conducted experiment for the evaluation of 
optimal culture condition of IVD cells, to regain cytokine mRNA level measured in 
biopsy. 
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Monitored mRNA level of these four different conditions revealed that already culturing 
of IVD cells in a “microenvironment” with low glucose and low pH contribute to the 
regain of the mRNA cytokine level detected in biopsy. This observation is also true when 
cells are cultured in a 3D system for TNF-α, IL-6 and IL-8 but not IL-1β. The most 
adequate culture method for IVD is the combination of both conditions with the reach of 
almost biopsy mRNA level for all measured cytokines (Figure 6). 
 
 
 
Figure 6. Comparison of mRNA level of cytokine TNF-α, IL-1β, IL-6 and IL-8 in 2D 
monolayer system, 3D system (alginate beads), under normal condition (DMEM/F12, 
10% FCS, 1% antibiotics, 37°C, 5% CO2) or in a “microenvironment” (low glucose 
DMEM/F12, 10% FCS, 1% antibiotics, 37°C, 400 mOsm, pH 6.5) to cells from biopsy. 
Gene expression was first normalized to the housekeeping gene TATA-Box binding 
Protein (TBP) before comparing expression to biopsy which was as 1 (n=2, Mean ± 
SEM). Student’s t-test was considered statistically significant at a level of p<0.05. 
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7.2.1. Methods 
For the comparison of cytokine gene expression levels of biopsies of herniated disc to 
trauma patients, mRNA was isolated by TRI Reagent (Sigma) and 1-Bromo-3-
Chloropropane (BCP, Sigma) followed by using the RNA Purification Kit (Invitrogen). 
In order to compare the cytokine levels of biopsies to cultured IVD cells (from the same 
biopsies), isolated disc cells were either cultured up to passage 1 or passage 3 before 
isolating mRNA with the RNA Purification Kit. For evaluating culture condition which is 
comparable to biopsy by comparing cytokine level, cells from biopsy of herniated disc 
were first expanded either to 70% confluency (for subsequent 2D culturing) or to 100% 
confluency (for subsequent 3D system) under normal condition (DMEM/F12, 10% FCS, 
1% antibiotics, 37°C, 5% CO2). Afterwards, the same amount of cells was cultured for 2 
weeks in either a 2D monolayer or 3D (alginate beads) system under normal conditions 
or in a “disc-typical microenvironment” (low glucose DMEM/F12, 10% FCS, 1% 
antibiotics, 37°C, 400 mOsm, pH 6.5). mRNA isolation from cells expanded in the 
different culture conditions was conducted by mRNA Purification Kit. 1 µg mRNA was 
reverse transcribed to cDNA (TaqMan, Applied Biosystems) and then used for real-time 
RT-PCR measurements using TaqMan Gene Expression assays (Applied Biosystems) for 
detection of cytokines (IL-6, IL-8, TNF-α, IL-1β). Gene expression was first normalized 
to the housekeeping gene TATA-Box binding Protein (TBP) before comparing all mRNA 
level to either lowest expressed cytokine (TNF-α) or to biopsy cytokine level (2-ΔΔCt 
method). Statistical analysis was performed using the student’s t-test, with a significance 
level of p < 0.05. 
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7.3. Receptor detection of TLR2, TLR4, CD44 and RHAMM in 
IVD cells in vitro 
For monitoring gene expression levels of receptors on IVD cells investigated in fHA 
experiments in vitro, mRNA level was first measured of TLR2, TLR4, CD44 and 
RHAMM/(IHABP) of cultured IVD cells by real-time RT-PCR. Comparison of ct values 
revealed that RHAMM and TLR4 were most expressed (both 27%), followed by TLR2 
(24%) and CD44 (22%) (Figure 7). 
 
 
 
Figure 7. Comparison of basal gene expression profile of investigated receptors TLR2, 
TLR4, CD44 and RHAMM/(IHABP) in culture IVD cells. 
 
Protein detection by wester blot of whole cell extract of cultured IVD cells revealed a 
successful staining of RHAMM/(IHABP) at already low applied amount of cells (ca. 
2000 cells) followed by CD44 (ca. 30’000 cells). Only a faint staining for TLR4 (250’000 
cells) was visible on the same level of the signal of recombinant TLR4 (positive control), 
but no clear TLR2 staining was detectable. Also TNF-α stimulated IVD cells (served as 
positive control) did not show any signal for TLR2 (Figure 8). 
 
 
 
 
  123 
 
 
 
 
Figure 8. Receptor detection by Western blot of RHAMM/(IHABP), CD44, TLR2 and 
TLR4 in whole cell extract of cultured IVD cells. 
 
 
Surface protein expression detection was achieved by FACS analysis. As a positive 
control, fresh isolated peripheral blood mononuclear cells (PBMC) were used for TLR2, 
TLR4 and CD44, MDA-MB-231 cell line was used for RHAMM. All used antibodies 
revealed a positive signal (Figure 9). 
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Figure 9. Monitoring of surface-receptor staining (black curve) by FACS analyis of 
TLR2, TLR4 and CD44 by using PBMC and RHAMM by using MDA-MB-231 cell line 
as positive control cells. Respective IgG antibody (grey curve) served as control for 
unspecific binding. The grey area represents the amount of positive stained cells, 
indicated as percentage. 
 
RHAMM antibody was further evaluated by staining intracellular RHAMM/(IHABP) by 
first permeabilizing MDA-MB-231 cells. FACS analysis revealed 30% staining by 
additional intracellular RHAMM=IHABP detection (Figure 10). 
 
Figure 10. Permeabilized MDA-MB-231 cells for monitoring additional intracellular 
RHAMM/(IHABP) (black curve) by FACS analysis to control antibody staining. 
Respective IgG antibody (grey curve) served as control for unspecific binding. The grey 
area represents the amount of positive stained cells, indicated as percentage. 
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Staining of investigated cell surface receptor on cultured IVD cells was only positive for 
CD44 (95%), but no signal was detected for TLR2, TLR4 as well as for RHAMM 
(Figure 11).  
 
 
Figure 11. Cell surface-receptor stainig (black curve) of CD44, RHAMM, TLR2 and 
TLR4 of cultured IVD cells by FACS analysis. Respective IgG antibody (grey curve) 
served as control for unspecific binding. The grey area represents the amount of positive 
stained cells, indicated as percentage. 
 
Receptors were additionally stained by immunofluorescence. Unfortunately, none of the 
used antibodies (all from abcam) was able to stain receptors in IVD cells as well as not in 
cells used as positive control (PBMC and MSC for TLR2, TLR4 and MDA-MB-231 for 
RHAMM), except CD44 (Biolegend, data not shown).  
 
7.3.1. Methods 
For comparison of receptor gene expression levels, mRNA of cultured IVD cells was 
isolated by mRNA Purification Kit, 1 µg/ml reverse transcribed and cDNA measured by 
real-time RT-PCR using TaqMan Gene Expression assays (Applied Biosystem). 
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For detection of receptors on protein level by Western blot, IVD cells were harvested by 
trypsin, collected and washed with PBS buffer. Cells were lysed with lysis buffer 
containing 50 mM HEPES (pH 7.5), 450 mM NaCl, 15% glycerol, 2 mM EDTA, 1 mM 
PMSF with freshly added 0.1% protease inhibitors pepstatin-A, leupeptin and bestatin, 
incubated on shaker for 10 min at 4°C and centrifuged for 30 min at 14’000 rpm. 
Supernatant was collected and protein concentration measured by Bradford assay and 
used for Western blot. Used antibodies were RHAMM (GeneTex), TLR2, TRL4 
(GeneTex, Invivogen and R&D) and CD44 (Biolegend). Applied respective secondary 
antibody was HRP labeled and after washing, chemiluminescence was detected using 
SuperSignal West Dura on Hyperfilm. 
For surface receptor staining, FACS analysis was perfomed. Therefore cultured IVD cells 
were harvested by scraping, pooled and washed with PBS. Cells were resuspended in 
FACS buffer (PBS/BSA 1%) at 1x10^6 cells/ml and distributed in a 96 well plate. After 
centrifugation, cells were resuspended in PBS/BSA 2% with additional respective serum 
(5% v/v) to block unspesific binding and incubated for 20 min at 4°C. After washing 
three time with cold FACS buffer, PE conjugated antibody was applied for 30 min at 4°C 
in the dark, washed again three times, resuspended in 400 µl 4% paraformaldehyd (PFA) 
in PBS and transferred to FACS tubes. For additional intracellular RHAMM/IHABP 
staining, cells were prefixed for 10 min with 4% PFA before permeabilizing with 0.1% 
Triton-X100 (Fluka) in FACS buffer for 10 min. Used antibodies RHAMM (antibodies-
online.com), TLR2 and TLR4 (Biolegend) were all PE conjugated, except CD44 
(Biolegend), which was stained by applying ALEXA Fluor488 conjugated secondary 
antibody (Molecular probe). As negative control, the respective PE conjugated IgG 
(GeneTex and Biolegend) antibodies were used. Fluorescence was monitored on CyAnTM 
with excitation-emission wavelength of 480-578 nm for PE, using Dako Summit 
software, v 4.3. 
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7.4. Further effects of fHA (6-12 ds) on cultured IVD cells 
The detected increased IL-6 and MMP1 mRNA level upon fHA treatment of cultured 
IVD cells we could also monitor on protein level by Western blot using precipitated 
protein from the supernatant. We could already detect an increased IL-6 protein level 
after treatment of cells with 1 µg/ml fHA. MMP1 showed an increased signal after 
treatment with 50 µg/ml fHA (Figure 12).  
 
       
 
 
          
 
 
Figure 12. Staining of precipitated IL-6 and MMP1 of supernatant of IVD cells by 
Western blot (n=3, ctrl = untreated cells). Coomassie staining of SDS-gel served as 
loading control for IL-6, ponceau S staining of membrane served as loading control for 
MMP1. 
µg/ml fHA ctrl 1 5 20 50 
23.7 kDa 
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IL-6 
- - - 
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Furthermore, fragments of CD44 were monitored in conditioned media of IVD cells. 
Whole cell extract (WCE) of HeLa cells was used as a control, where we could see a 
clear band on the expected size of 81.5 kDa. In the supernatant of IVD treated cells 
instead we detected a smaller size which might be cleaved CD44 (55 kDa), already 
present at untreated cells with a slightly increased signal at cells treated with 50 µg/ml 
fHA (Figure 13). It has been reported that ECM fragments are able to provoke cleavage 
of CD44. This has been demonstrated for fHA 3-7 ds and 17 ds in tumor cells, where the 
membrane bound cleavage product of CD44 (25 kDa) was detected [203]. It might 
therefore be that fHA provokes the cleavage of CD44 in IVD cells. 
 
 
 
 
Figure 13. Staining of CD44 by Western blot in whole cell extract (WCE) of HeLa cells 
(as control) and in supernatant of fHA treated IVD cells. 81.5 kDa represents the full size 
of CD44, lower band might indicate cleaved CD44 product (near 55 kDa) (n=1). 
 
Helenalin is promoted as a specific NF-κB inhibitor and claimed to specifically and 
irreversibly alkylating free sulfhydryls of the cystein residues on the NF-κB subunit p65 
and thereby preventing the interaction with its target DNA sequence [255]. But it is also 
described to specifically inhibit activation of NF-κB by preventing the degradation of 
IκB-α and IκB-β [256]. It is used in different studies to investigate NF-κB dependent 
reactions where the monitored effects are claimed to be NF-κB dependent just due to the 
observed altered signals in helenalin treated cells [211, 213]. In our study, we revealed 
that helenalin indeed had inhibitory effects by decreasing IL-6 secretion in IL-1β as well 
as in fHA treated IVD cells (Figure 14), but as fHA had no effect on p65 shuttling into 
nucleus and obviously not activates NF-κB pathway (see results in fHA paper in 
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preparation), it seems that helenalin is targeting also other pathways involved in 
inflammatory signalling and is not restricted to the NF-κB pathway. 
 
 
Figure 14. IL-1β provoked IL-6 protein production in IVD cells was downregulated by 1 
µg/ml helenalin (left) as well as in fHA treated cells (right) (n=5, Mean ± SEM). 
Student’s t-test was considered statistically significant at a level of p<0.05. 
 
Western blot analysis revealed that helenalin did not prevent p65 nuclear shuttling in 
IL-1β treated IVD cells (Figure 15), indicating at least that helenalin does not intervene 
in this step of NF-κB activation by e.g inhibiting degradation of IκB as described by 
Hehner et al. [1998] [256], but may then rather inhibit binding of p65 on DNA as it is 
discussed by Lyss et al. [1997, 1998] [255, 257]. 
 
 
 
Figure 15. Staining of nuclear p65 by Western blot of IVD cells treated with 5 ng/ml IL-
1β or thogether with 1 µg/ml helenalin (promoted as a specific NF-κB inhibitor) (n=2). 
  130 
The 3D alginate bead system has shown to be an ideal environment for the study of IVD 
cells, at least concerning cytokine expression. Therefor we started conducting fHA 
experiments in IVD cells cultured in alginate beads. Viability assay indicated comparable 
toxic effects of 250 µg/ml fHA on IVD cells in the 3D culture system (Figure 16 right) to 
the 2D monolayer system (Figure 16 left). These are already promissing results to 
conduct future experiments in this 3D culture system as it represent the in vivo 
environment more closely than 2D culture.  
 
 
 
Figure 16. Viability assay for fHA (0-250 µg/ml) on IVD cells conducted in a 2D 
monolayer system (left, n=3) or in a 3D system (right, alginate beads, n=5, Mean ± 
SEM). Student’s t-test was considered statistically significant at a level of p<0.05. 
 
7.4.1. Methods 
For Western blot analysis, conditioned media (10 ml) of cells in 150 ccm flasks was 
collected after the experiment and proteins were precipitated by adding 1/100 sodium 
deoxycholate for 30 min at 4°C and 1/100 of 100% trichloracetic acid o/n at 4°C. Pellet 
was resolved after centrifugation in lysis buffer (50 mM HEPES, pH 7.5, 420 mM NaCl, 
0.5% NP-40, 15% glycerol, 2 mM EDTA, 1 mM PMSF with freshly added 0.1% protease 
inhibitors pepstatin-A, leupeptin and bestatin) by ultrasonication for a few seconds. 
Protein concentration was measured by using Bradford reagents and proteins were 
separated on a 12% polyacrylamid gel by SDS-PAGE and transferred to a PVDF 
membrane. After blocking with BSA, the membrane was incubated first with primary 
antibody for 2 hours against IL-6 (Sigma), MMP1 (GeneTex) and CD44 (GeneTex), 
washed three times with TBS-Tween 20 and incubated for 1 hour with the respective 
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secondary HRP labeled antibody. After washing, chemiluminescence was detected using 
SuperSignal West Dura on Hyperfilm. For loading control, SDS-gels were stained with 
coomassie brilliant blue (Fluka) and membrane with ponceau S (Fluka) (n=3). 
In inhibition experiments with Helenalin (ENZO Life Science), cells were seeded in 12 
well plates (130’000 cells/well) one day before treatment. Cells were pretreated with or 
without 1 µg/ml helenalin in serumfree media for 1 hour before adding 5 ng/ml IL-1β or 
20 µg/ml fHA. After 18 hours, supernatant was used for ELISA measurements (n=5). 
For pathway analysis by Western blot for staining nuclear p65, cells were treated the 
same like described above, but harvested after 1 hours by usage of a cell scraper, 2 wells 
per condition were pooled and washed with buffer A containing 10 mM HEPES (pH 7.9), 
1.5 mM MgCl2, 10 mM KCl, 1 mM PMSF, 5 mM DTT with freshly added 0.1% protease 
inhibitors pepstatin-A, leupeptin and bestatin and then lysed with 0.1% NP-40 for 5 min. 
After centrifugation at 10’000 rpm for 5 min at 4°C, supernatants were discarded and 
nuclear pellets were washed with 0.1% NP-40 and lysed for 20 min with 20 mM HEPES 
(pH 7.9), 1.5 mM MgCl2, 420 mM NaCl, 25% glycerol, 1 mM PMSF and 5 mM DTT. 
After centrifugation, supernatants were measured for nuclear protein concentration by 
Bradford assay and stored at -80°C. Western blotting was performed as already described 
with a first antibody against p65 (Santa Cruz) or PARP1 (Santa Cruz) used as a loading 
control (n=2). 
2D viability assay was performed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay. For this, cells were seeded in 24-well plates (50‘000 
cells/well) or in alginate beads. The respective fHA concentrations were analyzed in 
triplicates for each donor. After 18 hours, cells were analyzed for cell proliferation and 
viability. A fresh sterile solution of MTT (Sigma, Switzerland) with a concentration of 
0.5 mg/ml in DMEM/F12 medium was prepared, 500 µl added to each well and 
incubated for 3 hours at 37°C. MTT was discarded, cells were lysed with dimethyl 
sulfoxide for 10 minutes at 37°C, and absorbance was measured at 565 nm. Absorbance 
of treated cells was calculated relative to absorbance of untreated control cells, which is 
set to 1 (n=3). 
3D viability assay was performed by counting dead cells stained with trypan blue by 
using a hemocytometer (n=5). 
  132 
7.5. Effects of a mixture of larger size of fHA < 25 ds on 
cultured IVD cells 
We also tested pro-inflammatory and catabolic effects on IVD cells in culture of a 
mixture of larger size of fHA < 25 ds. Interestingly, results of 18 hours treatment with 
different concentration indicated that IVD cells responded to fHA < 25 ds at only low 
dose (1 µg/ml) monitored by the increased mRNA level of IL-6 (28 fold, Figure 17 left), 
MMP1 (8 fold) and MMP3 (9 fold) (data not shown). We also observed minor increase of 
MMP13 (3.7 fold) and IL-8 (2.5 fold) but no increase of COX-2, TLR2, TLR3, TLR4, 
IL-1β, Hyal1 and Hyal2 (data not shown) (n=2). On protein level, we also saw this dose 
dependency, with higher secretion of IL-6 measured at lower dose.  
 
 
Figure 17. Effects of different concentration of a mixture (size) of fHA < 25 ds on IVD 
cells after 18 hours on gene expression (left, measured by real-time RT-PCR) and protein 
expression (right, measured by ELISA with precipitated protein of supernatant) (n=2, 
Mean ± SEM). Student’s t-test was considered statistically significant at a level of 
p<0.05. 
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We also performed a time course and treated IVD cells with 1 and 5 µg/ml fHA < 25 ds 
for 1, 2, 3, 6, 9, 14, 18, and 24 hours (n=2). Again, only after 18 hours we saw an 
increase of mRNA level of IL-6 (Figure 18 left), also detected on protein level  (Figure 
18 right), but only with 5 µg/ml fHA < 25 ds. The increase was not statistical significant. 
This would indicate a greater inflammatory and catabolic potency of smaller fragments 
on IVD cells which we saw with fHA = 6-12 ds treatment. (see results in fHA paper in 
preparation). 
 
Figure 18. Effects of 1 and 5 µg/ml of a mixture (size) of fHA < 25 ds on IVD cells after 
different time points on gene expression (left, measured by real-time RT-PCR) and 
protein expression (right, measured by ELISA of directly applied supernatant) (n=2, 
Mean ± SEM). Student’s t-test was considered statistically significant at a level of 
p<0.05. 
 
Pathway analysis also indicated a NF-κB independent action of fHA < 25 ds, evaluated 
by Western blot (Figure 19A) and NF-κB binding assay (Figure 19B), which we also 
observed in cells treated with small fHA (6-12 ds, see results in fHA paper in 
preparation). The MAP kinase p38 was not activated by fHA < 25 ds (Figure 19C), which 
we could see partially with small fHA. 
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Figure 19 A-C. Pathway analysis of NF-κB and the MAP kinase p38 investigated in IVD 
cells treated with fHA < 25 ds. Nuclear p65 was stained by Western blot and signal was 
compared of untreated, IL-1β treated or fHA (1-50 µg/ml) treated cells, where PARP1 
served as loading control (A, n=3). NF-κB binding activity was measured with a NF-κB 
transcription factor assay and absorption was recorded at λ=655 nm (B, n=2). MAP 
kinase p38 was monitored by staining of phosphorylated and unphosphorylated p38 with 
tubulin as additional loading control (C, n=2). 
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7.5.1. Methods 
For the dose and time dependency experiments with mixed size fHA < 25 ds, cells were 
treated as already described. Cells were harvested at respective time points by TRI 
Reagent and proteins of supernatant were either first precipitated (dose dependent 
experiment) or directly used for ELISA (time course experiment).  
Protein isolation of nuclear extract for NF-κB pathway analysis by immunoblotting or 
NF-kB (p65) Transcription Factor assay is described in chapter 7.4.1. Western blotting 
was performed as already described with a first antibody against p65 (Santa Cruz, 1:200) 
or PARP1 (Santa Cruz, 1:1000) used as a loading control (n=3). 
For NF-κB (p65) Transcription Factor assay (n=2), which was used as a further analysis 
of NF-κB DNA binding, nuclear extracts were analysed using the NF-κB (p65) 
Transcription Factor Assay (Cayman, Estonia) as recommended by the manufacturer. 
Double stranded DNA (dsDNA) containing NF-κB binding site (coated on a 96 well 
plate) was incubated with the samples and specific binding was detected with an antibody 
against p65 as well as a secondary HRP conjugated antibody. Data analysis and 
quantification was performed by colorimetric measurement (655 nm). 
Protein isolation of whole cell extracts for Western blot for p38 was performed as 
described in 7.3.1. and stained for phosphorylated or unphosphorylate p38 (1:500) (all 
Cell signaling) and tubulin (1:1000) (Cell signaling) (n=2). 
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DISCUSSION AND PERSPECTIVES  
 
8. Summary of Results 
8.1.  fHA as a trigger of discogenic back pain? 
Evidence from the literature suggests that symptomatic degenerated discs are 
characterized by elevated cytokine levels. These cytokines are thought to play a major 
role in the pain mediation by diffusing to the outer part of the disrupted disc tissue 
resulting in an irritation of nociceptors. In accordance to this hypothesis, pro-
inflammatory cytokines within the NP tissue have been shown to evoke radicular pain via 
irritation of the DRG [67, 69, 70]. It is therefore of relevance to reveal the responsible 
factors which might provoke a pro-inflammatory cascade in a degenerated disc. Based on 
this knowledge, novel therapeutic approaches can be developed. 
In the first part of this thesis, we were interested in identifying degeneration products 
with inflammatory and catabolic effects as these could possible contribute to the 
development to discogenic back pain and worsen the progress of IVD degeneration. 
During disc degeneration, there is an overall matrix breakdown, leading to an 
accumulation of certain ECM fragments with increased degeneration grade, which has 
been demonstrated so far for fibronectin [29, 31, 258] and aggrecan [27, 32]. HA is an 
important compound within the ECM of the IVD, and as a high molecular weight 
hyaluronic acid (HMWHA), together with other proteoglycans and glycosaminoglycans 
(GAGs), responsible for tissue hydration. HMWHA can be degraded to fragments either 
enzymatically by Hyals or by radicals occurring during oxidative stress. Furthermore, 
AGE and CML, which are shown to be increased in degenerated discs [46], may 
contribute to the fragmentation of HMWHA in vivo due to their radical nature as 
indicated by cell-free in vitro experiments [259].  
In this work, we were able to show that fHA with a size of 2.4-4.6 kDa (6-12 ds, 12-24-
mer) increased mRNA level of cytokines and MMPs in IVD cells in vitro, namely IL-1β, 
IL-6, IL-8, MMP1, MMP3, MMP13 and COX-2. Results were furthermore verified on the 
protein level for IL-6 and MMP1. As COX-2 is an important enzyme for the generation 
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of prostaglandines, its increase might play a major role in pain sensation in symptomatic 
patients. Furthermore, the increased MMP levels observed upon fHA treatment could 
worsen the degenerative state, as MMPs are responsible for the degradation of structure 
proteins in the ECM. 
IL-6 was traditionally considered as an activator of acute phase responses and a 
lymphocyte stimulatory factor [260]. Several studies conducted in animal models have 
now demonstrated a pain-mediating role for IL-6. As its levels are known to be elevated 
in symptomatic IVDs [60], we investigated the underlying pathway leading to the 
increased IL-6 secretion in IVD cells upon fHA treatment. Potentially involved receptors 
in this event are the main receptors of HA, namely RHAMM and CD44, as well as 
important receptors in immune reactions such as TLRs which are already shown to be 
engaged by fHA in several other cell types. In recent years, it has been recognized that 
TRLs are not restricted to immune cells, as they were also discovered to be expressed on 
synovial fibroblast [85-87], chondrocytes [83, 89] and hepatic cells [90]. Various studies 
investigating the reaction upon fHA exposure have demonstrated that depending on cell 
type and readout, the engaged TLR type varies. In dendritic cells for instance, fHA led to 
an increased TNF-α synthesis through TLR4 while being TLR2 independent [215]. In 
contrast, MIP-1α production was promoted through TLR2 in murine alveolar 
macrophages, but not through TLR4 [206]. Interestingly, TLR4 was responsible for the 
increased IL-8 synthesis but not for the increased MMP2 level due to fHA treatment in 
melanoma cells [207]. This fact is also pointing out the diversity of fHA engaged 
pathways, depending on the readout. In primary human chondrocytes which resemble the 
cells in center of the IVD, very small fHA induced an increase in IL-6, which was due to 
TLR4 and CD44 together with an involvement of the NF-κB pathway. However, in our 
study on human IVD cells, we revealed a significant dependency of TLR2 by knock-
down experiments using siRNA. fHA induced IL-6 production was significantly 
decreased upon TLR2 gene silencing which could not be observed in TLR4, CD44 or 
RHAMM knock-down cells. TLR2 engagement was further proven through antibody-
mediated inhibition studies, where functional loss of TLR2 activity led to a decrease in 
IL-6 production in cultured IVD cells. The involvement of NF-κB in mediating the 
effects of fHA has been well documented in multiple cell types [202, 206, 208, 211, 212]. 
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Several studies have also investigated the MAP kinases in fHA treated cells and have 
identified p38, ERK as well as JNK to be activated by fHA. MAP kinases are involved in 
regulating cell cycle, differentiation and are important in immune and inflammatory 
responses due to extracellular stimuli (mitogens). In the present study, we were able to 
exclude NF-κB dependent signal transduction as being responsible for mediating the 
effects of fHA in IVD cells due the lack of any evidence of its activation following fHA 
stimulation. Instead, MAP kinases p38, ERK and JNK were all activated by fHA, as 
determined by Western blot analysis. Furthermore, inhibition of either ERK or JNK 
resulted in a significant decrease of fHA induced IL-6 secretion in IVD cells. 
This is the first study demonstrating that fHA is a potential trigger of the pro-
inflammatory cascade in primary human IVD cells in vitro. Similar to fibronectin and 
aggrecan, there is evidence that fragmentation of the HMWHA may also occur during 
aging in IVDs in vivo. During aging/degeneration of the IVD, an accumulation of AGE 
has been reported, which has been shown to play a role in depolymerization of HA in 
other tissues due to free radical related metabolism, e.g. in the vitreous body of the eye 
[261-264]. These non-enzymatic glycated proteins (AGE) have been proved to efficiently 
degrade HA in vitro [218, 259]. Furthermore, a free radical depolymerization of HA has 
been demonstrated in a murine keratinocyte cell line. The inhibition of ROS formation 
led to a decrease in fHA production together with a melioration of the inflamed condition 
[219]. The increased AGE and NO formation measured in degenerating IVDs might 
therefore trigger HA fragmentation under certain circumstances and would be interesting 
to investigate in the future.  
The degree of accessible fHA engaged receptors might be of importance for the observed 
increase in IL-6 production and may therefore be of particular significance in the 
nociception in discogenic back pain. For instance, Campo et al. [2010] measured an 
elevated gene expression of the engaged receptor TLR4 and CD44 in human 
chondrocytes upon fHA treatment, which they also observed at protein level [208]. To 
evaluate changes in the expression pattern of receptors investigated in our fHA 
experiments, we conducted the detection of receptors in IVD cells by different methods. 
Gene expression analysis revealed that basal mRNA level were highest for RHAMM and 
TLR4, followed by TLR2 and CD44. Western blot analysis confirmed protein expression 
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of RHAMM and CD44, although TLR2 and TLR4 could not be identified. However, we 
were most interested in the basal amount of expressed surface-receptors on IVD cells, 
and thus performed FACS. The only receptor detectable was CD44, which was also 
confirmed by immunocytostaining. Although we were able to confirm their presence on 
PBMCs and MDA-MB-231 by FACS analysis, we were unable to detect RHAMM, 
TLR2 or TLR4 on IVD cells. PBMCs are generally known to express TLRs, whereas 
breast cancer cells like MDA-MB-231 are characterized by elevated RHAMM basal 
level. It might therefore be that the basal expression level of surface RHAMM receptors 
as well as of TLRs on IVDs were below the detection limit. Alternatively, the method of 
analysis may need to be optimized as it is reported (e.g. for TLR4) that cell surface 
receptors can be internalized immediately upon engagement, which might have occured 
during FACS preparation. RHAMM is discussed to be a non-integral cell surface 
hyaluronan receptor [177], and thus it might be that the preparation for FACS analysis 
destroys its interaction with the cell surface on IVD cells. However, there are no study 
available so far that has successfully shown cell surface-receptor staining of RHAMM 
and TLRs on IVD cells. 
We could further demonstrate that the inflammatory fHA potency might be size 
dependent, as a mixture of larger sized fragments (< 25 ds) did not induce such a 
noticeable increase in IL-6 production like the small fHA (6-12 ds), and in some patients 
had no effect at all. Thus, this may have significant implications with regard to the 
involvement of fHA in IVD degeneration, assuming that there exists a disproportional 
amount of smaller fHA as compared to larger fHA in symptomatic degenerated discs. 
There are also several studies demonstrating size dependent key functions, reviewed by 
Stern et al. [2006] [265].  
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8.2. Anti-inflammatory and anti-catabolic effects of Resveratrol, 
Curcuma and Triptolide  
Current treatment options for discogenic back pain involve either pharmacological 
agents, physiotherapy, spinal injections of pain relieving drugs or operative intervention 
by spinal fusion, which all are lacking evidence for long-term improvement. 
Pharmacological pain relieving medicaments include opioids, non-opioids and non-
steroidal anti-inflammatory drugs. The non-steroidal drugs used to relieve inflammatory 
pain mainly block the synthesis of PGE2 with the disadvantage of also blocking other 
prostaglandins, which may have tissue protective function. Thus there is a significant 
need to develop new and more effective treatment options.  
The use of natural herbs for medical treatments already has a long tradition. The great 
interest nowadays to use these herbs against various diseases is shown by the significant 
number of studies performed in the past decades. Over 5000 new studies are currently 
available investigating the beneficial effects of resveratrol in diseases such as 
inflammation, autoimmune diseases and cancer. In the current study, we could show 
evidence to support the positive properties of compounds of natural herbs namely 
resveratrol, curcuma (curcumin) and triptolide by demonstrating their preventative effects 
on inflammatory and catabolic events. For the in vitro experiments, we first pre-
stimulated cultured IVD cells with IL-1β to provoke an inflammatory and catabolic 
cascade. With this method, all genes of interest (IL-6, IL-8, MMP1, MMP3, MMP13 and 
TLR2) were significantly up-regulated on the mRNA level. The application of 50 µM of 
resveratrol, a phytoalexin found mostly in grapes, berries and peanuts, reduced gene 
expression with the highest reduction for IL-6 (76%). We were able to confirm these 
results also on protein level for IL-6, IL-8, MMP1, MMP3 and MMP13, as determined by 
Western blot using precipitated proteins from the supernatant of IVD treated cells. We 
also demonstrated that resveratrol could decrease the active form of each measured 
MMP, indicating that resveratrol not only affects expression levels, but also depletes the 
activation of the pro-form of MMPs, thereby disturbing matrix breakdown. Investigating 
the underlying pathway, we focused on NF-κB and MAP kinases p38, ERK and JNK. 
We could not detect any intervention in these signalling pathways by resveratrol, as 
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determined using different methods such as immunofluorescence, EMSA and Western 
blot. Resveratrol not only showed anti-catabolic and anti-inflammatroy effects in vitro, 
but also demonstrated an analgesic potential in a rat model of painful radiculopathy. 
Comparisons of animal behavior were made between resveratrol treated and untreated 
groups in response to mechanical stimulation using von Frey filaments by evaluating hind 
paw withdrawal. The pain was evoked by application of autologous NP on the DRG of 
rats, which resulted in a lower threshold of the paw withdrawal after mechanical stimulus 
as compared to a sham control group. A lower threshold indicated that these rats were 
more sensitive to the mechanical stimulus. If co-application of NP tissue and resveratrol 
was performed at the DRG, rats were less sensitive to the mechanical stimulus as 
compared to the sham group, indicating a pain relieving effect of resveratrol in vivo. As 
production and release of pro-inflammatory cytokines seem to play a pivotal role in NP 
mediated pain and as resveratrol was able to reduce inflammatory and catabolic cell 
responses  in vitro as well as pain in vivo, resveratrol may hold promise as a medical 
application for discogenic back pain. 
Investigations conducted with curcuma, a yellow powder generated from dried rhizomes 
of Curcuma longa, also demonstrated interesting effects on IVD cells in vitro. IL-1β-
induced increases in gene expression of IL-6, MMP1, MMP3 and MMP13 as well as 
TLR2 were significantly decreased by application of 100 µg/ml curcuma, with an 
exception for TNF-α, which was even further up-regulated. The main components of 
curcuma were curcumin, demethoxycurcumin and bisdemethoxycurcumin, as confirmed 
by HPLC/MS measurements, with curcumin being present at the highest concentration (6 
mg/ml of 320 mg/ml stock solution of curcuma). When treating IVD cells with curcumin 
(purchased from Sigma) at 20 µM, mRNA alterations were very comparable to effects 
observed upon curcuma treatment. Western blot as well as DNA binding assays revealed 
that the NF-κB pathway does not seem to play a role in the anti-inflammatory and anti-
catabolic effect of curcumin observed in IVD cells. This was in contrast to a recent study 
in chondrocytes, where curcumin inhibited degradation of IκB and thus prevented p65 
shuttling into the nucleus [266]. Curcumin instead showed an inhibitory effect on the 
MAP kinase JNK, although it had a stimulatory effect on p38 and ERK, as evaluated by 
Western blot analysis. The observed increase in TNF-α mRNA levels upon 
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curcuma/curcumin treatment could potentially be a consequence of the activated ERK or 
p38, but a causal relationship needs confirmation by further analyses. However, before 
considering curcumin for use in clinical trials, its analgesic effects need first to be 
demonstrated in animal models.  
Triptolide also demonstrated potential beneficial effects for the treatment of disc-related 
pain. Triptolide is a diterpene lacton and an extract of the herb Tripterygium wilfordii. 
The application of 50 nM of triptolide to IVD cells in vitro exerted an inhibitory effect on 
IL-1β induced IL-6, IL-8, MMP1, MMP2, MMP3 and MMP13 gene expression. 
Furthermore, IL-1β pretreated IVD cells showed a reduced gene expression of structure 
proteins Col-I and Col-II and the proteoglycan aggrecan. Col-II and aggrecan synthesis 
was rescued and even enhanced by triptolide treatment. We could also detect reduced 
expression of TLR2, TLR4 and COX-2 by triptolide. Similar to curcuma/curcumin, we 
detected an up-regulation of TNF-α on the mRNA level. Furthermore, we also confirmed 
that triptolide had no influence on the NF-κB pathway, as demonstrated by 
immunocytostaining and Western blot analysis. However, it did induce a strong 
inhibitory effect on p38 activation, and a slight effect on ERK pathway transduction.  
As bioavailability and diffusion rates are not known in vivo, our results obtained in this in 
vitro study only provide first evidence for a possible application in disc disease. 
Particularly, the observed TNF-α increase needs to be examined and further investigated.  
All together, resveratrol, curcuma as well as triptolide showed anti-inflammatory and 
anti-catabolic effects in IVD cells in vitro. With resveratrol, we were additionally able to 
demonstrate an analgesic effect in vivo. 
Clinical trials for a variety of applications (but not IVD disease) are being performed for 
all three tested substances. 63 studies are currently running for resveratrol, 75 for 
curcumin and 1 for triptolide, conducted in different countries (http://clinicaltrials.gov). 
Resveratrol is tested e.g. for cardiovascular diseases, memory, friedreich ataxia, diabetes 
type II, obesity, colon cancer and Alzheimer’s disease. Curcumin is tested for colon 
cancer, dermatitis, multiple myeloma, irritable bowel syndrome, Alzheimer’s disease, 
multiple sclerosis, depression, osteosarcoma, RA and OA. One clinical trial for triptolide 
is currently conducted in East Asia for the treatment of polycystic kidney diseases at the 
status of recruiting participants.  
  143 
 
Current treatments of discogenic back pain are either conservative or operative. So far, 
both methods do not provide the anticipated improvement in the long term. For instance, 
pain relieving pharmacological treatments do not address the problem of IVD 
degeneration. Surgical interventions, such as spinal fusion, have the downside of a loss of 
flexibility and movement. Furthermore, adjacent discs are more prone to degeneration 
due to altered biomechanics and increased strain [267-269]. To overcome these problems, 
alternative methods of treatment are being investigated either in vitro, by using explants 
IVD culture models, or by conducting in vivo studies. Biological treatment options 
currently under investigation include either injections of growth factors or stem cell 
therapy. So far, results were only positive for small animals, but are not yet distinct for 
large animals [270-272]. 
The investigated natural herbs in this work may provide another treatment strategy. 
Compounds such as resveratrol, curcuma or triptolide promise an alternative treatment 
option for discogenic back pain, as demonstrated by their anti-inflammatory, anti-
catabolic and anabolic effect in vitro, as well as analgesic potential in vivo. Thus, a better 
understanding of the source and the underlying pathway involved in the progression of a 
painful degenerated disc could help in development of more precise treatment strategies. 
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